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Abstract 
Cardiovascular diseases (CVD) are the leading causes of deaths representing 31% of global 
deaths. A healthy dietary eating pattern characterised by a greater intake of fruit and 
vegetables is associated with a reduction in the risk of CVD. Whether specific fruit and 
vegetables differ in the health benefits need further research.  
The systematic reviews and meta-analysis of previous relevant literature that were 
undertaken for this PhD programme showed positive associations between higher tomato 
and/or lycopene intake or status were associated with significant reductions of 26% in stroke 
(p=0.001), 14% in CVD (p=0.003); while high serum lycopene concentration was associated 
with significant reduction of 37% in mortality (p>0.001). In addition, previous dietary 
intervention studies have shown that supplementing tomatoes were associated with 
significant reductions of LDL-cholesterol by 0.22 mmol/L (p=0.006) and IL-6 by 0.25 
pg/mL (p=0.03) and improvement of FMD by 2.53% (p=0.01); while supplementing 
lycopene was associated with significant reduction in SBP by 5.66 mmHg (p=0.002), but its 
effects on other markers of endothelial function has not been fully investigated.  
These literature reviews informed further research in this PhD programme. Previous RCT 
investigating the effects of tomato consumption have focused only on red tomatoes, red-
tomato products, or lycopene supplementations, and the effects of different tomato varieties 
on markers of cardiovascular risk had not been previously evaluated, and was therefore 
identified as a gap in the literature. With new varieties of tomato available to the public, it is 
important to evaluate whether other varieties exert the same effect, and this was the aim of 
further work on this research programme.  
A 12-week, cross-over, randomised controlled dietary interventional study was undertaken 
to compare the effects of supplementing 300 g of two tomato varieties, red cherry tomato 
(Piccolo) and orange cherry tomato (Oranjstar) on cardiovascular health. Overall, this study 
provided evidence on the benefits of consumption Piccolo, for four weeks, has a significant 
impact on reducing both nighttime ambulatory SBP by 4.52 mmHg (p=0.039) and DBP by 
3.82 mmHg (p=0.016), improving FMD by 3.43% (p=0.026), while Oranjstar has significant 
impact on reducing adhesion molecules sICAM-1, sVCAM-1 and E-selectin by 59.14 ng/mL 
(p<0.001), 67.35 ng/mL (p=0.003) and 6.65 ng/mL(p<0.016) respectively. Therefore, 
lowering the risk of cardiovascular disease in healthy, particularly in older, adult males.  
The findings reported in the present thesis could be valuable to different health professionals 
to develop more effective interventions and could also help the public to make better 
informed food choices relating to cardiovascular health.  
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   Chapter 1 
1 
Chapter 1 Introduction 
1.1 Cardiovascular Diseases: Aetiology and Epidemiology 
1.1.1 Definition of cardiovascular diseases 
Cardiovascular diseases (CVD) commonly involve the degeneration and interruption of 
arteries which subsequently result in inadequate supply of blood to the heart muscle 
(coronary heart disease, CHD), the brain (cerebrovascular disease) and the extremities, 
especially lower limbs (peripheral vascular disease) (Figure 1.1) (Frayn et al., 2005). 
 
Figure 1.1 Types of Cardiovascular diseases. 
 Coronary heart disease (CHD) 
CHD, also known as ischaemic heart disease (IHD), is the most common type of CVD 
(Townsend et al., 2015). CHD is a condition in which coronary arteries supplying blood to 
the heart muscle become thickened by a build-up of atheroma; a deposit of fatty material 
and/or scar tissue in the lining of the arteries wall. Constriction or blockage of coronary 
arteries interrupts the supply of blood to the heart muscle (the myocardium) and produces 
chest discomfort and pain on exertion, known as angina (Townsend et al., 2015). In more 
severe cases, when the fibrous cap covering the plaque ruptures, exposing the underlying 
tissue and lipid to the circulation, thrombosis (blood clotting) may occur within arteries and 
obstruct the blood flow completely, causing a heart attack (myocardial infarction, MI) 
(Bentzon et al., 2014). Sudden cardiac death may be due to MI or cardiac arrhythmia 
(irregular heart rate). Stress or illness may aggravate cardiac arrhythmia which is more 
common and more frequently lethal for those individuals who have IHD or any other causes 
of cardiac dysfunction such as hypertension or excess alcohol consumption. Therefore, the 
main risk factors observed for cardiac arrhythmia and sudden cardiac death are similar 
(Frayn et al., 2005).  
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 Cerebrovascular diseases 
Cerebrovascular disease involves disorders of the arteries which supply the brain and the 
meninges (membranes covering the brain), causing a stroke or transient ischaemic attack 
(TIA). Stroke occurs when the blood flow to the brain is interrupted, causing damages to 
brain cells. Therefore, a stroke may affect body function permanently. TIA, also known as a 
mini-stroke, is a temporary disruption in blood supply causing non-permanent damage to the 
brain and the associated symptoms usually disappear within 24 hours. 
There are two types of stroke, haemorrhagic stroke and ischaemic stroke. Haemorrhagic 
stroke occurs when a blood vessel in the brain bursts and the pressure of the leaked blood 
damages brain cells. High blood pressure (hypertension) is a major risk for haemorrhagic 
stroke (Frayn et al., 2005). Ischaemic stroke, which is the most common type of stroke in 
Western countries, is a blockage of the blood supply to the brain. The reduced blood supply 
to a specific region of the brain may lead to irreversible damage to that part of brain tissue. 
The blockage most commonly begins from the process of thromboembolism, in which a 
blood clot is formed in the carotid artery and is subsequently lodged into other sites and 
impedes blood flow within the brain (cerebral arteries). Atherosclerotic plaques narrowing 
the intracerebral arteries may also increase the risk of blood clot formation. The main risk 
factors for stroke are thus similar to those for CHD (Frayn et al., 2005).  
 Peripheral vascular disease (PVD) 
The narrowing of arteries supplying other regions excluding the myocardium and brain is 
classified as peripheral vascular disease (PVD). It commonly occurs in the arteries supplying 
blood to the lower limbs, resulting in pain on exertion (claudication). More seriously, 
inadequate blood supply may lead to the death of limb tissues, which may require amputation 
(Frayn et al., 2005). Functional PVD and organic PVD are the main types of PVD. 
Functional PVDs do not cause defects in blood vessel structure, while organic PVDs are 
caused by structural changes in the blood vessels, including inflammation and tissue damage. 
Peripheral artery disease (PAD) is a type of organic PVD caused by the build-up of fatty 
deposits (atherosclerosis) in the inner walls of arteries supplying blood to parts of the body 
(Townsend et al., 2015).  
According to the Quality and Outcomes Framework (QOF) data (2013/14) in the UK, around 
13.8% of people lived with hypertension, 3.4% with CHD, 1.8% with stroke, 1.6% was 
diagnosed with atrial fibrillation (AF), 0.7% of people lived with heart failure and 0.7% 
suffered from PAD (Table 1.1).  
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Table 1.1 Prevalence of cardiovascular conditions in the UK (2013/14). 
Total UK population 66953292 100.0% 
Hypertension  9252607 13.8% 
CHD  2286532 3.4% 
Stroke  1184551 1.8% 
Atrial Fibrillation  1063093 1.6% 
Heart Failure 492814 0.7% 
PAD 446018 0.7% 
1.1.2 Epidemiology of CVD 
Worldwide, mortality due to CVD is still prominent, even though when cardiovascular 
medicine has advanced in the past few decades (Oikonomou et al., 2016). Among the top 25 
causes of death in the world in both 1990 and 2010, IHD and stroke were the top two causes 
of death during this period, the percentage change in numbers of deaths with stroke and IHD 
remarkably increased by 26% and 35% respectively (Figure 1.2) (GBD 2010 Causes of 
death Collaborators, 2012). The top three leading causes of years of life lost (YLLs) globally 
were IHD, lower respiratory infections and stroke in 2010; the total number of YLLs from 
IHD and stroke increased by 28% and 177% respectively in the interval of 1990-2010 
(Figure 1.3) (GBD 2010 Causes of death Collaborators, 2012). Globally, in 2015, 39.5 
million, or 70% of global deaths (56.4 million) were due to non-communicable diseases 
(NCDs) (World Health Organization, 2016). CVD were the leading causes of NCDs deaths 
(17.7 million deaths, or 45% of all NCDs deaths), and represented 31% of global deaths 
(World Health Organization, 2016) (Figure 1.4). In the UK, CHD and stroke were the main 
forms of CVD, CHD being the largest single cause of death; 45% of CVD deaths were 
caused by CHD and 25% were caused by stroke in 2014 (Townsend et al., 2015). 
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Figure 1.2 Global death ranks with 95% UIs for the top 25 causes in 1990 and 2010, and the percentage change with 95% UIs between 1990 and 2010. 
(GBD 2010 Causes of death Collaborators, 2012).  
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Figure 1.3 Global years of life lost (YLLs) ranks with 95% UIs for the top 25 causes in 1990 and 2010, and the percentage change with 95% UIs between 1990 and 2010. 
(GBD 2010 Causes of death Collaborators, 2012).  
   Chapter 1 
6 
 
Figure 1.4 Global deaths in 2015 for individuals. 
 
The largest causal category among CVD deaths was CHD (13.1%), closely followed by 
stroke (11.9%) (Table 1.2). Together, CHD and stroke killed an estimate of 14.1 million 
people in 2015, which was a quarter of the global deaths that year, compared with one in 
five deaths worldwide 20 years earlier (World Health Organization, 2015). 
Table 1.2 Global death population caused by CVD in 2015. 
Total Global death (million) 
Population (millions) % total 
56.4 100.0% 
Non-Communicable Diseases (NCDs) 39.5 70.0% 
  CVD  17.7 31.4% 
   CHD deaths 7.4  13.1% 
    Stroke deaths 6.7  11.9% 
The burden of CVD was rising disproportionately among lower income countries and 
populations. Over three quarters of NCDs deaths, 30.7 million, occurred in low and middle-
income countries in which early death are high with about 48% of deaths happening before 
the age of 70 years (World Health Organization, 2016).  
The burden of CVD was not only reflected in the mortality rate, but also by non-fatal 
cardiovascular events and their long-term consequences of having survived a damaging heart 
attack or stroke on health and social service (Dahlöf, 2010). According to British Heart 
Foundation (BHF), in the UK, over 1.2 million people have survived a stroke and nearly 
200,000 hospital visits were due to heart attacks and at least 7 out of 10 people survived 
(Townsend et al., 2015). The total healthcare costs of CVD in the UK in 2014 were estimated 
at £9 billion (Townsend et al., 2015). Therefore, the prevention and management of CVD 
are major public health challenges. 
Communicable 
Diseases, 16.9 million; 
30%
Other NCD, 7.5
million; 13%
Cancers, 8.8 million; 
16%
Diabetes, 1.6 million; 3%
CVD, 17.7
million; 31%
Respiratory 
Diseases, 3.9
million; 7%
NCDs, 39.5 million; 
70%
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1.1.3 Pathogenesis of CVD 
CVD, influencing the coronary, cerebral or peripheral arteries, involve the same 
pathophysiology: atherosclerosis and thrombosis, with the addition of changes to the 
function of the blood vessel lining (Frayn et al., 2005). Atherosclerosis is the chronic 
deposition of inflammatory plaques in blood vessel wall leading to hardened and narrowed 
blood vessels. This is the first step in development of CVD (Figure 1.5) (Kraakman et al., 
2016; Ray et al., 2014). 
 
Figure 1.5 Illustration of Inflammation in Atherosclerosis.  
(Libby, 2002). 
Lipid, especially low-density lipoprotein (LDL) cholesterol, from the circulation enters the 
intima (subendothelial space) through the endothelium (Bentzon et al., 2014). LDL-
cholesterol is susceptible to be attacked by free radicals or other reactive oxygen species and 
becomes oxidised-LDL (oxLDL) upregulating adhesion molecules and cytokines which 
recruit monocytes and T-lymphocytes (Palmefors et al., 2014). Monocytes uptake oxLDL 
and differentiate to macrophages. As macrophages fail to break down the oxLDL, they 
become lipid-laden foam cells after taking up numerous amounts of oxLDL and continue to 
accumulate in the intima, developing an atherosclerotic plaque (Libby et al., 2011). The 
growth of plaque stimulates inflammatory responses including the secretion of cytokines, 
which stimulates proliferation and migration of smooth muscle cells to the plaque and 
collagen accretion causing the narrowing of arteries, known as fibrous cap or fibrin cap 
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(Figure 1.5). Plaques with gradual accumulation of foam cells have a thicker fibrous cap on 
the lesion matures plaques, which tend to be stable and are not prone to rupture. However, 
if the plaque grows more quickly as a result of more rapid lipid deposition which have thinner 
fibrin caps then it is susceptible to rupture. When a plaque ruptures, it initiates acute 
thrombosis by activating platelets and the clotting cascade (Libby, 2002). 
1.1.4 Endothelial function in cardiovascular disease 
The vascular endothelium is one of the largest organs by area lining inside the surface of 
blood vessels in both arteries and veins. The vascular endothelium has a main role in the 
pathophysiology of diseases such as atherosclerosis, diabetes and hypertension, which 
consequently translates into cardiovascular mortality and morbidly. It is an active flattened 
monolayer cell regulating the blood flow in micro- and macrovascular of the body and is 
recognised to be essential to the regulation of vascular homeostatic and organ perfusion (Ray 
et al., 2014). The endothelial layer secretes numerous vasoactive mediators regulating a state 
of balance in vascular tone, cell growth, vascular homeostatic, leucocyte adhesion, 
thrombosis, and platelet aggregation (Donato et al., 2015). The endothelium senses and 
responds to local mechanical stimuli and metabolic conditions through complex cell 
membrane receptors and signal transduction mechanisms, leading to the synthesis and 
release of mediators, such as nitric oxide and Prostaglandin. Nitric oxide (NO) in particular 
has an important role in protecting against the initiation and progression of atherosclerosis. 
NO has vasodilatory activity and inhibitory activity against growth of vascular smooth 
muscle cell, nuclear transcription of cell adhesion molecules, platelet aggregation and 
leukocyte adhesion to vascular endothelial cells (Ray et al., 2014; Tomiyama and 
Yamashina, 2010).  
 Nitric Oxide synthase (NOS) 
Nitric oxide (NO) is a highly reactive, diffusible and dissolved gas with vasodilator 
properties through the guanylate cyclase-cGMP-PKG pathway and synthesised from L-
arginine by nitric oxide synthase (NOS) (Figure 1.6); NOS comprises of three enzyme 
isoforms, the neuronal (nNOS, NOS I), the inducible (iNOS, NOS II) and endothelial NOS 
(eNOS, NOS III) forms (Levick, 2010). The nNOS, predominantly expressed in the central 
and peripheral nervous systems, mediates central control of BP, smooth muscle relaxation, 
and vasodilatation and penile erection via peripheral nitrergic nerves (Forstermann and 
Sessa, 2012). The iNOS is mostly expressed in the immune system cells, such as 
macrophages, and expression of iNOS is only induced by bacterial infection and secretion 
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of cytokines such as tumour necrosis factor alpha (TNF-α) (Leifeld et al., 2002). The eNOS 
is constitutively expressed in endothelial cells mediated vasodilation in response to shear 
stress exerted by flowing blood and agonists such as ACh and substance P (Figure 1.6) 
(Levick, 2010). 
 
Figure 1.6 Regulation of NO production and its effects on neighbouring vascular smooth muscle. 
eNOS, endothelial nitric oxide synthase; ER, endoplasmic reticulum; GTP, guanylyl 
triphosphate; cGMP, cyclic guanosine monophosphate; PDE-5, phosphodiesterase 5 
(inhibited by sildenafil, Viagra); PI-3 kinase, phosphatidyl inositol-3 kinase; PKB, 
protein kinase B (akt); BKca, big calcium-activated potassium channel; ROC Ca2+, 
receptor-operated Ca2+channel; SOC Ca2+, store-operated Ca2+ channel; PLC, 
phospholipase in membrane; IP3, cytosolic trisphosphate; DAG, diacyl glycerol. 
(Levick, 2010). 
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 Synthesis of NO from NOS 
All NOS monomers include a C-terminal reductase domain and N-terminal oxygenase 
domain (Figure 1.6). The C-terminal reductase domain is structurally homologous to 
cytochrome P450 reductase (CPR) containing a reductase domain including flavin adenine 
dinucleotide (FAD), flavin mononucleotide (FMN) and nicotinamide adenine dinucleotide 
phosphate (NADPH) (Forstermann and Sessa, 2012). The N-terminal oxygenase domain 
contains a ferric heme complex and binding sites for tetrahydrobiopterin (BH4) and arginine. 
The C-terminal reductase domain and N-terminal oxygenase domain are connected via a 
calmodulin (CaM)-binding amino acid sequence (Forstermann and Sessa, 2012). The NOS 
enzymes synthesises NO in two sequential monooxygenase reactions. Firstly, L-arginine is 
hydroxylated to N-hydroxy-L-arginine. Secondly, N-hydroxy-L-arginine is subsequently 
further oxidised to generate NO and L-citrulline (Andrew and Mayer, 1999). Electrons 
derived from the NADPH are transferred to the flavins (FAD and FMN) in the C-terminal 
reductase domain and CaM transfers electrons to the heme complex located in the oxygenase 
domain. The conversion from a ferric (Fe3+) to ferrous (Fe2+) heme allows the binding of 
oxygen to synthesise NO (Figure 1.7) (Forstermann and Sessa, 2012). Ca2+ interacts with 
CaM (Ca2+-calmodulin complex) which enhances nNOS and eNOS activity and hence NO 
synthesis (Figure 1.6) (Levick, 2010). For iNOS, due to a different amino acid structure of 
the CaM-binding site, CaM already binds at extremely low intracellular Ca2+ concentrations, 
thus iNOS is not regulated by intracellular Ca2+ concentrations (Levick, 2010). 
 Physiological function of NO 
NO released by the eNOS is one of the major determinants of vascular tone, vascular smooth 
muscle cell (VSMC) proliferation, platelet and leukocyte aggregation and adhesion to the 
vascular wall (Forstermann and Sessa, 2012). 
There are two mechanisms of NO action in vasodilation, cGMP dependent and cGMP 
independent. The eNOS derived NO is highly membrane permeable and freely diffuses to 
neighbouring VSMC binding the haem group of soluble cytosolic soluble guanylate cyclase 
(Levick, 2010). As NO is chemically similar to O2, it has high affinity for haem and activate 
guanylate cyclase to synthesise cyclic guanosine monophosphate (cGMP) from guanylyl 
triphosphate (GTP) (Figure 1.6). cGMP then activates cGMP-dependent protein kinase 
(cGMP-PKG) which promotes vascular relaxation. NO can also regulate intracellular Ca2+ 
levels. High concentrations of NO directly activate conductance BKCa channels in the 
smooth muscle membrane reducing intracellular Ca2+ concentrations which hyperpolarises 
the smooth muscle leading to vascular relaxation (Figure 1.6) (Levick, 2010). 
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The eNOS-derived NO reduces the expression of monocyte chemoattractant protein (MCP-
1) and inhibits the leukocyte adhesion to vascular endothelium and migration into the intima 
by inhibiting CD11/CD18 expression on leukocytes (Forstermann and Sessa, 2012). 
Furthermore, NO decreases permeability and uptake of lipoprotein into vascular wall via 
endothelium and inhibition of lipoprotein oxidation. This protects against the onset of 
atherogenesis, an early stage in the development of atherosclerosis (Libby et al., 2011). 
In addition, NO released towards the vascular wall can protect against thrombosis by 
inhibiting platelet aggregation and adhesion to the blood vessels which is an early phase of 
atherogenesis. NO also inhibits the release of platelet-derived growth factors stimulating 
VSMC proliferation (Forstermann and Sessa, 2012). In addition, NO also inhibit the 
migration of VSMC to the plaque and collagen accretion causing the narrowing of arteries 
(Forstermann and Sessa, 2012). This protects against the final stage of atherogenesis (Libby 
et al., 2011). 
 
Figure 1.7 Structure and catalytic mechanisms of NOS. 
FAD, flavin adenine dinucleotide; FMN, flavin mononucleotide; NADPH, 
nicotinamide adenine dinucleotide phosphate; e-, electron; L-Arg, L-arginine; CaM, 
calmodulin; BH4, tetrahydrobiopterin; Fe3+, ferric; Fe2+, ferrous.  
(Forstermann and Sessa, 2012). 
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1.1.5 Endothelial dysfunction  
Physical or biochemical injury coupled with genetic predisposition can lead to impaired 
production or dysregulation of pivotal mediators of NO (Mudau et al., 2012). Excess 
production of reactive oxygen species (ROS) is one fundamental change that triggers 
vascular endothelial dysfunction which is a pathologic state characterised by reduced NO 
bioavailability due to increase the production of reactive oxygen species (ROS) and 
superoxide anion radical. L-arginine and the cofactors BH4 and FAD are readily oxidised in 
the presence of ROS (Figure 1.7). As discussed above, L-arginine and the cofactors BH4 
and FAD, are necessary for the production of NO by the eNOS; eNOS uncoupling occurs 
under lower than optimal concentrations of these substrates (Forstermann and Munzel, 
2006). When uncoupling of eNOS occurs, eNOS switches its function from a primarily NO-
synthesizing enzyme, to a superoxide-producing enzyme generating superoxide anion 
radical (O2-•) (Forstermann and Sessa, 2012), and thus it exacerbates endothelial oxidative 
stress levels. Decreased NO production results in a proinflammatory and expression of 
proadhesive phenotype with the loss of the ability of the endothelial cells to interact with 
each other (Comba et al., 2016). Furthermore, endothelial dysfunction enhances LDL 
oxidation, vasoconstriction, upregulate the expression of adhesion molecules, increases 
cytokine secretion, pro-coagulative, increases cellular permeability, and promotes the 
proliferation and migration of VSMC (Comba et al., 2016; Donato et al., 2015; Mudau et 
al., 2012). Therefore, endothelial dysfunction is one of the initial steps in the development 
of atherosclerotic lesion formation and progression, as well as pathogenesis of 
atherosclerosis.  
In addition to traditional risk factors, blood pressure and blood lipid, endothelial dysfunction 
is a significant predictor of atherosclerosis, CVD and cardiovascular events (Seals et al., 
2014). Thus, a direct measure of endothelial function may provide a powerful tool to guide 
diagnosis, treatment, and prognosis of patients with pre-existing CVD. There are several 
non-invasive assessments to measure the vascular function. 
 Endothelial-dependent vasodilation – Flow mediated dilation (FMD) 
Flow mediated dilation (FMD) is the most commonly used method for measuring EF 
(Mahmud and Feely, 2001). It involves ultrasonic measurement of brachial artery dilation in 
response to increased blood flow (five- to sevenfold) and shear stress generated by 
hyperaemia of the brachial artery (Flammer et al., 2012). Although it is unusual for the 
brachial artery to have significant atheroma, the brachial artery is of similar size to coronary 
arteries. The responses of brachial artery on hyperaemic stimulus have been shown to 
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correlate with responses in the coronary circulation (Takase et al., 1998). The hyperaemic 
stimulus is commonly induced through inflation of a pneumatic cuff. On deflation of the 
cuff, the increased blood flow results in shear stress, which activates eNOS to release NO. 
The NO diffuses to the vascular smooth muscles, resulting in vasodilation (Arrebola-Moreno 
et al., 2012). FMD is measured as the percentage change in the diameter of the brachial 
artery from baseline to the maximum increase in diameter. FMD is mediated by NO and 
impaired by classical risk factors for CVD. FMD is a widely used non-invasive 
measurement, but it is technically demanding and requires considerable training, expertise 
and expensive equipment for its assessment. 
 Arterial stiffness – Pulse Wave Velocity (cf-PWV) and Pulse Wave Analysis 
(PWA) 
Arteries, with elastic walls, are able to buffer rapid changes in blood volume taken up during 
systole is returned during diastole (Avolio, 2013). Arterial stiffness, also known as the loss 
of arterial elasticity, which is an important in the pathophysiology of CVD and manifestation 
of vascular ageing (Frayn et al., 2005). The loss of elasticity of the artery wall leads to 
stiffening of the conduit vessels, reducing arterial storage capacity as well as increasing the 
speed of the propagating pulse along the blood vessel wall (Avolio, 2013). For a given 
ventricular stroke volume, increases in arterial stiffness is a major contributor of high pulse 
pressure due to the combined influence on the capacitive effects of the artery wall to absorb 
the pulsatile energy and the wave propagation effects that influence peripheral wave 
reflection (Avolio, 2013).  
Pulse wave velocity (PWV), a direct measure of arterial stiffness, is calculated as the 
propagation speed of pulse wave in the artery by simultaneously detecting the arrival of the 
wave at both locations with gating to a contemporaneously electrocardiogram (Arrebola-
Moreno et al., 2012; McCall et al., 2011). Thus, PWV, which is used to directly measure the 
regional stiffness, is generally accepted as the simplest, most robust, reproducible and non-
invasive method of detecting arterial stiffness. Aortic PWV is the gold standard for assessing 
arterial stiffness as aorta makes the largest contribution to the buffering function and is 
responsible for most of the pathophysiological effects of arterial stiffness (Chen et al., 2017). 
Aortic PWV is usually measured between the carotid and femoral artery (cf-PWV) 
(Tomiyama and Yamashina, 2010). Increased propagation speed of pulse wave is associated 
with increased arterial stiffness (Levick, 2010).  
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Pulse wave analysis (PWA) is used to measure systemic arterial stiffness indirectly and 
expressed as the augmentation index (AIx, %). Augmentation pressure is the result of the 
sum of the forward wave, which is the cardiac pressure impulse and the reflected wave 
generated by the peripheral vascular system at the interface between large arteries and 
resistance vessels (arterioles) (Arrebola-Moreno et al., 2012). AIx is calculated as the 
percentage of the augmentation pressure (AG) to central pulse pressure (AP) (AG/PP) 
(Figure 1.8) (Hashimoto et al., 2008; Stoner et al., 2012). Augmentation pressure (AG) is 
the pressure difference between second systolic peak and first systolic peak (i.e. Ps-Pr in 
Figure 1.8). Central pulse pressure (PP) is the pressure difference between the maximum 
systolic pressure (Ps) and minimum diastolic pressure (Pd) (Figure 1.8). Therefore, arterial 
stiffness is associated particularly with increased systolic pressure rather than diastolic 
pressure (Keane et al., 2016; Mahmud and Feely, 2001).  
 
 
Figure 1.8 Aortic pulse pressure waveform in old healthy man. 
Pd, minimum diastolic pressure; Pf; the forward pressure wave; Ps; peak systolic 
pressure (P2); ED, left ventricular ejection duration; PP, central pulse pressure; AG, 
Augmented pressure; AIx, Aortic augmentation index (AG/PP). 
 
The location of Pf peak differs depending on the age and disease status. In young individuals, 
Pf peak is mostly the second peak (Figure 1.9A) which give negative value on AIx. This 
slow return of the reflective wave boosts coronary artery perfusion (Levick, 2010). By 
contrast, in older or hypertensive individuals, Pf peak is mostly the first peak (Figure 1.9B) 
which gives a positive value on AIx. The early return of reflecting wave increases the systole 
AG 
Pd 
Pr 
Ps 
PP (Ps-Pd) 
ED 
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pressure and therefore the left ventricle has to eject blood against an increase afterload 
(Levick, 2010). Increased arterial stiffness results in a high velocity of the forward wave as 
well as hastens the return of reflected wave (Keane et al., 2016). A high AIx is associated 
with arterial stiffness and has been shown to be a predictor of adverse cardiovascular events 
in a variety of patient populations (Shimizu and Kario, 2008).  
 
 
Figure 1.9 Pulse waveform of young healthy volunteer (A) and old healthy volunteer (B). 
Arrow show the arrival of reflective wave.  
(A)
(B)
Reflected wave
Reflected wave
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 Microvascular vasodilation – Laser Doppler Imaging (LDI) 
Laser Doppler imaging (LDI) with iontophoresis is another modern measurement of vascular 
function by assessing skin microvascular function, which measures cutaneous perfusion 
accompanied by iontophoresis of acetylcholine (ACh) and sodium nitroprusside (SNP) 
(Ferrell et al., 2002). ACh, which measures endothelium-dependent vasodilation, activates 
the endothelial nitric oxide synthase (NOS) to produce NO. SNP, which measures 
endothelium-independent vasodilation, directly causes relaxation of SMCs without the 
endothelium (Figure 1.10) (Turner et al., 2008). Iontophoresis is the use of electric current 
to drive charged chemicals into the skin. ACh, positively charged, is driven into skin at the 
positive anode while SNP, negatively charged, is driven into skin at the cathode (Ferrell et 
al., 2002). It is a safe procedure and has been used to measure blood vessel function in 
children and pregnant women successfully and without difficulty (Frayn et al., 2005). An 
infrared laser beam over the skin, which penetrates two to three millimetres below the skins 
surface and reflects light with red blood cells, produces a signal detecting the magnitude of 
blood flow. The degree of endothelial dysfunction occurring in the peripheral circulation has 
been shown to be proportional to that occurring in the coronary arteries (Turner et al., 2008).  
 
Figure 1.10 Endothelium-dependent and endothelium-independent vasodilation.  
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1.2 Risk Factors of CVD 
CVD and atherosclerosis are the results of complex interaction between environmental and 
genetic factors rather than just a single significant risk factor. However, wide differences in 
CHD incidence and mortality rates between populations or ethnic groups are not fully 
explained by their respective distribution of modifiable traditional cardiovascular risk factors 
(TCRFs) such as hypertension, dyslipidaemia, diabetes, obesity, and smoking. Indeed, some 
populations may have a higher burden of CHD than others despite similar rates of TCRFs. 
In Afro-Caribbeans, patients with CHD had higher rates of hypertension (78.7% vs 30.1%), 
hypercholesterolemia (52.8% vs 15.0%), and diabetes (53.9% vs 14.8%) and were more 
often men (64.0% vs 43.7%) and smokers (27.5% vs 13.4%) compared with non-CHD 
controls (all p<0.001) (Larifla et al., 2016). TCRFs can predict the risk of CHD in most 
populations around the world. It is estimated that in the USA population, 54% of the men’s 
and 49.6% of the women’s CVD deaths could be prevented through the complete elimination 
of increased cholesterol levels, diabetes, hypertension, obesity, and smoking (Patel et al., 
2015). Different types of cardiovascular risk scores, such as the Framingham Risk Score, the 
European Systematic COronary Risk Evaluation (SCORE) algorithm, the German 
Prospective Cardiovascular Münster (PROCAM) model, the UK QRISK2 equations, are 
used to estimate the risks of developing CVD in individuals before its clinical onset. The 
CVD risk scores mainly incorporate the effects of well-established (or traditional) risk 
factors including age, sex, blood pressure, total cholesterol, LDL-cholesterol, high density 
lipoprotein (HDL)-cholesterol, smoking status, diabetes mellitus and family history of CHD 
to estimate the prospect of developing coronary death, angina pectoris, coronary 
insufficiency or myocardial infarction in future of 10 years. All these factors were well 
established and highly related to CVD risk. These risk scores aid in decision making for 
primary prevention in individuals who have not developed the clinical manifestations of 
CVD (Karmali et al., 2017). 
1.2.1 Traditional CVD risk factors 
 Age 
Ageing is one of the non-modifiable independent predictors for CVD in risk scores in 
middle-aged persons. Starting from the age of 50, cardiovascular and circulatory diseases 
begin to rise steadily to become the largest cause of death in 2010 (Figure 1.11) (GBD 2010 
Causes of death Collaborators, 2012). As the average lifespan of humans has extended, there 
is a trend in the increase of population aged 65 and older that will continue over the next 20 
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years (North and Sinclair, 2012). In this age group, CVD result in 40% of all deaths and rank 
as the leading cause of death years (North and Sinclair, 2012). Although ageing is an 
unavoidable part of human life, many of the risks associated with ageing are modifiable. 
Therefore, it is widely acknowledged that ageing is plastic (Kirkwood, 2008) and therefore 
by targeting the modifiable factors healthy ageing is a realistic and achievable target 
(Mathers, 2015). 
 Blood lipid profile 
Blood lipid, total cholesterol (TC), LDL-cholesterol, HDL-cholesterol and triglyceride (TC), 
are well-recognised risk factors for CVD and used to predict overall CVD. Cholesterol is a 
fatty substance, found in blood and most tissues especially nerve tissues. Cholesterol, the 
main component of cell membranes, is also a precursor of many hormones and bile acid, 
synthesised mainly in the liver. As cholesterol is a lipid, it requires a transport vesicle to 
shield it from blood, which is aqueous in nature (Daniels et al., 2009). A complex of various 
proteins and lipids achieve cholesterol transport through the vascular system. These 
complexes, intuitively known as lipoproteins, are heterogeneous in size, shape, composition 
and function and are classified according to their density. Low-density lipoproteins (LDL) 
cholesterol and high-density lipoproteins (HDL) cholesterol are perhaps most frequently 
related to CVD. Homeostasis of cholesterol is centred on the metabolism of lipoproteins, 
which mediate transport of the lipid to and from tissues (Daniels et al., 2009). 
High total cholesterol (TC) was the ninth and tenth-leading risk factor attributable to 
disability-adjusted life-years (DALYs) for men and women respectively in 2015 (Figure 
1.12) (GBD 2015 Risk Factors Collaborators, 2016). A positive association between a 
reduction of 1 mmol/L of TC with lower IHD mortality was observed in both genders at 
middle age (40-49years) (HR 0.44, 95% CI 0.42 to 0.48) and older ages (70-89years) (HR 
0.83, 95% CI 0.81 to 0.85) (Lewington et al., 2007). 
LDL-cholesterol, known as “bad cholesterol”, carries cholesterol to the tissues that need it. 
Excessive accumulation of blood LDL-cholesterol at the arterial wall can lead to the build-
up of atheroma, eventually causing atherosclerosis and CVD. Lower LDL-cholesterol levels 
were independently associated with a lower IHD mortality. On average, a reduction of 1 
mmol/L of LDL-cholesterol was associated with a reduction in about a third of IHD 
mortality within every age group and in both sexes (Gupta and Smith, 2014; Lewington et 
al., 2007).  
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HDL-cholesterol, known as “good cholesterol”, carries cholesterol away from the tissues 
and delivers it back to the liver, where it is broken down and excreted in the bile (Daniels et 
al., 2009). High levels of HDL-cholesterol had cardioprotective effect, while low levels of 
HDL-cholesterol were an independent predictor of cardiovascular risk and were associated 
with an increased risk of atherosclerosis (Townsend et al., 2015). A study has shown that 
reduced HDL-cholesterol was an independent risk factor for IHD (Linton et al., 2009). On 
average, an increase of 0.33 mmol/L HDL-cholesterol was associated with a reduction of 
IHD mortality by about a third within every age group and in both genders (Lewington et 
al., 2007).  
Triglyceride (TG) is the main form of dietary fat consisting of glycerol combined with three 
fatty acids. TG plays an important role in metabolism, synthesis of hormones and building 
cells. However, high levels of TG in the bloodstream increase the risk atherosclerosis. 
Current evidence indicates that elevated TG is an independent risk factor for IHD risk among 
different ethnic groups (Linton et al., 2009). A meta-analysis of 29 studies has shown that 
there was a significant association between TG values and CHD risk in Western populations 
(Odds Ratio (OR) 1.72; 95% confidence interval (CI), 1.56 to 1.90) (Sarwar et al., 2007). 
Raised circulating TG levels were associated with increased CHD risk, adjustment for 
established coronary risk factors, especially HDL-cholesterol, substantially attenuated the 
magnitude of this association. Therefore, levels of cholesterol and related lipids circulating 
in blood are essential predictive tools employed clinically to measure risk of a cardiac event.  
In high CVD risk patients, rigorous control of blood cholesterol is recommended. The 
optimal TC target is less than 4 mmol/L, LDL-cholesterol less than 2 mmol/L, HDL-
cholesterol higher than 1 mmol/L and triglyceride less than 1.7 mmol/L (British Cardiac 
Society, 2005).
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Figure 1.11 Percentage of global deaths for male (A) and female (B) individuals in 2010 by cause and age.  
(GBD 2010 Causes of death Collaborators, 2012).
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Figure 1.12 Global disability-adjusted life-years attributable to risk factors for men (A) and women 
(B) in 2015. 
(GBD 2015 Risk Factors Collaborators, 2016). 
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 High blood pressure 
High blood pressure including both systolic blood pressure (SBP) and diastolic blood 
pressure (DBP), are directly related to the progression of CVD (Lewington et al., 2002). 
Elevated BP was a well-established risk factor for CVD. An increase of every 20 mmHg in 
SBP and 10 mmHg in DBP doubled the risk of CVD, across the BP range from SBP <115 
mmHg to >180 mmHg and from DBP <75 mmHg to >105 mmHg (Lewington et al., 2002). 
According to the WHO, normal adult BP is defined as 120/80 mmHg, while BP equal to or 
above 140/90 mmHg is indicative of hypertension. Individuals with hypertension are at four 
times the risk of developing CVD. In 2015, high SBP was the top third leading risk factors 
among other leading risks for both sexes, contributing to 9.2% (8.3 to 10.2) of DALYs for 
men and 7.8% (6.9 to 8.7) of DALYs for women (Figure 1.12) (GBD 2015 Risk Factors 
Collaborators, 2016). Additionally, from 1990-2015, high BP were the leading three risk 
factors for attributable DALYs and from 2005 to 2015, the numbers of DALYs due to high 
SBP increased 11.7% (Figure 1.13) (GBD 2015 Risk Factors Collaborators, 2016). In the 
UK, nearly 30% of adults have high BP (Townsend et al., 2015). The World Health Report 
2002 estimated that nearly 11% of all burden of diseases in developed countries were leaded 
by high BP (World Health Organization, 2002). In addition, about 49% of IHD and 62% of 
cerebrovascular disease were attributable to suboptimal SBP (>115 mmHg) (World Health 
Organization, 2002). Throughout middle and old age, usual blood pressure was strongly and 
directly related to vascular mortality. Meta-analysis of prospective data on over one million 
adults aged 40-69 years has shown that every 20 mmHg increase to normal SBP (115 mmHg) 
or 11 mmHg to normal DBP (75 mmHg), had a doubling of mortality from both IHD and 
stroke (Figure 1.14) (Lewington et al., 2002). Therefore, the WHO voluntary targets for 
NCDs have called for a 25% reduction in the prevalence of high BP by 2025 (GBD 2013 
Risk Factors Collaborators, 2015). 
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Figure 1.13 Leading 30 Level 3 global risk factors for DALYs for both sexes combined, 1990, 2005, and 2015, with percentage change in number of DALYs, and all-
age, and age-standardised rates. 
(GBD 2015 Risk Factors Collaborators, 2016).  
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Figure 1.14 Ischemic heart disease (IHD) mortality rate in each decade of age versus usual blood pressure at the start of that decade. 
(Lewington et al., 2002).  
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Compared with the traditional method of taking a BP reading under clinical setting, 
ambulatory blood pressure monitoring (ABPM) offers the ability to collect BP readings 
across a 24-Hour period which can be aggregated to yield overall 24-Hour BP pattern or 
grouped to reflect daytime and nighttime BP patterns (Turner et al., 2015). The various BP 
categorisations facilitated by ABPM are valuable for clinical management of hypertension 
since they increase accuracy for diagnosis and the prediction of cardiovascular risk (Krakoff, 
2013). In addition, ABPM enables us to rule out white-coat effect hypertension and identify 
masked hypertension (Turner et al., 2015). A meta-analysis has shown a two-fold higher 
incidence of CVD (HR 2.00, 95% CI 1.58 to 2.52) in people with masked hypertension 
compared with those with normal BP and ABP (Fagard and Cornelissen, 2007). Strong 
evidence have shown oxidative stress, inflammatory processes, endothelial dysfunction and 
subsequent vascular remodelling are associated with the pathogenesis of hypertension 
(Widlansky et al., 2003). 
1.2.2 Other risk factors 
The role of plasma lipids, especially LDL-cholesterol, in atherosclerosis showed the reason 
of elevated serum TC level has long been recognised as a predisposing factor to CVD. 
However, over the past few decades, more epidemiological evidence has highlighted the 
importance of other processes, including endothelial dysfunction, the tendency of oxidation 
in the subendothelial space, the inflammatory processes involved in formation of plaque, 
and blood clotting. In addition, recent research has been directed to identify and develop 
biomarkers, other than blood lipids, of CVD risks that could be useful in stratifying 
individuals and also in measuring the impact of interventions (Lara et al., 2015; Morrow and 
de Lemos, 2007). These biomarkers are involved at various stages of the atherosclerosis 
process.  
 Inflammation-related factors  
Inflammation is a basal element of atherogenesis through all stages of its development, from 
initiation, through progression to its thrombotic complication (Frayn et al., 2005). 
Inflammatory cytokines are protein molecules secreted by various immune cells and vascular 
cells that act as enhancing mediators for immune responses. Endothelial cells are major 
targets of cytokines that could mediate endothelial dysfunction and vascular inflammation 
(Sprague and Khalil, 2009). Cytokines promote adhesion of leukocytes to endothelial cells 
and cause an increase in vascular permeability. They also stimulate VSMC to migrate from 
the medial portion of the arterial wall towards the intima (Sprague and Khalil, 2009).  
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Interleukin-6 (IL-6) 
IL-6 is a major pro-inflammatory glycosylated cytokine released by activated leukocytes, 
adipocytes, and endothelial cells with diverse humoral and cellular immunomodulatory 
effects. IL-6, one of the plasma cytokines that stimulates the production of C-reactive protein 
(CRP) and fibrinogen, is secreted by monocytes and macrophages in inflammatory response 
(Figure 1.15) (Frayn et al., 2005). The study of Schnabel et al. (2013) found that there were 
significant associations between high levels of IL-6 and increased CVD mortality risk (HR 
1.16, 95% CI 1.01 to 1.32, p=0.03 (Schnabel et al., 2013). In addition, the study of Danesh 
et al. (2008) has shown that increased IL-6 levels were associated with progressively 
increased CHD risk (OR 1.61, 95% CI 1.42 to 1.83) (Danesh et al., 2008). 
Tumour necrosis factor alpha (TNF-α) 
TNF-α, also known as Cachectin and TNFSF1A, is a pro-inflammatory cytokine that is 
essential in the initiation of an inflammatory response. TNF-α is expressed by a variety of 
cells, including macrophages, foam cells, monocytes, T-cells, VSMCs, adipocytes, and 
fibroblasts. TNF-α regulates and interferes with lipid metabolism, suppresses free fatty acid 
(FFA) uptake, promotes lipogenesis, induces lipolysis, inhibits lipid-metabolism-related 
enzymes activity, regulates cholesterol metabolism and regulates other adipocyte-derived 
adipokines (Chen et al., 2009). In patients with hyperlipidaemia, high TNF-α levels 
correlated significantly to the concentrations of very-low-density lipoprotein (VLDL) 
cholesterol, TG and TC and negatively to HDL-cholesterol (Jovinge et al., 1998). TNF-α 
also stimulates additional cytokine and adhesion molecules expression, which increases 
plaque instability and augments VSMCs proliferation and migration (Libby, 2006). 
C-reactive protein (CRP) 
CRP, an acute phase reactant, is synthesised in the liver and is secreted in response to 
secretion of the cytokine, IL-6. However, CRP has also been found in the endothelium of 
atherosclerotic plaques, in smooth muscles cells, macrophages and in adipocytes (Figure 
1.15) (Frayn et al., 2005; Kressel et al., 2009; Ridker and Silvertown, 2008). Like other acute 
phase reactants, CRP reflects the inflammatory response to atherosclerotic damage, in 
addition to enhancing clot formation, lipid oxidation and cell activation (Frayn et al., 2005). 
CRP is a predictor of risk for CVD, even in individuals with low LDL-cholesterol levels and 
at all levels of the Framingham Risk Score (Danesh et al., 2000; Ridker and Silvertown, 
2008). Meta-analysis of a prospective study with 18,569 participants has shown that 
participants in the top third of the group (2 mg/L) with respect to baseline CRP values had 
increased risks of CHD compared with those in the bottom third (0.78 mg/L) (OR 1.45, 95% 
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1.25 to 1.68) (Danesh et al., 2004). In addition, meta-analyses of CVD mortality risk has 
shown significant associations with CRP (HR 1.31, 95% CI 1.02 to 1.68, p=0.033) (Barron 
et al., 2015). 
Fibrinogen 
Fibrinogen is the precursor of fibrin and plays a dual role in atherosclerosis as the major 
coagulation factor in the blood and a pro-inflammatory molecule (Figure 1.15) (Frayn et al., 
2005). Like CRP, fibrinogen is an acute phase reactant synthesised in liver, whose 
circulating levels can fluctuate enormously during acute responses to tissue damage or 
infection. Many studies have found that fibrinogen is a strong predictor of CHD and 
associates strongly with other inflammation factors. Meta-analysis of 18 studies with 4018 
CHD cases, comparing individuals in the top third with those in the bottom third of the 
baseline measurements yielded a combined risk ratio of 1.8 (95% CI 1.6 to 2.0), and showed 
differences in long-term usual mean fibrinogen levels of 2.9 µmol/L between the two groups 
(10.3 vs 7.4 µmol/L) (Danesh et al., 1998). 
 
Figure 1.15 Interrelationship between inflammatory risk factors. 
 
 Adhesion molecules  
Adhesion molecules are involved in the initiation and progression of atherosclerosis. They 
mediate the attachment and transmigration of leukocytes into the subendothelial space 
(Frayn et al., 2005). Endothelial dysfunction increases the expression of adhesion molecules 
which plays a crucial role in the recruitment of leukocytes to the endothelium, triggers 
transmigration of leukocyte into the subendothelial space and consequently leads to 
atherosclerosis (Comba et al., 2016). The key adhesion molecules related to atherosclerosis 
are the selectins and Immunoglobulin (Ig) superfamily (Frayn et al., 2005). Their expression 
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and therefore their concentrations are influenced by oxidised LDL and other inflammatory 
cytokines including IL-6 and TNF-α (Frayn et al., 2005). 
Selectins  
The selectins (cluster of differentiation 62, CD62) are transmembrane glycoproteins 
expressed on leukocytes (L-selectin), endothelial cells (E-selectin), and platelets (P-selectin) 
(Figure 1.15) (Krieglstein and Granger, 2001). Selectins mediate tethering and rolling of 
leukocytes on endothelial cells, platelet-leukocyte aggregation, and ultimately 
atherosclerosis (Bonaterra et al., 2010; Krieglstein and Granger, 2001). 
E-Selectin, also known as endothelial leukocyte adhesion molecule-1, ELAM-1, or CD62E, 
is expressed only on endothelial cells and after activation by inflammatory cytokines 
(Bonaterra et al., 2010). A prospective study and meta-analysis has shown a non-significant 
increase in the incidence of CHD among individuals in the top third of soluble E-selectin 
levels (75 ng/mL) compared with those in the bottom third of sE-selectin levels (52 ng/mL) 
(OR 1.08, 95% CI 0.84 to 1.39) after adjustments for age, town, smoking and risk factors 
(Malik et al., 2001). 
P-Selectin, also known as GMP-140, LECAM-3, PADGEM, and CD62P, is an adhesion receptor 
expressed on activated endothelial cells, which mediates the so called ‘rolling’ of leukocyte 
along the endothelium (Bonaterra et al., 2010). A prospective study and meta-analysis has 
shown a non-significant increase in the incidence of CHD among individuals in the top third 
of soluble P-selectin levels (150 ng/mL) compared to those in the bottom third of sP-selectin 
levels (95 ng/mL) (OR 1.02, 95% CI 0.79 to 1.32) after adjustments for age, town, smoking 
and risk factors (Malik et al., 2001). There was a positive linear association between sP-
selectin levels and the rate of incidence of CHD (HR 1.63, 95% CI 1.15 to 2.30) after 
adjustments for traditional risk factors (Bielinski et al., 2015). 
Immunoglobulin (Ig) superfamily  
The Ig superfamily, including a wide range of molecules with multiple Ig like domains, is 
relevant to CVD (Krieglstein and Granger, 2001). They play a key role in the process of 
atherosclerosis by reinforcing leukocyte binding via its integrin ligands and trans-endothelial 
migration (Bonaterra et al., 2010).  
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Intercellular Adhesion Molecule 1 (ICAM-1, CD54), a glycoprotein receptor, is part of the 
Ig superfamily (Krieglstein and Granger, 2001). It functions as mediators of leukocyte 
adhesion. Expression of ICAM-1 increases during infection and upon stimulation of 
cytokines. The main binding site of ICAM-1 are the leukocyte integrins LFA-1 
(CD11a/CD18) and Mac-1 (CD11b/CD18) (Jun et al., 2001). Soluble forms of ICAM-1 
(sICAM-1) is generated via proteolytic cleavage and hence be detected with significantly 
raised levels under various disease states (Krieglstein and Granger, 2001). Elevated levels 
of sICAM-1 were associated with the development of atherosclerosis in healthy men 
(Pradhan et al., 2002). A prospective study and meta-analysis has shown an significant 
increase in the incidence of CHD among middle age men within the top third of sICAM-1 
levels (338 ng/mL) compared to those in the bottom third of sICAM-1 levels (261 ng/mL) 
(OR 1.49, 95% CI 1.14 to 1.94) after adjustments for age, town, smoking and risk factors 
(Malik et al., 2001). However, sICAM-1 was not associated with events of acute thrombosis 
or vessel occlusion (Malik et al., 2001).  
Vascular Cell Adhesion Molecules (VCAM-1, CD106) are part of the Ig superfamily 
(Krieglstein and Granger, 2001). They can be expressed on endothelial cells, smooth muscle 
cells, fibroblasts and macrophages. VCAM-1 binds to both α4β1 (VLA-4) and α4β7 (LPAM-
1) integrin which are expressed on all leukocytes (Bonaterra et al., 2010). VCAM-1 mediates 
the adhesion of circulating leukocytes to the endothelium and their migration into 
subendothelial spaces. Similar to ICAM-1, VCAM-1 was also associated with the extent of 
atherosclerosis (Ley and Huo, 2001). A prospective study and meta-analysis has shown a 
significant increase in the incidence of CHD among individuals in the top third of sVCAM-
1 levels (516 ng/mL) compared with those in the bottom third of sVCAM-1 levels (37 
ng/mL) (OR 1.35, 95% CI 1.05 to 1.75) after adjustments for age, town, smoking and risk 
factors (Malik et al., 2001). 
1.2.3 Behavioural risk factors 
Epidemiological evidence indicates that health-related behaviours such as smoking, a poor 
diet, excessive alcohol, or obesity, linked to fourfold increase in risk for dying early. The 
mortality risk for those with four compared to zero health behaviours was equivalent to being 
14 years younger in chronological age (Khaw et al., 2008).  
In developed countries, around 12% of major burdens of disease were caused by tobacco 
smoking which was the top leading risk (World Health Organization, 2002). Tobacco 
smoking increases risk of CHD by elevating blood pressure and the tendency of blood 
clotting while lowering exercise tolerance and blood levels of HDL-cholesterol (Townsend 
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et al., 2015). One 50 years cohort study has shown that the risk of CHD mortality of a current 
Smoker was around 60% higher compared to a lifelong non-smoker (Doll et al., 2004). In 
England in 2013, around 17% (estimated 78,200) of deaths among adults aged 35 and over 
were attributed to smoking, including around 13% (estimated 16,700) of deaths from 
circulatory diseases (Health and Social Care Information Centre, 2015). 
Physical activity means all forms of physical movement including activities of daily life and 
exercise (Frayn et al., 2005). A physically inactive lifestyle contributes to traditional 
cardiovascular risk factors, such as high BP, higher triglycerides, lower HDL-cholesterol, 
diabetes and obesity (Townsend et al., 2015). Physical activity has also been shown to 
decrease levels of novel cardiovascular risk factors and improve EF, such as IL-6, sICAM-
1 and sVCAM-1 (Palmefors et al., 2014). Physical activity was associated with a 35% 
reduction in CVD mortality and 33% reduction in all-cause mortality in comparison with 
sedentary lifestyle (Nocon et al., 2008). Compared with low physical activity, moderate and 
high physical activity were associated with graded reduction in mortality (hazard ratio 0.80, 
95% CI 0.74-0.87 and 0.65, 0.60-0.71; p<0.0001 for trend), and major CVD (0.86, 0.78-
0.93; p<0.001) (Lear et al., 2017). 
 Dietary patterns  
Dietary patterns also influence risk of CVD and associate strongly with other cardiovascular 
risk factors. Dietary habits in developing countries have changed from consumption of 
carbohydrate rich foods with modest fat content to, the so-called “Western” diet with a high 
amount of meat and milk products. Western diet tends to include high intakes of saturated 
fatty acid (SFA), trans-fat, salt, free sugar and excess calories; conversely, intakes of 
polyunsaturated fatty acids (PUFA), monounsaturated fatty acids (MUFA), fibre, fruit and 
vegetables are insufficient (Martin et al., 2012). A poor diet comprising high intakes of 
saturated fatty acids, trans fatty acids and free sugar (processed starches and added sugars) 
can lead to an energy imbalance, where energy intake is greater than energy expenditure, 
thus resulting in overweight and obesity (Romieu et al., 2017). Obesity is also a driver of 
cardiovascular risk. In developed countries, over 7% of all disease burden was caused by 
raised body mass index (BMI) (World Health Organization, 2002). It associates with other 
cardiovascular risk factors, such as hypertension, diabetes, and high cholesterol. Around a 
third of CHD and ischaemic stroke and almost 60% of hypertensive disease in developed 
countries was due to overweight (World Health Organization, 2002). In 2012, more than 
75% of mortality caused by CVD in developing countries was driven by the changes of 
industrialisation, urbanisation, related lifestyle changes, and dietary habits (Dahlöf, 2010; 
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Gupta et al., 2016). A diet with a low intake of fruit and vegetables was estimated to cause 
about 31% of CHD and 11% of stroke worldwide; overall, low fruit and vegetables intake 
contributed to 2.7 million (4.9%) deaths and 26.7 million (1.8%) of DALYs respectively and 
of those burdens that were attributable to low fruit and vegetable intake, about 85% was from 
CVD and 15% from cancers (World Health Organization, 2002). Contrastingly, higher 
consumption of total fruit and vegetable was inversely associated with major cardiovascular 
disease, myocardial infarction, cardiovascular mortality, non-cardiovascular mortality, and 
total mortality in the models adjusted for age, sex, and centre (Figure 1.17) (Miller et al., 
2017). Lock et al. (2005) estimated that inadequate consumption of fruit and vegetable 
contributed to 2.6 million deaths per year around the world and increasing fruit and vegetable 
to 600 g/d could reduce 1.8% of total global burden of disease. Globally, 31% and 19% of 
IHD and ischaemic stroke could be reduced by achieving this dietary target (Lock et al., 
2005). Therefore, a healthy dietary pattern and eating habits can reduce the burden of CVD. 
There are different types of healthy dietary patterns such as Japanese diet, the traditional 
Asian diet and the Mediterranean diet (MD). Among these dietary patterns, MD has received 
the most attention. The MD is characteristic of populations from countries bordering the 
Mediterranean Sea, including Italy, France, Greece, and Spain. Although the MD varies by 
region, it is largely based on vegetable, fruit, nuts, beans, cereal grains, olive oil and fish. 
A meta-analysis of 15 studies has shown a significant reduction in total cholesterol in those 
trials describing the intervention as a MD (-0.23 mmol/L, 95% CI -0.27 to -0.2) when 
compared with control (-0.06 mmol/L, 95% CI -0.13 to 0.01) (Rees et al., 2013). A 
prospective cohort study has shown that higher adherence to a MD (higher Mediterranean 
diet score) was associated with a statistically significant reduction in total mortality (0.864, 
95% CI 0.802 to 0.932). When vegetables were excluded from the Mediterranean diet score 
of the mortality ratio, it reduced the apparent effect by 16.2% (Trichopoulou et al., 2009). It 
indicated that vegetables influence and lead to the health beneficial effects.  
However, not all fruit and vegetables have equal cardioprotective effects. Specific fruits and 
vegetables found in Mediterranean diet were individually associated with significant 
reductions of CVD. Fruit and vegetables with a high content of various antioxidants were 
suggested to have cardioprotective effects (Ruxton et al., 2006). High intake of tomato and 
lycopene have shown improvements in cardiovascular health. As mentioned in the above 
section, oxidation of LDL-cholesterol has been considered as one of the mechanisms causing 
CVD. Tomato is one of the main ingredients in the MD that plays a key role in reducing the 
prevalence of CVD. The antioxidant activity of lycopene in tomato has been investigated as 
one preventive factor of CVD (Bohm, 2012). 
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1.3 Tomato and Cardiovascular Health 
Carotenoids, the yellow, orange and red coloured pigments of several fruit and vegetables 
are one class of compounds being discussed for a long time as cardioprotective food 
ingredients (Figure 1.16) (Natalia Di Pietro et al., 2016; Voutilainen et al., 2006). 
 
Figure 1.16 Chemical structure of the main carotenoids in the human diet.
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Figure 1.17 Association of fruit intake (A) and vegetable (B) with cardiovascular outcomes and mortality (Adjusted for age, sex, and centre (random effect)). 
(Miller et al., 2017). 
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Tomatoes and tomatoes product are a rich source of carotenoids, especially lycopene in our 
diet (Bohm, 2012). Tomatoes and tomato product provided an estimated 85% of lycopene in 
the American diet and are an essential component of the MD (Basu and Imrhan, 2007). 
Tomatoes are top vegetable and vegetable products consumed in USA per capita which just 
below the consumption of potatoes, lettuce/vegetable salads and onions (FAOSTAT, 2015a). 
According to USDA’s loss-adjusted food availability data, Americans consumed 13.4 kg of 
tomatoes in 2016 and 42% (5.7 kg) of tomato were consumed in fresh and 58% (7.7 kg) 
consumed as processed tomatoes (USDA, 2018). In the UK, the average consumption of 
fresh tomatoes was 8.32 kg per capita per year (British Tomato Growers' Association, 2015) 
while the consumption of tomatoes in European countries were 14.4 kg per capita per year 
(European Commission, 2016). Among European countries, Mediterranean countries were 
particularly high consumption in tomato (Figure 1.18). 
 
Figure 1.18 Fresh tomato and tomato products consumption in 2013 (kg per capita)  
(FAOSTAT, 2015b). 
Lycopene is a polyunsaturated carotenoid with 11 liner conjugated and two non-conjugated 
double bonds. Therefore, lycopene exists in a variety of geometric isomers including all-
trans and various forms of cis-isomers (the most common are 5-cis, 9-cis, 13-cis and 15-cis) 
(Figure 1.19) (Agarwal and Rao, 2000). The all-trans conformation is the most predominant 
isomer found naturally in plants and is the most thermodynamically stable form (Shi and Le 
Maguer, 2000). When exposed to heat during food processing, especially with the presence 
of fat, lycopene is converted to cis-isomer forms (Kong et al., 2010). Apart from food 
processing, under acidic condition in gastric milieu also enhance isomerisation of the all 
trans lycopene to cis-isomers (Re et al., 2001). 
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Figure 1.19 Structures of all-trans and cis-isomers of lycopene.  
 
Cis-isomers of lycopene have distinct physical characteristics and chemical behaviours from 
all-trans-form, including decreased colour intensity, lower melting points, greater polarity, 
lesser tendency to crystallisation, and greater solubility in oil and hydrocarbon solvents 
(Edge and Truscott, 2018). Cis-lycopene isomers are more readily absorbed by enterocytes 
and preferentially accumulate in tissues than all-trans lycopene due to the reduced length of 
cis-isomers more readily allows them to be incorporated into micelles and cis-isomers less 
readily form crystals, severely increase their uptake by micelles (Boileau et al., 2002). As 
well as influencing lycopene absorption via isomerisation of trans- to cis-form, food 
processing may improve its bioavailability by breaking down cell walls, which weakens the 
bonding forces between lycopene and the tissue matrix, thus making lycopene more 
accessible (Shi and Le Maguer, 2000).  
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The highly conjugated double bonds give lycopene antioxidant properties scavenging radical 
species (R•) such as singlet oxygen (1O2) and peroxyl radical (ROO•) (Edge and Truscott, 
2018). The mechanism of action for lycopene towards the radical species (R•) scavenging 
activity were predicted through three possible mechanisms: (I) Radical adduct formation 
(RAF), (II) electron transfer (EF) to the radical and (III) Hydrogen atom transfer (HAT) 
(Galano and Francisco-Marquez, 2009). 
I. Radical adduct formation (RAF):  R• + Lycopene ® [R-Lycopene]• 
II. Electron transfer (EF):   R• + Lycopene ® R- + Lycopene•+ 
III. Hydrogen atom transfer (HAT):  R• + Lycopene ® RH + Lycopene(−H)• 
 
Among all of the carotenoid pigments, lycopene is the most potent singlet oxygen quencher 
(Sinha and Dua, 2015). In vitro study, singlet oxygen quenching ability of lycopene was 
found to be twice more than that of β-carotene and 10 times more than that of α-tocopherol 
(Shi and Le Maguer, 2000). The potent antioxidant chemical properties of lycopene enable 
to inhibit LDL oxidant, which is central to the initiation of atherosclerosis.  
Accumulating epidemiological findings have established that high consumption of tomato 
(4.4 servings/day) (Jacques et al., 2013) and lycopene (1450-7900 µg/day) (Hirvonen et al., 
2000; Jacques et al., 2013) inversely associated with CVD and mortality. High plasma 
lycopene level (0.27-0.45 µmol/L) has been associated with reductions in CVD risk (Ford et 
al., 2014; Hirvonen et al., 2000; Rissanen et al., 2001) and has also been reported to improve 
biomarkers associated with CVD, including LDL-cholesterol, interleukin-6, flow mediated 
dilation (FMD), and systolic blood pressure (SBP) in healthy population (Cheng et al., 2017).  
1.4 Research Questions Raised from The Present Chapter 
The work described in this chapter raised the following questions: 
1. What is the epidemiological evidence on tomato consumption and its association 
with CVD risk? 
2. What is the epidemiological evidence on lycopene consumption and its association 
with CVD risk? 
These questions will be addressed in Chapter 2 by systematically and quantitatively 
evaluating the evidence from epidemiological cohort studies reporting the associations 
between tomato intake and risk of CVD. We hypothesised that lycopene and tomato may 
play a beneficial role in preventing cardiovascular diseases and early death. 
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Chapter 2 Lycopene and Tomato and Risk of Cardiovascular Diseases: A Systematic 
Review and Meta-Analysis of Epidemiological Evidence 
This study was designed to answer the research questions in section 1.4.  
This chapter is presented as originally published in: Critical Reviews in Food Science and 
Nutrition 2017; 1-18. 
2.1 Introduction 
Low intakes of fruit and vegetables are important global risk factors for the development of 
morbidity, acceleration of the ageing process and occurrence of early mortality (GBD 2015 
Risk Factors Collaborators, 2016). A number of epidemiological studies of disease endpoints 
provide strong and consistent evidence for a beneficial effect of fruit and vegetables, 
combined or separately, on cardiovascular health (Mozaffarian et al., 2011). Fruit and 
vegetables intake in the range commonly recommended (e.g. >5 servings) is associated with 
a 21 to 26% reduction in the risk of stroke (He et al., 2006; Hu et al., 2014) and 17 to 25% 
in the risk of CHD (Dauchet et al., 2006; He et al., 2007; Ness and Powles, 1997). 
In addition, epidemiological studies have shown that specific fruit and vegetables are 
individually associated with significant reductions for different types of cancers. On this 
area, recent systematic reviews and meta-analyses of epidemiological studies have reported 
that higher consumption of tomato products is associated with a significantly reduced risk 
of gastric cancer (27%) (Yang et al., 2013). Tomato is a rich source of lycopene, a major 
carotenoid in human plasma with strong antioxidant properties (Mein et al., 2008). Both 
higher consumption of, and higher blood levels of, lycopene, are also associated with a lower 
risk of prostate cancer (Chen et al., 2013b; Chen et al., 2015b; Etminan et al., 2004). These 
findings have triggered an interest on the effects of lycopene and tomato consumption on 
health outcomes. 
A recent systematic review of interventions trials by our group has shown that tomato or 
lycopene supplementation successfully improved important cardiovascular risk factors, 
including LDL-cholesterol, interleukin-6, flow mediated dilation (FMD), and systolic blood 
pressure (SBP) in healthy population (Cheng et al., 2017). In addition, observational cohort 
studies seem to add support by reporting positive associations between higher tomato and/or 
lycopene intake or status and lower risk of cardiovascular diseases (CVD) (Jacques et al., 
2013). 
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A previous meta-analysis on the association of lycopene and stroke reported a reduction in 
risk of stroke (19.3%) only (Li and Xu, 2014). However, it is now 4 years old and further 
epidemiological evidence on consumption of lycopene and tomatoes associated with other 
CVD and mortality are likely to be available. Therefore, here we present an updated 
systematic review of the literature and meta-analysis on the associations between lycopene 
or tomato consumption and CVD risk and mortality in epidemiological studies. In addition, 
the present systematic review aimed to explore the impact of important covariates as 
potential sources of heterogeneity in studies.  
2.2 Methods  
This systematic review was undertaken following standard guidance by the Cochrane 
collaboration (Higgins and Green, 2011) and the Centre for Reviews and Dissemination 
(Centre for Reviews and Dissemination, 2009). This manuscript is reported according to the 
PRISMA guidelines (Figure 2.1 and Appendix A1) (Moher et al., 2010). The systematic 
review protocol was registered in PROSPERO, the International Prospective Register of 
Systematic Reviews (CRD42016049526).  
In July 2017, three databases including Medline, Web of Science, and Scopus were searched 
from inception. In addition, reference lists of identified publications were screened in an 
attempt to identify further relevant studies. 
The searches included the following terms/keywords related to the exposures and outcomes 
of interest: tomato, lycopene, cardiovascular disease (CVD), coronary heart disease (CHD), 
myocardial infarction (MI), stroke, atherosclerosis, atrial fibrillation (AF), congestive heart 
failure (CHF), sudden cardiac death, mortality, and morbidity. The terms related to outcome 
measures thus included a number of conditions under the umbrella of CVD, as well as 
associated disorders such AF. Data for each of these outcomes was extracted if explicitly 
reported in the original papers. The present systematic review was restricted to articles 
published in English. 
Two authors (HMC, JL) screened articles independently for eligibility. The decision to 
include/exclude studies was hierarchical and consisted on screening firstly the titles and 
abstracts of studies; if the authors were unable to reach decision at this stage, then the full-
text of the article was evaluated. 
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2.2.1 Inclusion/exclusion criteria  
The following specific inclusion criteria were used to identify eligible articles: 1) Study 
Design: longitudinal and cross-sectional studies; 2) Subjects: Adult subjects >18 years of 
age; 3) Exposure: data related to tomato or lycopene dietary intakes or serum concentration; 
4) Outcomes: CVD morbidity and associated disorders and mortality outcomes (CVD, CHD, 
MI, stroke, atherosclerosis, AF, CHF, sudden cardiac death, mortality) expressed as Hazard 
Ratio (HR), Relative Ratios (RR), and Odd Ratios (OR) with 95% confidence interval (CI).  
Exclusion criteria included: 1) Study Design: Non-epidemiological studies; 2) Subjects: 
Subjects <18 years of age; 3) Exposure: different exposures; 4) Outcomes: risk factors, non-
CVD related outcomes. 
2.2.2 Data extraction 
Extracted information included: study design (country, assessment of tomato and/or 
lycopene intake, serum lycopene concentrations, cohort name, follow-up length); participant 
characteristics (sample size, population, mean age, body mass index and ethnicity); outcome 
measures (CVD and associated disorders, and mortality, as stated above); adjustments for 
covariates.  
Information related to the outcomes of interest was extracted and analysed as reported in the 
original papers. If studies reported associations of tomato or lycopene with CVD, but also 
reported associations for specific CVD such as stroke or CHD, all these were extracted and 
analysed separately. This procedure was adopted in order to provide differential associations 
between the exposures and specific outcomes of interest.  
2.2.3 Outcome measures and exposures 
Primary outcomes of interest were risk of stroke, CVD, CHD, MI, atherosclerosis, AF, CHF, 
all-cause mortality, cardiovascular mortality and sudden cardiac death. 
We were interested in studies associating these outcomes with exposures such as intakes of 
lycopene or tomato products, and lycopene concentrations in blood or any other body tissues 
such adipose tissue.  
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2.2.5 Statistical analysis 
Meta-analysis of results was undertaken using the Review Manager (RevMan Version 5.1 
for Windows Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 
2011). Random effects models, accounting for inter-study variation and minimizing 
potential bias due to methodological differences between studies, were used.  
Results are informed as HR or OR with 95% confidence intervals (CI) and two-sided P-
values. In this meta-analysis, five studies evaluated multiple arms of cardiovascular diseases 
and associated disorders. Meta-regression analysis was undertaken to explore the association 
of effect size (Q-test) with continuous variables such as age and BMI of study participants, 
or length of follow-up. In addition, we undertook subgroup analysis to explore the impact of 
variables such as sex, or country of origin. 
Statistical heterogeneity was evaluated using the I2 statistic describing the percentage of 
variation across studies (Centre for Reviews and Dissemination, 2009; Higgins and Green, 
2011), with I2 values greater than 50% representing high levels of heterogeneity. Publication 
bias was assessed by inspecting the funnel plot of effect size against the standard error (SE), 
with asymmetry assessed formally with Egger’s regression test (Egger et al., 1997). 
2.3 Results  
A total of 3970 articles were identified (Figure 2.1). Twenty-eight articles fulfilled our 
inclusion criteria (Table 2.1) (Ascherio et al., 1999; Ford et al., 2014; Hak et al., 2004; Hak 
et al., 2003; Han and Han, 2016; Han et al., 2016; Hirvonen et al., 2000; Iribarren et al., 
1997; Ito et al., 2006; Jacques et al., 2013; Kabagambe et al., 2005; Karppi et al., 2013a; 
Karppi et al., 2013b; Karppi et al., 2012a; Karppi et al., 2012b; Karppi et al., 2013c; Karppi 
et al., 2012c; Klipstein-Grobusch et al., 2000; Kohlmeier et al., 1997; Mayne et al., 2004; 
Osganian et al., 2003; Rissanen et al., 2001; Sesso et al., 2004; Sesso et al., 2005; Sesso et 
al., 2003; Street et al., 1994; Tavani et al., 2006; Wood and Johnson, 2004) were included in 
this review, and 25 of these provided quantitative results for meta-analysis (Ascherio et al., 
1999; Ford et al., 2014; Hak et al., 2004; Hak et al., 2003; Han et al., 2016; Hirvonen et al., 
2000; Iribarren et al., 1997; Ito et al., 2006; Jacques et al., 2013; Kabagambe et al., 2005; 
Karppi et al., 2013a; Karppi et al., 2013b; Karppi et al., 2012a; Karppi et al., 2012b; Karppi 
et al., 2013c; Karppi et al., 2012c; Klipstein-Grobusch et al., 2000; Kohlmeier et al., 1997; 
Mayne et al., 2004; Osganian et al., 2003; Rissanen et al., 2001; Sesso et al., 2004; Sesso et 
al., 2005; Sesso et al., 2003; Tavani et al., 2006). 
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Figure 2.1 PRISMA flow diagram of selection of studies on lycopene or tomato consumption and 
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Table 2.1 Characteristics of studies with exposure tomato/lycopene included in systematic review. 
Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Lycopene associations 
Ascherio et 
al., 1999 
(USA)  
 
 
 
 
 
 
 
 
 
Intake of 
lycopene 
from diet 
 
Food 
frequency 
questionnaire 
Prospective 
study 
(The Health 
Professionals 
Follow-up 
Study)  
43738 
(Male) 
8 40-75 25.5 Total Stroke  
 
RR 0.96 (0.68, 1.36) 
Highest (Median value 18798 µg/d) 
and lowest (Median value 3442 
µg/d) (Ref) quintiles for intake of 
lycopene 
Total energy intake, smoking, 
alcohol consumption, history of 
hypertension, parental history of 
MI, profession, and quintiles of 
BMI and physical activity, age 
N/A 
 
 
 
 
 
 
  Ischaemic Stroke 
 
RR 1.01 (0.65, 1.57) 
Highest (Median value 18798 µg/d) 
and lowest (Median value 3442 
µg/d) (Ref) quintiles for intake of 
lycopene 
Haemorrhagic Stroke 
 
RR 1.04 (0.52, 2.07) 
Highest (Median value 18798 µg/d) 
and lowest (Median value 3442 
µg/d) (Ref) quintiles for intake of 
lycopene 
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Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Ford et al., 
2014 (USA)  
Serum level 
of lycopene 
Prospective 
study (National 
Health and 
Nutrition 
Examination 
Survey III) 
1429 
(Mixed 
Sex) 
14 55.7 (20-
79) 
26.5 All-cause Mortality  
 
HR 0.8 (0.67, 0.95) 
(inverse association) for serum 
level of lycopene as continuous 
variable (Mean±SE, for total 
participants 0.45±0.01 µmol/L) 
Age, sex, race, ethnicity, 
education, smoking, alcohol 
consumption, leisure-time 
physical activity, use of vitamin 
or mineral supplements, SBP, 
HDL-cholesterol, non-HDL-
cholesterol, BMI, CRP, albumin: 
creatinine ratio, health status, 
diabetes, history of MI and 
history of stroke 
White: 
83.5%; 
Black 
American: 
7.5%; 
Other: 
6.8%; 
Mexican 
American: 
2.2% 
Hak et al., 
2003 (USA)  
Plasma level 
of lycopene 
Prospective 
nested case-
control  
(Physicians’ 
Health Study) 
1061 
(Male) 
13 58±8.5 25.2 MI 
 
OR 1.43 (0.87, 2.35) 
Highest (Median value 578.8 
ng/mL) and lowest (Median value 
217.7 ng/mL) (Ref) quintiles for 
plasma of lycopene 
Age, smoking, BMI, total and 
HDL-cholesterol, history of 
hypertension, diabetes mellitus, 
and parental history of MI < age 
60, physical activity, alcohol 
consumption; multivitamin use, 
and assignment to aspirin or β-
carotene treatment or placebo 
N/A 
Hak et al., 
2004 (USA)  
Plasma level 
of lycopene 
Prospective 
nested case-
control  
(Physicians’ 
Health Study) 
594 
(Male) 
13 60.5 (40-
84) 
25.3 Ischaemic stroke 
 
OR 0.72 (0.38, 1.37) 
Highest (Median value 606.8 
ng/mL) and lowest (Median value 
216.4 ng/mL) (Ref) quintiles for 
plasma level of lycopene 
Age, smoking, BMI, total and 
HDL-cholesterol, history of 
hypertension, diabetes mellitus, 
and parental history of MI < age 
60, physical activity, alcohol 
consumption, multivitamin use, 
and assignment to aspirin or β-
carotene treatment or placebo 
N/A 
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Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Han and 
Han, 2016 
(USA) 
Serum level 
of lycopene 
Prospective 
study (National 
Health and 
Nutrition 
Examination 
Survey III) 
37 
(Mixed 
Sex) 
17.5 45±16.8 26±7 Mortality rate for low lycopene 
level group 33% 
Mortality rate for high lycopene 
level group 5.3% 
N/A non-
Hispanic 
white: 
43%; 
non-
Hispanic 
black: 
30%; 
Mexican 
American: 
27% 
Han et al., 
2016 (USA)  
Serum level 
of lycopene 
Prospective 
study (National 
Health and 
Nutrition 
Examination 
Survey) 
2499 
(Mixed 
Sex) 
5-10 Three 
aged 
group 
(20-39; 
40-59; 
≥60) 
Three 
groups 
(<24.9; 
25-
29.9; 
≥30) 
All-cause Mortality  
 
HR 0.61 (0.42, 0.89)  
Highest (Mean value 0.626 
µmol/L) and lowest (Mean value 
0.204 µmol/L) (Ref) tertiles for 
serum level of lycopene 
Race, sex, age, BMI, smoking, 
alcohol consumption, physical 
activity, fruit consumption, 
vegetable consumption, and 
cancer 
non-
Hispanic 
white: 
55.9%; 
non-
Hispanic 
black: 
13.5%; 
Mexican 
American: 
23.9%; 
Other: 
6.7% 
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Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Hirvonen et 
al., 2000 
(Finland)  
Intake of 
lycopene 
from diet 
 
Food 
frequency 
questionnaire 
Prospective 
study 
(The Alpha-
Tocopherol, 
Beta-Carotene 
Cancer 
Prevention 
(ATBC) Study) 
26593 
(Male) 
6.1 57 (50-
69) 
26.6 Cerebral Infarction 
 
RR 0.74 (0.59, 0.92) 
Highest (Median value 1.45 mg/d) 
and lowest (Median value 0.14 
mg/d) (Ref) quartiles for intake of 
lycopene 
Age, supplementation group, 
SBP, DBP, total and HDL-
cholesterol, BMI, height, 
smoking, number of cigarettes 
daily, history of diabetes or 
CHD, alcohol consumption, and 
education 
N/A 
26.8 Intracerebral Haemorrhage  
 
RR 0.45 (0.24, 0.86) 
Highest (Median value 1.45 mg/d) 
and lowest (Median value 0.14 
mg/d) (Ref) quartiles for intake of 
lycopene 
26 Subarachnoid Haemorrhage 
 
RR 0.63 (0.33, 1.20)  
Highest (Median value 1.45 mg/d) 
and lowest (Median value 0.14 
mg/d) (Ref) quartiles for intake of 
lycopene 
Iribarren et 
al., 1997 
(USA)  
Serum level 
of lycopene 
Case-control 
(the 
Atherosclerosis 
Risk in 
Communities 
(ARIC) study) 
462 
(Mixed 
sex) 
N/A 59±5 27.3 Asymptomatic Carotid 
Atherosclerosis  
 
OR 0.81 (0.60, 1.08) 
Per 1-SD increase in serum 
lycopene (Mean value 0.44 
µmol/L) 
Age, blood storage time, total 
cholesterol, triglycerides, 
education level, smoking, BMI, 
alcohol consumption, 
hypertension, diabetes mellitus 
and vitamin supplementation use 
White: 
90%; 
Black: 10% 
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Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Ito et al., 
2006 (Japan)  
Serum level 
of lycopene 
Prospective 
study 
3061 
(Mixed 
sex) 
11.9 39-80 N/A CVD  
 
HR 0.77 (0.57, 1.04) 
Highest and lowest (Ref) serum 
level of lycopene per each 
logarithmically transformed value 
of serum 
Age, sex, smoking, alcohol 
consumption, BMI, SBP, total 
cholesterol, triglyceride and 
alanine transaminase activity 
Japanese 
population 
Stroke 
 
HR 0.78 (0.51, 1.19) 
Highest and lowest (Ref) serum 
level of lycopene per each 
logarithmically transformed value 
of serum 
CHD 
 
HR 0.74 (0.48, 1.13) 
Highest and lowest (Ref) serum 
level of lycopene per each 
logarithmically transformed value 
of serum 
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Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Jacques et 
al., 2013 
(USA)  
Intake of 
lycopene 
from diet 
 
Harvard 
semi-
quantitative 
food 
frequency 
questionnaire 
Longitudinal 
(Framingham 
Heart Study) 
5135 
(Mixed 
sex) 
9 54 (26-
79) 
27.2 CVD  
 
HR 0.83 (0.70, 0.98) 
75th and 25th (Ref) percentiles 
intake of lycopene (Mean 7.9 mg/d) 
Age, sex, SBP, total and 
cholesterol/HDL ratio, BMI, 
smoking, hypertension 
treatment, diabetes, energy 
intake and intake of saturated fat, 
β-carotene, flavonol, vitamin C 
and vitamin E 
N/A 
9 Stroke 
 
HR 0.82 (0.59, 1.16) 
75th and 25th (Ref) percentiles 
intake of lycopene (Mean 7.9 mg/d) 
11 CHD  
 
HR 0.74 (0.58, 0.94) 
75th and 25th (Ref) percentiles 
intake of lycopene (Mean7.9 mg/d) 
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Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Kabagambe 
et al., 2005 
(Costa Rica)  
Lycopene 
level in 
adipose 
tissue 
Intake of 
lycopene 
from diet 
 
Semi-
quantitative 
food-
frequency 
questionnaire 
Case-control  
 
2912 
(Mixed 
sex) 
9 58±11 N/A MI 
 
OR 0.91 (0.67, 1.24) 
Highest (Median value 1.47 
µmol/kg) and lowest (Median value 
0 µmol/kg) (Ref) quintiles for 
intake of lycopene 
Smoking, alcohol intake, history 
of diabetes, history of 
hypertension, abdominal obesity, 
physical activity, income, intake 
of saturated fat, polyunsaturated 
fat, trans-fat, total energy, and 
dietary fibre 
Hispanic 
Americans 
MI 
 
OR 1.05 (0.78, 1.42) 
Highest (Median value 0.62 µg/g) 
and lowest (Median value 0.11 
µg/g) (Ref) quintiles for intake of 
lycopene 
Karppi et al., 
2012a 
(Finland)  
Serum level 
of lycopene 
Prospective 
study (Kuopio 
Ischaemic Heart 
Disease Risk 
Factor (KIHD) 
cohort) 
1031 
(Male) 
11.5 56.2±6.6 27.5 Acute MI 
 
RR 1.55 (1.05, 2.30) 
Lowest (<0.08 µmol/L) and highest 
(>0.19 µmol/L) (Ref) tertiles for 
serum level of lycopene 
Age, examination year, BMI, 
SBP, smoking, alcohol intake, 
LDL-cholesterol, years of 
education, physical activity, 
symptomatic 
CHD or CHD history, diabetes, 
antihypertensive medication, 
drug for high cholesterol and any 
b-adrenergic blocking agent 
Finnish 
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Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Karppi et al., 
2012b 
(Finland)  
Serum level 
of lycopene 
Prospective 
study (Kuopio 
Ischaemic Heart 
Disease Risk 
Factor (KIHD) 
cohort) 
1031 
(Male) 
15.9 56.4±6.5 27.4 CVD mortality 
 
HR 1.51 (0.86, 2.67) 
Lowest (≤0.03 µmol/L) and highest 
(>0.22 µmol/L) (Ref) quartiles for 
serum level of lycopene 
Age, examination year, BMI, 
SBP, smoking, alcohol 
consumption, physical activity, 
years of 
education, LDL-cholesterol, 
symptomatic CHD or CHD 
history, use of antihypertensive 
drugs, use of any b-blockers, 
serum hs-CRP 
and diabetes 
Finnish 
Karppi et al., 
2012c 
(Finland)  
Serum level 
of lycopene 
Prospective 
study (Kuopio 
Ischaemic Heart 
Disease Risk 
Factor (KIHD) 
cohort) 
1031 
(Male) 
12.1 56.2 (46-
65) 
27.5 Stroke  
 
HR 0.45 (0.21, 0.95)  
Highest (>0.22 µmol/L) and lowest 
(≤0.03 µmol/L) (Ref) quartiles for 
serum level of lycopene 
Age, examination year, BMI, 
SBP, smoking, LDL-cholesterol, 
diabetes, and stroke 
Finnish 
Karppi et al., 
2013a 
(Finland)  
Plasma level 
of lycopene 
Prospective 
study (Kuopio 
Ischaemic Heart 
Disease Risk 
Factor (KIHD) 
cohort) 
1847 
(Mixed 
sex) 
2.8 71.1 (61-
82) 
27.4 Risk of AF 
 
HR 1.21 (0.68, 2.13) 
Lowest (≤0.05 µmol/L) and highest 
(>0.11 µmol/L) (ref) tertiles for 
serum level of lycopene  
Age, examination year, gender, 
education, SBP, smoking, 
alcohol consumption, diabetes 
and the use of antihypertensive 
medication, CHF, recurrent AF, 
prevalent CHD and baseline 
prevalence of MI 
Finnish 
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Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Karppi et al., 
2013b 
(Finland)  
Serum level 
of lycopene 
Prospective 
study (Kuopio 
Ischaemic Heart 
Disease Risk 
Factor (KIHD) 
cohort) 
1031 
(Male) 
17.8 56.2±6.6 27.6 CHF 
 
HR 1.99 (0.83, 4.77) 
Lowest (≤0.03 µmol/L) and highest 
(>0.22 µmol/L) (Ref) quartiles for 
serum level of lycopene 
Age, examination year, BMI, 
years of education, smoking, 
alcohol consumption, physical 
activity, serum hs-CRP and 
serum LDL-cholesterol, 
diabetes, hypertension with 
antihypertensive medication, 
prevalent CHD and HF at 
baseline examination 
Finnish 
Karppi et al., 
2013c 
(Finland)  
Serum level 
of lycopene 
Prospective 
study (Kuopio 
Ischaemic Heart 
Disease Risk 
Factor (KIHD) 
cohort) 
1031 
(Male) 
15.9 56.2 (46-
65) 
27.5 Sudden cardiac death (SCD) 
 
HR 1.93 (0.92, 4.04) 
Lowest (≤0.08 µmol/L) and highest 
(>0.19 µmol/L) (ref) tertiles for 
serum level of lycopene 
Age, SBP, waist circumference, 
smoking, alcohol consumption, 
years of education, LDL-
cholesterol, CRP, diabetes, 
prevalent CHD and CHF 
Finnish 
Klipstein-
Grobusch et 
al., 2000 
(Netherland)  
Serum level 
of lycopene 
Case-control 
(Subsample of 
the Rotterdam 
Study) 
217 
(Mixed 
sex) 
N/A 66.8 
(7.2) 
26.4 Atherosclerosis  
 
OR 0.66 (0.29, 1.49) 
Highest (>0.166 µmol/L) and 
lowest (<0.058 µmol/L)) (ref) 
quartiles for serum level of 
lycopene 
Age, sex, cholesterol, season, 
waist-to-hip ratio, pack-years 
smoked, alcohol consumption 
N/A 
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Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Kohlmeier et 
al., 1997 
(USA)  
Lycopene 
level in 
adipose 
tissue 
Case-control  
(EURAMIC 
study) 
1379 
(Male) 
N/A 54 26.3 MI 
 
OR 0.42 (0.25, 0.7) 
Highest (Median value 0.62 µg/g) 
and lowest (Median value 0.11 
µg/g) (Ref) quintiles for intake of 
lycopene 
Age, BMI, smoking, maternal, 
paternal history of disease, 
history of high blood pressure, 
study site and α-tocopherol 
intake 
N/A 
Mayne et al., 
2004 (USA)  
Plasma level 
of lycopene 
Longitudinal 
study (Yale 
University 
cancer 
prevention trial) 
259 
(Mixed 
sex) 
7.5 61.8 (20-
79) 
N/A All-cause Mortality  
 
HR 0.53 (0.30, 0.93) 
Above versus below (Ref) Median 
plasma level of lycopene (Median 
value 280 µg/l) 
Age, gender, treatment arm, 
time-dependent smoking, 
baseline plasma cholesterol, 
study site 
N/A 
CHD Mortality  
 
HR 0.42 (0.14, 1.30) 
Above versus below (Ref) Median 
plasma level of lycopene (Median 
value 280 µg/l) 
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Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Osganian et 
al., 2003 
(USA)  
Intake of 
lycopene 
from diet 
 
Semi-
quantitative 
food-
frequency 
questionnaire 
Longitudinal 
study (Nurses’ 
Health Study) 
73286  
(Female) 
12 50 (30-
55) 
25 Coronary artery disease 
 
RR 0.93 (0.77, 1.14) 
Highest (Median value 15830 µg/d) 
and lowest (Median value 3570 
µg/d) (ref) quintiles for serum level 
of lycopene 
Age, smoking, postmenopausal 
hormone use, parental history of 
MI, history of high blood 
pressure, history of high 
cholesterol, diabetes, BMI, 
physical activity, aspirin use, 
alcohol consumption, total 
energy intake and intake of 
saturated fat, polyunsaturated fat, 
trans unsaturated fat, cereal 
fibre, folate, dietary glycaemic 
load, and vitamin B-6 
N/A 
Rissanen et 
al., 2001 
(Finland)  
Serum level 
of lycopene 
Prospective 
study (Kuopio 
Ischaemic Heart 
Disease Risk 
Factor (KIHD) 
cohort) 
725 
(Male) 
4 46-64 27 Acute coronary events or Stroke 
 
HR 3.3 (1.7, 6.4) 
Lowest quarter (≤0.07 µmol/L) 
versus every other quarter of serum 
level of lycopene (≥0.08 µmol/L) 
(Ref) 
Age, examination years, SBP 
and three nutritional factors 
(serum b-carotene, folate and 
plasma vitamin C) 
Finnish 
Acute coronary events  
 
HR 2.8 (1.4, 5.4) 
Lowest quarter (≤0.07 µmol/L) 
versus every other quarter of serum 
level of lycopene (≥0.08 µmol/L) 
(Ref) 
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Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Sesso et al., 
2003 (USA) 
Intake of 
lycopene 
from diet 
 
Semi-
quantitative 
food-
frequency 
questionnaire 
Prospective 
study 
(Women’s 
Health Study) 
38445 
(Female) 
7.2 54.0±7.0 26 CVD  
 
RR 0.90 (0.69, 1.17) 
Highest (Median value 16741 µg/d) 
and lowest (Median value 3326 
µg/d) (Ref) quintiles for intake of 
lycopene 
Age, randomized aspirin, 
randomized vitamin E, 
randomized β-carotene, BMI, 
exercise, smoking, 
postmenopausal hormone use, 
parental history of MI < age 60, 
diabetes, hypertension, high 
cholesterol, and the intake of 
fruit and vegetables, alcohol, 
fibre, folate, nonsupplemental 
vitamin E and saturated fat 
N/A 
Stroke 
 
RR 0.91 (0.57, 1.45) 
Highest (Median value 16741 µg/d) 
and lowest (Median value 3326 
µg/d) (Ref) quintiles for intake of 
lycopene 
MI 
 
RR 0.69 (0.41, 1.15) 
Highest (Median value 16741 µg/d) 
and lowest (Median value 3326 
µg/d) (Ref) quintiles for intake of 
lycopene 
  Chapter 2 
 (Table 2.1 continues on next page) 54 
Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Sesso et al., 
2004 (USA)  
Plasma level 
of lycopene 
Nested case-
control 
(Women’s 
Health Study) 
966 
(Female) 
4.8 58.8±8.4 26.6 CVD  
 
RR 0.67 (0.41, 1.11) 
Highest (≥21.0 µg/dL) and lowest 
(<11.7 µg/dL) (Ref) quartiles for 
plasma of lycopene 
Age, smoking, adjusted for 
randomized aspirin treatment, 
randomized vitamin E treatment, 
randomized β-carotene 
treatment, plasma cholesterol 
concentration, BMI, physical 
activity, postmenopausal 
hormone use, parental history of 
MI < age 60, diabetes, 
hypertension, high cholesterol, 
alcohol, fibre, folate, saturated 
fat, and fruit and vegetable 
intakes 
N/A 
Sesso et al., 
2005 (USA)  
Plasma level 
of lycopene 
Nested case-
control 
(Physicians’ 
Health Study) 
499  
(Male) 
2.1 69.7±8.1 24.5 CVD  
 
RR 1.03 (0.65, 1.64)  
Highest (>12.7 µg/dL) and lowest 
(≤6.4 µg/dL) (Ref) quartiles for 
plasma of lycopene 
Age, smoking, adjusted for 
randomized aspirin treatment, 
randomized vitamin E treatment, 
randomized β-carotene 
treatment, plasma cholesterol 
concentration, BMI, physical 
activity, postmenopausal 
hormone use, parental history of 
MI < age 60, diabetes, 
hypertension, high cholesterol, 
alcohol, fibre, folate, saturated 
fat, and fruit and vegetable 
intakes 
N/A 
  Chapter 2 
 (Table 2.1 continues on next page) 55 
Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Street et al., 
1994 (USA)  
Serum level 
of lycopene 
Nested case-
control  
369 
(Mixed 
sex) 
14 23-58 N/A MI 
 
OR 1.33 
Lowest and highest (Ref) quintiles 
for serum level of lycopene 
N/A N/A 
Tavani et al., 
2006 (Italy)  
Intake of 
lycopene 
 
Food-
frequency 
questionnaire 
Nested case-
control  
1442 
(Mixed 
sex) 
9 50-70 N/A Acute MI 
 
OR 1.19 (0.82, 1.70) 
Highest and lowest (Ref) quartiles 
for intake of lycopene (Mean 
lycopene intake 7189.5 µg/d)  
Age, sex, study site, education, 
smoking, alcohol consumption, 
coffee, non-alcohol total energy, 
BMI, physical activity, 
cholesterol level, diabetes, 
hyperlipidemia hypertension, 
and family history of acute MI in 
first degree relatives 
N/A 
Wood and 
Johnson, 
2004 (USA)  
 
  
Serum level 
of lycopene 
Cross-sectional 
analysis 
(Third National 
Health and 
Nutrition 
Examination 
Survey 
(NHANES III)) 
4087 
with 
periodon
titis 
(Mixed 
Sex) 
N/A 47.7 
(SEM 
0.4) 
23.9 CHF 
 
RR 0.65 (0.21, 2.03) 
Lowest (≤14 µg/dL) and highest 
(>29 µg/dL) (Ref) quartiles for 
serum level of lycopene 
Age, race, gender, BMI, waist to 
hip ratio, serum CRP, WBC 
count, smoking, history of 
diabetes, hypertension, 
socioeconomic status, and 
education level 
Caucasian, 
African-
American, 
Other 
1443 
without 
periodon
titis 
(Mixed 
Sex) 
47.7 
(SEM 
0.6) 
23.6 CHF 
 
RR 0.59 (0.15, 2.24) 
Lowest (≤14 µg/dL) and highest 
(>29 µg/dL) (Ref) quartiles for 
serum level of lycopene 
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Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Tomato associations 
Jacques et 
al., 2013 
(USA)  
Intake of 
tomatoes and 
tomato-based 
products 
 
Harvard 
semi-
quantitative 
food 
frequency 
questionnaire 
Longitudinal 
study 
(Framingham 
Heart Study) 
5135 
(Mixed 
sex) 
9 54 (26-
79) 
27.2 CVD 
 
HR 0.94 (0.878, 0.995) 
75th and 25th (Ref) percentiles for 
intake of tomatoes and tomato-
based products (Mean 4.4 
servings/wk) 
Age, sex, SBP, total cholesterol, 
total cholesterol/HDL ratio, 
BMI, smoking, hypertension 
treatment, diabetes, saturated fat, 
β-carotene, flavonol, vitamin C 
and vitamin E intakes and energy 
intake 
N/A 
9 Stroke  
 
HR 0.99 (0.90, 1.10) 
75th and 25th (Ref) percentiles for 
intake of tomatoes and tomato-
based products (Mean 4.4 
servings/wk) 
9 CHD 
 
HR 0.90 (0.83, 0.99) 
75th and 25th (Ref) percentiles for 
intake of tomatoes and tomato-
based products (Mean 4.4 
servings/wk) 
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Ref 
(Country of 
origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Sesso et al., 
2003 (USA)  
Intake of 
tomato based 
product 
 
Semi-
quantitative 
food-
frequency 
questionnaire 
Prospective 
study (Women’s 
Health Study) 
38445 
(Female) 
7.2 54.0±7.0 26 CVD 
 
RR 0.71 (0.42, 1.17) 
Highest (12 servings/wk) and 
lowest (1.4 servings/wk) (Ref) 
quintiles for intake of tomato based 
product per week 
Age, randomized aspirin, 
randomized vitamin E, 
randomized β-carotene, BMI, 
exercise, smoking, 
postmenopausal hormone use, 
parental history of MI <60 y, 
diabetes, hypertension, high 
cholesterol, and the intake of 
fruit and vegetables, alcohol, 
fibre, folate, nonsupplemental 
vitamin E and saturated fat 
N/A 
 
 
 
 
 
 
 
  Stroke 
 
RR 0.20 (0.05, 0.84) 
Highest (12 servings/wk) and 
lowest (1.4 servings/wk) (Ref) 
quintiles for intake of tomato based 
product per week 
MI 
 
RR 0.39 (0.12, 1.30) 
Highest (12 servings/wk) and 
lowest (1.4 servings/wk) (Ref) 
quintiles for intake of tomato based 
product per week 
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Ref 
(Country 
of origin) 
Exposure  Study design 
(Cohort name) 
Sample 
size 
(Sex) 
Mean 
length of 
follow-up 
(years) 
Mean 
Age±SD 
(Range) 
BMI 
(kg/m2) 
Effect size (95% CI) Confounders adjusted for Ethnicity 
Wood and 
Johnson, 
2004 (USA)  
Intake of 
tomato 
 
Semi-
quantitative 
food-
frequency 
questionnaire 
Cross-sectional 
analysis 
(Third National 
Health and 
Nutrition 
Examination 
Survey 
(NHANES III)) 
4087 
with 
periodon
titis 
(Mixed 
Sex) 
N/A 47.7 
(SEM 
0.4) 
23.9 CHF 
 
RR 5.10 (1.67, 15.57) 
Lowest (≤3) and highest (>17) 
(Ref) quartiles for monthly tomato 
consumption 
Age, race, gender, BMI, waist to 
hip ratio, serum CRP, WBC 
count, smoking, history of 
diabetes, hypertension, 
socioeconomic 
status, and education level 
Caucasian, 
African-
American, 
Other 
1443 
without 
periodon
titis 
(Mixed 
Sex) 
47.7 
(SEM 
0.6) 
23.6 CHF 
 
RR 1.68 (0.6, 4.76) 
Lowest (≤3) and highest (>17) 
(Ref) quartiles for monthly tomato 
consumption 
 
Ref, Reference; CI, confidence intervals; CVD, Cardiovascular diseases; CHD, Coronary heart disease; CHF, Congestive heart failure; AF, Atrial fibrillation; 
Intima-media thickness, IMT; HR, Hazard ratio; RR, Relative ratio; OR, Odd ratio; BMI, Body mass index; MI, Myocardial Infarction; SBP, Systolic blood 
pressure; DBP, Diastolic blood pressure; HDL, High density lipoprotein; LDL, Low density lipoprotein; CRP, C-reactive protein; WBC, White blood cell; d, 
Day; wk, week 
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2.3.1 Characteristics of studies  
Twenty-five of the included studies assessed lycopene alone (Ascherio et al., 1999; Ford et 
al., 2014; Hak et al., 2004; Hak et al., 2003; Han and Han, 2016; Han et al., 2016; Hirvonen 
et al., 2000; Iribarren et al., 1997; Ito et al., 2006; Kabagambe et al., 2005; Karppi et al., 
2013a; Karppi et al., 2013b; Karppi et al., 2012a; Karppi et al., 2012b; Karppi et al., 2013c; 
Karppi et al., 2012c; Klipstein-Grobusch et al., 2000; Kohlmeier et al., 1997; Mayne et al., 
2004; Osganian et al., 2003; Rissanen et al., 2001; Sesso et al., 2004; Sesso et al., 2005; 
Street et al., 1994; Tavani et al., 2006), and three studies assessed both lycopene and tomato 
(Jacques et al., 2013; Sesso et al., 2003; Wood and Johnson, 2004). These studies varied 
according to length of follow-up (2 to 17.5 years), sample size (range: 37 to 73286 
participants), mean age (45 to 71y), and mean BMI (24 to 28). The studies included in this 
review originated from USA (n=15), Finland (n=8) and single studies from Costa Rica, Italy, 
Japan and Netherland, and a multicentre European study. According to sex, 12 studies 
included only men and three included only women, while 13 studies were including mixed 
sex. Overall, the mean intakes of lycopene were 0.14 mg/d (lowest categories) and 18.8 mg/d 
(highest categories) (Table 2.2); mean serum concentration of lycopene were 0.0012 µmol/L 
(lowest categories) and 1.13 µmol/L (highest categories) (Table 2.3).  
Table 2.2 The mean intake of tomato/lycopene included in systematic review. 
Ref (Country of origin) 
Lowest 
category 
Highest 
category Unit 
Intake of tomatoes and/or tomato-based products 
Jacques et al., 2013 (USA) Mean❖ 4.4 Servings/ wk 
Sesso et al., 2003 (USA) Median* 1.4 12 Servings/ wk 
Wood and Johnson, 2004 (USA) Mean‡ ≤3 >17 Tomato intake per month 
Intake of lycopene 
Ascherio et al., 1999 (USA) Median*  3442 18798 µg/day 
Hirvonen et al., 2000 (Finland) Median‡ 140 1450 µg/day 
Jacques et al., 2013 (USA) Mean¤  7900 µg/day 
Kabagambe et al., 2005 (Costa Rica) Median* 0 1.47 µmol/kg of adipose tissue 
Osganian et al., 2003 (USA) Median* 3570 15830 µg/day 
Sesso et al., 2003 (USA) Median* 3326 16741 µg/day 
Tavani et al., 2006 (Italy) Mean‡ 7190 µg/day 
‡ Quartile 
* Quintile 
❖ Percentile  
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Table 2.3 The mean serum concentration of lycopene included in systematic review. 
Ref (Country of origin) 
Lowest category 
(µmol/L) 
Highest category 
(µmol/L) 
Ford et al., 2014 (USA) Mean 0.45 
Hak et al., 2003 (USA) Median*  0.41 1.08 
Hak et al., 2004 (USA) Median* 0.40 1.13 
Han and Han, 2016 (USA) Mean 0.23 0.55 
Han et al., 2016 (USA) Mean† 0.20 0.63 
Iribarren et al., 1997 (USA) Mean▲ 0.44 
Ito et al., 2006 (Japan) Mean# 0.33 
Karppi et al., 2012a (Finland) Mean† <0.08 >0.19 
Karppi et al., 2012b (Finland) Mean‡ ≤0.03 >0.22 
Karppi et al., 2012c (Finland) Mean‡ ≤0.03 >0.22 
Karppi et al., 2013a (Finland) Mean† ≤0.05 >0.11 
Karppi et al., 2013b (Finland) Mean‡ ≤0.03 >0.22 
Karppi et al., 2013c (Finland) Mean† ≤0.08 >0.19 
Klipstein-Grobusch et al., 2000 (Netherland) Mean‡ <0.058 >0.166 
Kohlmeier et al., 1997 (USA) Median* 0.11 0.62 
Mayne et al., 2004 (USA) Median  0.52 
Rissanen et al., 2001 (Finland) Mean‡ ≤0.07 ≥0.24 
Sesso et al., 2004 (USA) Mean‡ <0.0022 ≥0.0039 
Sesso et al., 2005 (USA) Median‡ ≤0.0012 >0.0024 
Street et al., 1994 (USA) Mean* N/A 
Wood and Johnson, 2004 (USA) Mean‡ ≤0.0026 >0.0054 
† Tertile 
‡ Quartile 
* Quintile 
▲1-SD increase  
# Logarithmically transformed value  
2.3.2 Meta-analysis: Lycopene and CVD 
Twenty-five studies, including 211704 participants, evaluated the association between 
lycopene and a number of cardiovascular diseases reported below (Ascherio et al., 1999; 
Ford et al., 2014; Hak et al., 2004; Hak et al., 2003; Han et al., 2016; Hirvonen et al., 2000; 
Iribarren et al., 1997; Ito et al., 2006; Jacques et al., 2013; Kabagambe et al., 2005; Karppi 
et al., 2013a; Karppi et al., 2013b; Karppi et al., 2012a; Karppi et al., 2012b; Karppi et al., 
2013c; Karppi et al., 2012c; Klipstein-Grobusch et al., 2000; Kohlmeier et al., 1997; Mayne 
et al., 2004; Osganian et al., 2003; Rissanen et al., 2001; Sesso et al., 2004; Sesso et al., 
2005; Sesso et al., 2003; Tavani et al., 2006). 
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2.3.4 Stroke 
Eight studies, including 119322 participants, evaluated intake or serum concentration of 
lycopene and incidence of stroke (Ascherio et al., 1999; Hak et al., 2004; Hirvonen et al., 
2000; Ito et al., 2006; Jacques et al., 2013; Karppi et al., 2012c; Rissanen et al., 2001; Sesso 
et al., 2003). Overall, meta-analysis showed that highest category intake or serum 
concentration of lycopene were significantly associated with reduced incidence of stroke 
(HR 0.74, 95% CI 0.62 to 0.89, p=0.001). Heterogeneity levels assessed by the I2 test were 
low at 32% (Figure 2.2A). Results from studies evaluating intake of lycopene showed that 
highest category intake was significantly associated with reduced incidence of stroke (HR 
0.79, 95% CI 0.64 to 0.97, p=0.02) (Ascherio et al., 1999; Hirvonen et al., 2000; Jacques et 
al., 2013; Sesso et al., 2003). Heterogeneity levels assessed by the I2 test were low at 44% 
(Figure 2.2A). Similarly, there was strong evidence that high serum concentration of 
lycopene was associated with lower risk of stroke (HR 0.61, 95% CI 0.40 to 0.92, p=0.02) 
(Hak et al., 2004; Ito et al., 2006; Karppi et al., 2012c; Rissanen et al., 2001). Heterogeneity 
levels assessed by the I2 test were low at 31% (Figure 2.2A). 
Visual inspection of the funnel plot and calculation of the Egger’s regression test indicated 
no publication bias (p=0.70) (Appendix A2) (Egger et al., 1997). 
In addition, meta-regression analysis on the association between high intake or serum 
concentration of lycopene and incidence of stroke showed no significant associations with 
the length of follow-up (8 studies), age (5 studies) or BMI (7 studies) (Appendix A3-
Appendix A5). However, this result should be interpreted cautiously due to the small 
number of studies. 
Subgroup analysis (Table 2.4) showed that four studies originating from Japan and Finland 
reported significant reduction in the incidence of stroke with high intake and serum 
concentrations of lycopene (HR 0.63, 95% CI 0.48 to 0.82, p<0.001; I2=30%); while four 
studies from the USA reported non-significant lower risk of stroke (HR 0.88, 95% CI 0.71 
to 1.07, p=0.20; I2=0%). Between-group comparison of these results according to 
geographical origins were not significantly different between groups (p=0.06).  
Subgroup analysis (Table 2.4) according to sex showed that high intake and serum 
concentrations of lycopene were significantly associated with reduced incidence of stroke in 
studies including men only (HR 0.71, 95% CI 0.51 to 0.99, p=0.04; I2=56%) and studies 
including both sexes (HR 0.75, 95% CI 0.58 to 0.98, p=0.03; I2=7%). One study including 
women only showed that high intake of lycopene was non-significantly associated with 
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reduced incidence of stroke (HR 0.91, 95% CI 0.57 to 1.45, p=0.69). The between-group 
comparisons according to sex was not significantly different between groups (p=0.69). 
Subgroup analysis (Table 2.4) by follow-up time showed that in studies with ≤ 8y follow-
up, high intake or serum concentration of lycopene were associated with non-significant 
reductions in the risk of stroke with high heterogeneity levels (HR 0.75, 95% CI 0.54 to 1.05, 
p=0.09; I2=62%). In studies with a follow-up >8y, high intake or serum concentration of 
lycopene were associated with significant reductions in the risk of stroke with low 
heterogeneity levels (HR 0.75, 95% CI 0.60 to 0.95, p=0.02; I2=0%). Between-group 
comparison of these results according to length of follow-up were not significantly different 
between groups (p=0.98).  
Subgroup analysis (Table 2.4) according to age showed that in studies with mean age ≤55y, 
high intake of lycopene was associated with non-significant lower risk of stroke (HR 0.85, 
95% CI 0.65 to 1.12, p=0.26; I2=0%); however, studies with mean age >55y, high intake or 
serum concentration of lycopene were associated with significantly lower risk of stroke (HR 
0.66, 95% CI 0.56 to 0.77, p<0.001; I2=0%). In addition, two studies in which mean age was 
not reported showed that high intake of lycopene was associated with non-significant 
reduction in the risk of stroke with high heterogeneity levels (HR 0.52, 95% CI 0.12 to 2.29, 
p=0.39; I2=77%). 
Subgroup analysis (Table 2.4) by BMI showed that in studies with mean BMI <26, high 
intake or serum concentration of lycopene were associated with non-significant lower risk 
of stroke (HR 0.90, 95% CI 0.70 to 1.16, p=0.44; I2=0%), while in studies with mean BMI 
≥26, high intake or serum concentration of lycopene were associated with significant lower 
risk of stroke with low heterogeneity levels (HR 0.64, 95% CI 0.48 to 0.86, p=0.003; 
I2=44%). In addition, one study not reporting mean BMI showed that high serum 
concentration of lycopene was associated with non-significant lower risk of stroke with high 
heterogeneity levels (HR 0.78, 95% CI 0.51 to 1.19, p=0.25; I2=77%).  
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Table 2.4 Subgroup analysis for risk of stroke. 
Variable (Number of studies 
or subgroups)  
HR  
(95% CI) 
P (Z-test) Heterogeneity 
I2% 
Between 
group 
comparisons 
(Chi2) 
Geographical origins 
USA (n=4)  
(Ascherio et al., 1999; Hak et 
al., 2004; Jacques et al., 2013; 
Sesso et al., 2003) 
0.88  
(0.71, 1.07) 
p=0.20 0 
p=0.06 Japan and Finland (n=4) 
(Hirvonen et al., 2000; Ito et al., 
2006; Karppi et al., 2012c; 
Rissanen et al., 2001) 
0.63  
(0.48, 0.82) 
p<0.001 30 
Sex 
Men (n=4)  
(Ascherio et al., 1999; Hak et 
al., 2004; Hirvonen et al., 2000; 
Rissanen et al., 2001) 
0.71  
(0.51, 0.99) 
p=0.04 56 
p=0.69 Mixed (n=3)  
(Ito et al., 2006; Jacques et al., 
2013; Karppi et al., 2012c) 
0.75  
(0.58, 0.98) 
p=0.03 7 
Women (n=1)  
Sesso et al., 2003 
0.91  
(0.57, 1.45) 
p=0.69 n/A 
Follow-up time 
≤8y (n=4)  
(Ascherio et al., 1999; Hirvonen 
et al., 2000; Rissanen et al., 
2001; Sesso et al., 2003) 
0.75  
(0.54, 1.05) 
p=0.09 62 
p=0.98 >8y (n=4)  
(Hak et al., 2004; Ito et al., 
2006; Jacques et al., 2013; 
Karppi et al., 2012c) 
0.75  
(0.60, 0.95) 
p=0.02 0 
Age 
≤55y (n=2)  
(Jacques et al., 2013; Sesso et 
al., 2003) 
0.85  
(0.65, 1.12) 
p=0.26 0 
p=0.25 
>55y (n=4)  
(Hak et al., 2004; Hirvonen et 
al., 2000; Ito et al., 2006; 
Karppi et al., 2012c) 
0.66  
(0.56, 0.77) 
p<0.001 0 
N/A (n=2)  
(Ascherio et al., 1999; Rissanen 
et al., 2001) 
0.52  
(0.12, 2.29) 
p=0.39 77 
BMI 
<26 (n=3)  
(Ascherio et al., 1999; Hak et 
al., 2004; Sesso et al., 2003) 
0.90  
(0.70, 1.17) 
p=0.44 0 
p=0.23 
≥26 (n=4)  
(Hirvonen et al., 2000; Jacques 
et al., 2013; Karppi et al., 
2012c; Rissanen et al., 2001) 
0.64  
(0.48, 0.86) 
p=0.003 45 
N/A (n=1)  
(Ito et al., 2006) 
0.78  
(0.51, 1.19) 
p=0.25 N/A 
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Figure 2.2 Forest plots of epidemiological studies evaluating associations between high serum 
level/intake of lycopene and risk of stroke (A); CVD (B) and mortality (C).  
The forest plots show individual studies, the weight allocated to each of them, and 
shown in the form of black diamonds, the subgroups and overall effect size as hazards 
ratios with 95% confidence intervals. 
  
(A) Stroke 
(B) CVD 
(C) Mortally 
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2.3.5 CVD 
Seven studies, including 121651 participants, evaluated intake or serum concentration of 
lycopene and incidence of CVD (Ito et al., 2006; Jacques et al., 2013; Mayne et al., 2004; 
Osganian et al., 2003; Sesso et al., 2004; Sesso et al., 2005; Sesso et al., 2003). Overall, 
meta-analysis showed that high intake or serum concentration of lycopene were significantly 
associated with a reduced incidence of CVD (HR 0.86, 95% CI 0.77 to 0.95, p=0.003). 
Heterogeneity levels assessed by the I2 test were low at 0% (Figure 2.2B).  
Results from studies evaluating intake of lycopene showed that higher intake was 
significantly associated with reduced incidence of CVD (HR 0.88, 95% CI 0.78 to 0.99, 
p=0.03) (Jacques et al., 2013; Osganian et al., 2003; Sesso et al., 2003). Heterogeneity levels 
assessed by the I2 test were low at 0% (Figure 2.2B). In addition, studies evaluating serum 
lycopene concentrations showed that high concentration was associated with non-significant 
lower risk of CVD (HR 0.78, 95% CI 0.63 to 0.98, p=0.03) (Ito et al., 2006; Mayne et al., 
2004; Sesso et al., 2004; Sesso et al., 2005). Heterogeneity levels assessed by the I2 test were 
low at 0% (Figure 2.2B). 
Meta-analysis of four studies (Ito et al., 2006; Jacques et al., 2013; Mayne et al., 2004; 
Osganian et al., 2003), including 81741 participants, indicated that there was strong evidence 
that high intake or serum concentration of lycopene were associated with lower incidence of 
CHD (HR 0.81, 95% CI 0.67 to 0.98, p=0.03). Heterogeneity levels assessed by the I2 test 
were low at 26% (Appendix A6).  
2.3.6 Mortality 
Five studies, including 6249 participants, evaluated serum concentration of lycopene and 
risk of mortality (Ford et al., 2014; Han et al., 2016; Karppi et al., 2012b; Karppi et al., 
2013c; Mayne et al., 2004). Overall, meta-analysis showed that high serum concentration of 
lycopene was significantly associated with a reduced risk of mortality (HR 0.63, 95% CI 
0.49 to 0.81, p>0.001). Heterogeneity levels assessed by the I2 test were low at 46% (Figure 
2.2C). 
In addition, two studies assessing mortality were not included in the meta-analysis. One 
study was not included in meta-analysis because the results were based on the use of a 
different reference group, reported that high serum concentration of lycopene was associated 
with non-significant lower risk of CHD mortality (HR 0.42, 95% CI 0.14 to 1.30, p=0.42) 
(Mayne et al., 2004). The second study reported that among people with lupus 
erythematosus, high serum concentration of lycopene were associated with a lower mortality 
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rate (5.3%) while the group with low serum lycopene concentration had a mortality rate of 
33% (Han and Han, 2016).  
2.3.7 Others cardiovascular-related disorders 
One study evaluating CHF, including 1031 participants, indicated that there was strong 
evidence that high serum concentration of lycopene was associated with lower incidence of 
CHF (HR 0.24, 95% CI 0.10 to 0.56, p=0.001) (Appendix A7) (Karppi et al., 2013b). In 
addition, Wood and Johnson (2004) evaluating CHF reported that lower lycopene levels was 
associated with non-significant reduction of CHF among individuals with periodontitis (HR 
0.65, 95% CI 0.21 to 2.03) and without periodontitis (HR 0.59, 0.15-2.24) (Wood and 
Johnson, 2004). One study by Karppi et al. (2013) evaluated AF and reported that high serum 
concentration of lycopene was associated with significant increased risk of AF (HR 0.45, 
95% CI 0.26 to 0.78, p=0.004) (Appendix A7) (Karppi et al., 2013a).  
Meta-analysis of five studies, including 7825 participants, indicated that there was not strong 
evidence that high serum concentration (Hak et al., 2003; Karppi et al., 2012a), or either 
adipose tissue (Kabagambe et al., 2005; Kohlmeier et al., 1997) or intake (Tavani et al., 
2006) of lycopene was associated with lower incidence of MI (OR 0.84, 95% CI 0.57 to 
1.23, p=0.37) (Appendix A8). In addition, another study on MI that was not included in 
meta-analysis because the results were based on the use of a different reference group, 
reported a non-significant higher risk of MI with lower serum lycopene concentration (OR 
1.33, CI not provided, p=0.54) (Street et al., 1994).  
Meta-analysis of two studies, including 679 participants, indicated that high serum 
concentration of lycopene was associated with a non-significant reduction in the risk of 
incidence of atherosclerosis (OR 0.79, 95% CI 0.60 to 1.04, p=0.09). Heterogeneity levels 
assessed by the I2 test were low at 0% (Appendix A8) (Iribarren et al., 1997; Klipstein-
Grobusch et al., 2000). 
2.3.8 Meta-analysis: Tomato and cardiovascular diseases 
Three studies, including 49110 participants, evaluated the association between consumption 
of tomato products and CVD reported below (Jacques et al., 2013; Sesso et al., 2003; Wood 
and Johnson, 2004).  
Jacques et al. (2013) and Sesso et al. (2003), evaluated intake of tomato and incidence of 
stroke and CVD (Jacques et al., 2013; Sesso et al., 2003). Meta-analysis of these studies, 
including 43580 participants, showed that high intake of tomato was associated with non-
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significant reductions in stroke (HR 0.53, 95% CI 0.12 to 2.42, p=0.41), and non-significant 
reductions in CVD (HR 0.91, 95% CI 0.77 to 1.07, p=0.26) (Appendix A9).  
Jacques et al. (2013) including 5135 participants, evaluated tomato product intake and 
incidence of CHD (Jacques et al., 2013). Higher intake of tomato product was significantly 
associated with a reduced incidence of CHD (HR 0.91, 95% CI 0.83 to 0.99, p=0.03). 
Sesso et al. (2003), including 38445 participants, reported that high intake of tomato based 
product was non-significantly associated with reduced risk of MI (RR 0.39, 95% CI 0.12 to 
1.30, p=0.13) (Appendix A9) (Sesso et al., 2003). 
In addition, Wood and Johnson (2004) reported that lower consumption of tomato were 
associated with significant increased risk of CHF among individuals with periodontitis (HR 
5.10, 95% CI 1.67 to 15.57) and without periodontitis (HR 1.68, 95% CI 0.60 to 4.76) (Wood 
and Johnson, 2004). 
2.4 Discussion  
2.4.1 Principal findings 
This systematic review and meta-analysis of epidemiological studies revealed that there is 
strong evidence indicating that lycopene intake or serum concentrations were associated with 
significant reductions of 26% in stroke, 14% in CVD; while high serum lycopene 
concentration were associated with significant reduction of 37% in mortality. In addition, 
subgroup analysis of the studies evaluating stroke revealed that the association of high 
intakes of lycopene and lower risk of stroke were significant among older and overweight 
individuals; studies with longer follow-up were also more likely to report significant 
associations (Table 2.4). This systematic review revealed a dearth of evidence on the 
associations with other cardiovascular outcomes such as atherosclerosis, MI, CHF, AF. 
Scarce evidence also indicated that high dietary and plasma lycopene, or high intakes of 
tomato were not associated with significant reduction of stroke, CVD, CHD, MI and CHF. 
These results have important public health implications given the high prevalence of CVD 
globally.  
2.4.2 Scientific analysis of findings and implications for health  
A focus on the health impacts of dietary patterns, as a whole, has been emphasised over the 
past couple of decades (Hu, 2002), and the important health benefits of major dietary 
patterns, such as the Mediterranean dietary pattern, are well documented (Estruch et al., 
2013). However, it is evident that the impact of dietary patterns is a result of the additive 
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effects of different food groups and previous evidence highlights this relative contribution 
of specific food groups to dietary patterns (Trichopoulou et al., 2009).  
CVD are the leading cause of death, followed by cancer (GBD 2015 Mortality and Causes 
of Death Collaborators, 2016). In addition, results from the Global burden of disease 
collaboration (GBD 2015 Risk Factors Collaborators, 2016), indicates that metabolic risk 
factors such as high blood pressure (1st) and blood cholesterol (7th), and behavioural risk 
factors such as low fruit (13th) and vegetable (20th) intakes are among the top 30 leading 
causes of death and disability. This meta-analysis showed that high lycopene consumption 
and serum concentrations were associated with significant reductions of 37% in mortality, 
26% in stroke, and 14% in CVD. The results of the present review on the association of 
lycopene and stroke are in line with those from a previous meta-analysis reporting a 
reduction in risk of stroke (19.3%) (Li and Xu, 2014). In addition, a recent meta-analysis on 
14 studies reporting significant reductions of stroke (RR 0.83, 95% CI 0.69 to 0.96), CVD 
(RR 0.83, 95% CI 0.76 to 0.90), and CHD (RR 0.87, 95% CI 0.76 to 0.98) with higher 
lycopene intake (Song et al., 2017). Compared with these previous meta-analyses, present 
systematic review identified 28 studies and 25 of those were meta-analysed on the 
association of lycopene and tomato and CVD and mortality. Also, this systematic review 
explored the impact of important covariates such as age, and BMI as sources of heterogeneity 
by means of meta-regression and subgroup analysis. 
Taken together, the results of this study and the results from systematic review and meta-
analysis on the impact of interventions on tomato and lycopene consumption on 
cardiovascular risk factors (Cheng et al., 2017), provide reasonable and consistent evidence 
supporting the health benefits and important role of tomato products and lycopene as part of 
a healthy cardioprotective diet. This is an important and reassuring finding given the 
criticism to which observational evidence is sometimes subjected (Taubes, 1995; Young and 
Karr, 2011).  
Inadequate consumption of fruit and vegetable contributes to 2.6 million deaths per year 
around the world, and increasing fruit and vegetable to 600 g/d could reduce 1.8% of total 
global burden of disease (Lock et al., 2005). Diets with high consumption of fruit and 
vegetables provide vitamins, minerals and fibre, as well as phytochemicals which contribute 
significantly to improvements in several risk factors, including blood pressure (BP), lipid 
levels, insulin resistance, inflammatory biomarker levels, endothelial function, and weight 
control (Mozaffarian et al., 2011). Tomatoes are one of the most consumed vegetable and 
vegetable products, just below the consumption of potatoes, lettuce and vegetable salads, 
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and onions (FAOSTAT, 2015a). Tomatoes are the primary source of lycopene, the most 
powerful antioxidant, and are therefore likely to lower oxidative stress induced by reactive 
oxygen species, inflammation and platelet aggregation, decrease lipid peroxidation and 
reduced low-density-lipoprotein (Bohm, 2012). All these factors play critical roles in 
development of atherosclerosis and CVD. The results of the present systematic review 
should encourage the development of well-designed randomised controlled trials, which 
may potentially have important implications in primary and secondary prevention of 
cardiovascular mortality and the global burden of disease. 
2.4.3 Strengths and limitations  
The strengths of this study include the consistency of findings across the studies which is 
reflected by low levels of heterogeneity surrounding the findings. In addition, the validity of 
the results is strengthened by a comprehensive search of the literature adhering to pre-
specified criteria.  
The potential limitations of these findings merit consideration. These are associated with the 
widely acknowledged limitations of self-reported intakes of lycopene according to food 
frequency questionnaire (FFQ) relying on dietary intakes assessed many years before the 
occurrence of the outcome, which allow for unavoidable changes in dietary habits. The 
uncertainty associated with the assessment of dietary exposure are unavoidable because of 
the lack of accurate information and are likely to affect the results (Prentice, 2010). Usual 
intakes and their distribution in a given population are difficult to ascertain given the 
inaccuracy of data collected by dietary methods. Sources of uncertainty associated with 
dietary methods such as FFQ, used by most studies reviewed in this paper, include 
measurement error such as portion sizes used to calculate amounts, frequency and duration 
of consumption (exposure), the levels and frequency of occurrence of compounds in foods, 
and the relationship between these variables and those unidentified. Recent studies on the 
evaluation of uncertainty in dietary intakes suggest that uncertainty in portion sizes may vary 
in relation with different food groups (Souverein et al., 2011).  
Dietary underreporting is a conspicuous and pervasive problem to most dietary studies, thus 
affecting the relationship between dietary variables and health outcomes (Rosell et al., 2003). 
Uncertainty, results in the overestimation or underestimation of risk. Significant debate exist 
over the value of self-reported methods traditionally used in nutritional epidemiology 
(Dhurandhar et al., 2015; Satija et al., 2015). Therefore, growing interest in identifying 
objective biomarkers of food intake is a priority in the field of nutrition and health to 
overcome some of these limitations (Fave et al., 2011). 
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Another potential limitation might be the decision to pool findings from studies using dietary 
intakes and studies using plasma/serum concentrations of lycopene since high serum 
lycopene levels might not necessarily mean high lycopene/tomato intakes. In addition, 
tomatoes also contain other antioxidants such as vitamin C which has also been associated 
with potential cardio protective effects in some individuals (Ashor et al., 2016). 
Bioavailability and absorption of lycopene might be affected by the degree of processing 
and preparation as well as on the composition of the food or diet an individual consumes. 
However, in order to ensure clarity of the current findings results are presented as subgroups 
in the forest plots. In addition, most studies included in the systematic review originated 
from the USA and their applicability to other populations and other ethnic groups is 
uncertain. Although this study undertook meta-regression analysis, it was not able to conduct 
subgroup analysis to explore the impact of important factors such as ethnicity. 
2.5 Conclusions 
Current evidence from epidemiological studies support the hypothesis that lycopene and 
tomato may play a beneficial role in preventing CVD and early death. These results 
complement previous findings on intervention trials indicating that lycopene and tomato 
supplementation significantly reduced important CVD risk factors. The current systematic 
review revealed that there is a limited number of studies assessing cardiovascular disorders 
such as MI, CHF, AF and atherosclerosis; the associations between lycopene and tomato 
consumption and these disorders need to be investigated in future studies. Overall, these 
results should encourage the development of promising individualised nutritional strategies 
to tackle CVD risk factors and diseases. 
2.6 Research Questions Raised from The Present Chapter 
The work described in this chapter raised the following questions: 
1. What is the interventional evidence on the effects of tomato supplementation on 
CVD risk factors? 
2. What is the interventional evidence on the effects of lycopene supplementation on 
CVD risk factors? 
These questions will be addressed in Chapter 3 by evaluating the evidence from randomised 
controlled trials reporting the effects of tomato/lycopene supplementation on CVD risk 
factors. We hypothesised that tomato/lycopene consumption improves cardiovascular risk 
factors. 
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Chapter 3 Tomato and Lycopene Supplementation and Cardiovascular Risk 
Factors: A Systematic Review and Meta-Analysis 
This study was designed to answer the research questions in section 2.6.  
This chapter is presented as originally published in: Atherosclerosis 2017; 257, 100-08. 
3.1 Introduction 
Globally, behavioural risk factors including a range of dietary risks, e.g. low intakes of fruit 
and vegetables, have the greatest potential to promote disease and impair human health 
(GBD 2015 Risk Factors Collaborators, 2016). A wealth of epidemiological evidence 
indicates that particularly cardiovascular health is strongly influenced by a healthy diet; fruit 
and vegetables are considered an important element of a cardioprotective diet (Mozaffarian 
et al., 2011). 
The benefit of consuming fruit and vegetables is often ascribed to specific components of 
food. Recent systematic reviews of the literature indicate that supplementation with dietary 
nitrates, or foods rich in these compounds such as beetroot, have the potential to lower blood 
pressure (Siervo et al., 2013) and improve endothelial function (Lara et al., 2016), both 
regarded as early indicators of CVD. These benefits are valuable when developing effective 
nutritional strategies targeting specific key metabolic risk factors for the prevention and 
management of CVD.  
Vegetables such as tomato are ubiquitous in most dietary patterns across the world and their 
contribution to health has been documented in longitudinal epidemiologic studies. High self-
reported intakes of tomato and tomato products, and of dietary lycopene (a carotenoid 
compound) are associated with lower risk for CVD (Jacques et al., 2013; Sesso et al., 2003). 
Lycopene is one of the most potent antioxidants and the most predominant carotenoid in 
human plasma and it is assumed to be one of the active compounds on the health benefits of 
tomato (Mein et al., 2008). While the epidemiological evidence indicates a consistent 
association between tomato products and/or lycopene and lower CVD risk (Jacques et al., 
2013; Sesso et al., 2003), the effects of nutritional interventions on tomato products and 
lycopene have been studied only recently and their efficacy on improving vascular function 
remains to be evaluated. The reduction in mortality associated with tomatoes consumption 
is due to the positive effects on a number of cardiovascular risk factors. Tomatoes 
consumption can potentially modify both traditional and well-established markers, such as 
blood pressure, lipids and glucose, and novel markers such as inflammatory factors, IL-6 
and FMD. The evidence from human intervention trials on the efficacy of tomato products 
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or lycopene supplementations on cardiovascular risk biomarkers, for example blood lipids 
(total-, HDL-, LDL-cholesterol, triglycerides, oxLDL) and vascular function (FMD, Pulse 
wave velocity, PWV), has not been meta-analysed and systematically reviewed previously 
and a critical appraisal of the literature should be useful in testing this hypothesis. Here, the 
present study reported the findings of a systematic review and meta-analysis of the evidence 
from intervention trials investigating the efficacy of tomato products or lycopene 
supplementations on cardiovascular risk factors in adult human individuals. This systematic 
review was decided to focus particularly on blood lipids (total-, HDL-, LDL-cholesterol, 
triglycerides, oxLDL), vascular function (FMD, PWV), inflammatory factors (CRP, IL-6) 
and adhesion molecules (ICAM-1).  
3.2 Method 
This systematic review was undertaken in adherence with guidance from Cochrane (Higgins 
and Green, 2011) and the Centre for Reviews and Dissemination guidelines (Centre for 
Reviews and Dissemination, 2009) and is reported according to PRISMA guidelines (Figure 
3.1 and Appendix B1) (Moher et al., 2010). The protocol of this systematic review has been 
previously registered with PROSPERO, the International Prospective Register of Systematic 
Reviews (Registration number CRD42016042092).  
In August 2016, Medline, Web of science, and Scopus were searched systematically from 
inception. Reference lists of identified publications were hand searched to identify other 
studies potentially eligible for inclusion. 
The search strategies included the following terms 1) tomato; 2) lycopene; 3) trial/clinical 
trials; 4) vascular risk factors; 5) biomarkers; 6) vascular function; 7) endothelial function; 
8) blood lipids. The systematic review was restricted to articles published in English. 
Two researchers (HMC, JL) assessed articles independently for eligibility. The decision to 
include studies was hierarchical and was made initially on the basis of screening the studies’ 
titles and abstracts, and if a decision was not reached at this stage, then the full-text of the 
article was evaluated to make such a judgement. The full text of the selected articles was 
independently assessed by the same researchers. 
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3.2.1 Inclusion/exclusion criteria  
The selection of references during the search strategy and the data extraction was performed 
according to specific criteria which are delineated below: 
Inclusion criteria included: 1) Study Design: intervention studies; 2) Subjects: adult subjects 
>18 years of age; 3) Interventions: nutritional/dietary interventions (tomato and tomato-
based products or lycopene supplements versus a control or placebo group); 4) Outcomes: 
cardiovascular health-related outcome measures (described below). Exclusion criteria 
included 1) Study Design: non-interventional studies; 2) Subjects: subjects <18 years of age; 
3) Interventions: interventions not involving tomato or lycopene, or interventions combined 
interventions in which the effects of tomato and lycopene cannot be singled out; 4) 
Outcomes: non-vascular outcome measures.  
3.2.2 Data extraction 
A standardised, pre-piloted form was used to extract data from the included studies for 
assessment of study quality and evidence synthesis. Extracted information included: study 
design (country of origin, randomisation, duration and length of follow-up, methods of 
analysis, completion rates); participant characteristics (population, settings of interventions, 
baseline characteristics); outcome measures (dietary and/or nutritional intake, BMI, 
cardiovascular biomarkers); intervention details (i.e. tomato or lycopene). Study quality was 
assessed using the Cochrane risk of bias tool (Cuevas-Ramos et al., 2013). 
3.2.3 Outcome measures 
The primary outcomes of this review were changes in cardiovascular risk factors after tomato 
or lycopene supplementation. Measures included blood lipids (Total-, LDL-, and HDL-
cholesterol, Triglycerides, oxLDL), assessment of vascular function by FMD, PWV, resting 
SBP and DBP, inflammatory factors (CRP, IL-6) and adhesion molecules (ICAM-1).  
3.2.4 Statistical analysis 
The Review Manager (RevMan Version 5.1 for Windows Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2011) was used to synthesise and meta-
analyse results from the individual studies. Pooled results are mostly reported as weighted 
mean differences with 95% CI and with two-sided P-values. However, variables (such as 
IL-6 or CRP, and ICAM) were reported on different scales, and standardised mean 
differences (SMD) were therefore used as a summary statistic for comparing effect sizes 
across studies. 
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A random effects model accounting for inter-study variation was used. Multiple dietary 
intervention arms from three studies were included in the meta-analysis. Following previous 
guidance (Higgins and Green, 2011), excessive weightings from “double counts” arising 
from the “shared” group (in this case, the control group) were controlled by splitting the 
sample size of the shared group into approximately equal smaller groups for the 
comparisons. In this analysis, reviewers sought to extract and analyse adjusted results from 
multivariate models, if reported in the studies.  
Heterogeneity was evaluated using the I2 statistic (Centre for Reviews and Dissemination, 
2009; Higgins and Green, 2011). Levels of heterogeneity are commonly regarded as high 
when I2 values are >50%. Publication bias was appraised by visually inspecting the funnel 
plot, and supplemented with calculations of the Egger’s regression test (Egger et al., 1997). 
Quality of studies was assessed using the Jadad system (Jadad et al., 1996). 
3.3 Results  
The searches yielded 1189 publications after de-duplication and results of the screening 
process are described in Figure 3.1. Twenty-two publications that met the inclusion criteria 
were included in the present systematic review and meta-analysis (Table 3.1) (Biddle et al., 
2015; Blum et al., 2006; Blum et al., 2007; Burton-Freeman et al., 2012; Collins et al., 2004; 
Cuevas-Ramos et al., 2013; Devaraj et al., 2008; Engelhard et al., 2006; Gajendragadkar et 
al., 2014; Ghavipour et al., 2013; Kim et al., 2011; Markovits et al., 2009; Misra et al., 2006; 
Paran et al., 2009; Ried et al., 2009; Samaras et al., 2014; Silaste et al., 2007; Stangl et al., 
2011; Thies et al., 2012; Tsitsimpikou et al., 2014; Upritchard et al., 2000; Xaplanteris et al., 
2012), and 21 of those publications were included in the meta-analysis (Biddle et al., 2015; 
Blum et al., 2006; Blum et al., 2007; Burton-Freeman et al., 2012; Collins et al., 2004; 
Cuevas-Ramos et al., 2013; Devaraj et al., 2008; Engelhard et al., 2006; Gajendragadkar et 
al., 2014; Ghavipour et al., 2013; Kim et al., 2011; Markovits et al., 2009; Misra et al., 2006; 
Paran et al., 2009; Ried et al., 2009; Samaras et al., 2014; Silaste et al., 2007; Stangl et al., 
2011; Thies et al., 2012; Tsitsimpikou et al., 2014; Xaplanteris et al., 2012). 
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Figure 3.1 PRISMA flow diagram of selection of studies on lycopene or tomato consumption and 
vascular risk factors. 
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Table 3.1 Characteristics of studies included in systematic review. 
Ref (Country of 
origin) 
Health 
status 
Sample/Sex Age (SD) BMI Study 
design  
Duration Intervention 
(Active 
component) 
Dose Control group Outcomes 
studied 
Biddle et al., 
2015 (USA)  
Patients with 
Heart Failure 
Intervention 
group (M=8, 
F=10); 
Control group 
(M=15, F=7) 
Intervention 
group (65±11); 
 
Control group 
(65±9) 
M=30.7 
F=31.9  
Parallel, 
RCT 
30 d Usual diet 
supplemented 
with tomato 
Juice 
11.5 ounces of 
V8 juice per 
day 
Usual diet 
without tomato 
juice (no 
placebo) 
CRP 
Blum et al., 
2006 (Israel)  
Healthy Tomato 
(M=16, F=34);  
Control 
(M=16, F=32) 
45.5±14.1 N/A Parallel, 
controlled 
4 wk Usual diet 
supplement 
with tomato  
300 g tomato 
products 
(including 
tomato sauce, 
tomato juice, 
fresh tomatoes, 
or soup) per day 
 
 
 
 
 
 
  
Usual diet 
without tomato 
(no placebo) 
TC,  
TG, 
HDL, 
LDL 
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Ref (Country of 
origin) 
Health 
status 
Sample/Sex Age (SD) BMI Study 
design  
Duration Intervention 
(Active 
component) 
Dose Control group Outcomes 
studied 
Blum et al., 
2007 (Israel)  
Healthy 
overweight 
Intervention 
group (M=17, 
F=33); 
Control group 
(M=18, F=35) 
Intervention 
group 
(45.5±14);  
 
Control group 
(45.1±13.5) 
N/A Parallel, 
controlled 
4 wk Usual diet 
supplement 
with tomato  
300 g tomato 
products 
(including 
tomato sauce, 
tomato juice, 
fresh tomatoes, 
or soup) per day 
 
 
 
 
Usual diet 
without tomato 
(no placebo) 
CRP,  
ICAM-1 
 
  
Burton-Freeman 
et al., 2012 
(USA) 
Healthy M=13; F=12 27±8 22 Cross-over, 
RCT 
360 min Usual diet 
with tomato-
containing 
meal 
Around 85 g of 
tomato paste 
Usual diet 
without tomato-
containing meal 
TG,  
oxLDL,  
FMD,  
IL-6 
Collins et al., 
2004 (USA)  
Healthy M=5, F=5 M (49 (43-68)); 
 
F (51 (35-63)) 
M=26.3 
F=29.1 
Cross-over, 
RCT 
3 wk Low lycopene 
diet 
supplemented 
tomato juice 
18.4 mg 
lycopene per 
day 
Low lycopene 
diet 
TC,  
TG,  
HDL 
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Ref (Country of 
origin) 
Health 
status 
Sample/Sex Age (SD) BMI Study 
design  
Duration Intervention 
(Active 
component) 
Dose Control group Outcomes 
studied 
Cuevas-Ramos 
et al., 2013 
(Mexico) 
Healthy Tomato (M=6, 
F=20);  
Control (M=5, 
F=19) 
42±15.5 27.1 Parallel, 
RCT, single-
blind 
4 wk Usual diet 
supplemented 
with raw 
tomato 
300 g of raw 
tomato per day 
Usual diet with 
300 g of raw 
cucumber 
TC, 
TG, 
HDL,  
LDL 
Devaraj et al., 
2008 (USA)  
Healthy 6.5 mg 
lycopene 
(M=4, F=17); 
 
15 mg 
lycopene 
(M=4, F=13); 
 
30 mg 
lycopene 
(M=7, F=14); 
 
Placebo (M=4, 
F=14) 
6.5 mg 
lycopene 
(51.1±5.9); 
 
15 mg 
lycopene 
(49.8±8.2); 
 
30 mg 
lycopene 
(51.2±9.7); 
 
Placebo 
(49.9±15.8) 
6.5 mg 
lycopene=29.6
; 
 
15 mg 
lycopene=25.4
; 
 
30 mg 
lycopene=26.4
; 
 
Placebo=28.1 
Parallel, 
RCT, 
doubled-
blind 
8 wk Lycopene 
restricted diet 
with 
supplemented 
lycopene 
capsules 
6.5, 15, or 30 
mg per day 
Placebo 
capsules 
(Lycopene 
restricted diet) 
TC, 
TG, 
HDL,  
LDL 
Engelhard et al., 
2006 (Israel)  
Hypertension 
without 
concomitant 
diseases 
M=18, F=12 48 29.5 Non-
randomised 
single-blind 
placebo-
controlled 
trial 
8 wk Usual diet 
supplemented 
with lycopene 
capsule (Lyc-
O-Mato) 
250 mg of 
tomato extract 
capsule 
containing 15 
mg lycopene 
per day 
Usual diet with 
identical-
looking placebo 
capsule 
TC, 
TG, 
HDL,  
LDL, 
SBP, 
DBP 
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Ref (Country of 
origin) 
Health 
status 
Sample/Sex Age (SD) BMI Study 
design  
Duration Intervention 
(Active 
component) 
Dose Control group Outcomes 
studied 
Gajendragadkar 
et al., 2014 (UK)  
Healthy and 
CVD 
patients 
Healthy (7 mg 
M=23, F=1; 
control M=10, 
F=2); 
 
CVD patients 
(7 mg M=15, 
F=9; 
Control 
(M=10, F=2)  
Healthy (7 
mg=61±13, 
control=68±5);  
 
CVD patients 
(7 mg =67±6, 
control=68±5)  
Healthy (7 
mg=25.2; 
control=26.7); 
  
CVD patients 
(7 mg 28.6; 
control=28.4)  
Parallel, 
RCT, 
double-blind 
8 wk Usual diet 
with lycopene 
capsule 
7 mg lycopene 
daily per day 
Usual diet with 
identical-
looking placebo 
capsule 
HDL, 
LDL,  
oxLDL, 
SBP, 
DBP, 
PWV, 
CRP, 
IL-6 
Ghavipour et al., 
2013 (Iran)  
Obese and 
overweight 
Intervention 
group (F=53); 
 
Control group 
(F=51) 
Intervention 
group 
(23.3±0.5 
(SEM)); 
 
Control group 
(23.2±0.4 
(SEM)) 
Intervention 
group=28.2; 
 
Control 
group=28.3 
Parallel, 
RCT 
20 d Usual diet 
supplemented 
with tomato 
juice 
330 mL tomato 
juice per day 
Usual diet with 
water 
CRP, 
IL-6 
Kim et al., 2011 
(Korea)  
Healthy 6 mg lycopene 
(n=41); 
 
15 mg 
lycopene 
(n=37); 
 
Control (n=38) 
6 mg lycopene 
(34.8±1.28); 
 
15 mg 
lycopene 
(34.7±1.23); 
 
Control 
(33.5±1.13) 
6 mg 
lycopene=25.3
;  
 
15 mg 
lycopene=23.9
; 
 
Control=24.9 
Parallel, 
RCT, 
double-blind 
8 wk Usual diet 
supplemented 
with lycopene 
capsules (Lyc-
O-Mato) 
6 mg or 15 mg 
lycopene per 
day 
Usual diet with 
placebo 
containing 
soybean oil 
capsules 
SBP, 
CRP,  
ICAM-1 
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Ref (Country of 
origin) 
Health 
status 
Sample/Sex Age (SD) BMI Study 
design  
Duration Intervention 
(Active 
component) 
Dose Control group Outcomes 
studied 
Markovits et al., 
2009 (Israel)  
Obesity and 
healthy 
Obesity (M=4, 
F=4); 
 
Healthy (M=4, 
F=4) 
47±6 (SEM) Obesity =37.5; 
 
Healthy=21.6 
Single 
treatment 
8 wk Usual diet 
supplemented 
with lycopene 
capsules (Lyc-
O-Mato) 
30 mg lycopene 
per day 
Usual diet with 
placebo 
capsules, made 
of edible soya 
oil 
CRP, 
IL-6 
Misra et al., 
2006 (India)  
Healthy 
postmenopau
sal women 
Lycopene 
supplement 
(F=20);  
 
Hormone 
replacement 
therapy (HRT) 
(F=21) 
46 Lycopene=25.
8 
 
HRT=25.3 
Parallel, 
RCT 
6 months Lycopene 
capsule 
(LycoRed) 
2 Lycopene 
capsule 
containing 2 mg 
of lycopene per 
day 
Hormone 
replacement 
therapy 
(estradiol 
valerate 2 mg 
and 
norethisterone 
acetate 1 mg) 
TC, 
TG, 
HDL, 
LDL 
Paran et al., 
2009 (Israel)  
Hypertension 
patient 
M=26, F=24 61.4±8.9 N/A Cross-over, 
RCT 
6 wk Usual diet 
supplemented 
with lycopene 
capsules (Lyc-
O-Mato) 
250 mg of 
tomato extract 
capsule 
containing 15 
mg lycopene 
per day 
Usual diet with 
identical-
looking placebo 
capsule 
SBP, 
DBP 
Ried et al., 2009 
(Australia)  
Pre-
hypertensive 
Lycopene 
(n=15);  
 
Control (n=10) 
Tomato extract 
(51.2±12.1);  
 
Control 
(57.9±13.4) 
N/A Parallel, 
RCT 
8 wk Usual diet 
supplemented 
with lycopene 
capsules (Lyc-
O-Mato) 
Tomato extract 
capsule 
containing 15 
mg lycopene 
per day 
Usual diet 
supplemented 
with identical-
looking placebo 
capsule 
containing 
mainly soy oil 
SBP, 
DBP 
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Ref (Country of 
origin) 
Health 
status 
Sample/Sex Age (SD) BMI Study 
design  
Duration Intervention 
(Active 
component) 
Dose Control group Outcomes 
studied 
Samaras et al., 
2014 (Greece)  
Ultra-
marathon 
runners 
Tomato Juice 
(n=15); 
 
Control (n=12) 
Tomato Juice 
(44.9±8.53); 
 
Control 
(46.6±15.3) 
Tomato 
Juice=24.1; 
 
Control=24.3 
Parallel, 
controlled 
8 wk Tomato juice Amount 
required to 
match subject’s 
usual 
carbohydrate 
supplementation 
Continued any 
usual 
supplementation 
consumption 
TC, 
TG, 
HDL, 
LDL, 
FMD 
Silaste et al., 
2007 (Finland)  
Healthy  M=5; F=16 30 23.5 Sequential 3 
weeks low 
tomato, 
3 weeks high 
tomato 
6 wk Usual diet 
supplemented 
with tomato 
juice 
400 ml tomato 
juice containing 
27 mg 
lycopene) 
Usual diet 
without tomato 
products 
TC,  
LDL 
Stangl et al., 
2011 (Germany)  
Healthy 
postmenopau
sal women 
F=19 58.9±6.3 25 Cross-over, 
RCT 
7 d Tomato free 
diet 
supplemented 
with buttered 
roll with 
tomato puree 
70 g tomato 
puree 
Tomato free diet 
supplemented 
with buttered 
roll without 
tomato puree 
FMD 
Thies et al., 
2012 (UK)  
Moderately 
overweight 
High tomato 
(M=35, F=46);  
 
Lycopene 
(M=28, F=40); 
 
Control 
(M=30, F=46) 
High tomato 
(51±0.7 
(SEM));  
 
Lycopene 
(51.1±0.9 
(SEM);  
 
Control 
(51±0.7 
(SEM)) 
High 
tomato=26.4; 
 
Lycopene=26.
7; 
 
Control=26.8 
Parallel, 
RCT,  
single-blind 
12 wk 1, High tomato 
based diet or  
 
2, low tomato 
diet 
supplemented 
with lycopene 
capsule 
1, High tomato 
diet were above 
the minimum 
target of 7 mg 
per day 
 
2, Low tomato 
diet with 
lycopene 
capsules 
containing 10 
mg lycopene 
Low tomato diet 
(low in tomato-
based foods) 
TC,  
TG, 
HDL, 
LDL, 
oxLDL, 
SBP,  
DBP,  
PWV, 
CRP,  
IL-6,  
ICAM-1, 
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Ref (Country of 
origin) 
Health 
status 
Sample/Sex Age (SD) BMI Study 
design  
Duration Intervention 
(Active 
component) 
Dose Control group Outcomes 
studied 
Tsitsimpikou et 
al., 2014 
(Greece) 
Patients with 
metabolic 
syndrome 
Tomato 
(M=13, F=2);  
 
Control 
(M=11, F=1) 
Tomato 
(53.5±9.8); 
 
Control 
(56.6±10.2) 
N/A Parallel, 
controlled 
8 wk Usual diet 
supplemented 
with tomato 
juice 
Tomato juice 
with 2.51 mg 
lycopene per 
100 ml 
Usual diet 
without tomato 
juice 
TC,  
TG, 
HDL,  
LDL,  
IL-6 
Upritchard et al., 
2000 (New 
Zealand)  
Patients with 
Type 2 
diabetes 
Tomato juice 
(M=10, F=5); 
 
Placebo 
(M=10, F=3) 
Tomato 
(63±8); 
 
Placebo (60±6) 
Tomato=30.9; 
 
Control=31.8 
Parallel, 
RCT 
4 wk Usual diet 
supplemented 
with tomato 
juice 
250 mL of 
tomato juice 
twice a day 
Usual diet with 
gelatin placebo 
capsule 
containing 
pharmaceutical 
starch 
CRP 
Xaplanteris et 
al., 2012 
(Greece)  
Healthy  M=8, F=11 39±13 24.8 Cross-over, 
RCT, single-
blinded 
2 wk usual diet 
supplemented 
with tomato 
paste  
70 g of tomato 
paste containing 
33.3 mg 
lycopene per 
day 
Usual diet 
without tomato 
paste 
FMD 
 
Ref, Reference; M, Male; F, Female; RCT, randomised controlled trial; wk, weeks; BMI, Body mass index; CRP, C-reactive protein; TC, Total cholesterol; TG, 
Triglyceride; HDL, High density lipoprotein; LDL, Low density lipoprotein; ICAM-1, Intercellular adhesion molecule 1; oxLDL, Oxidised low-density 
lipoproteins; FMD, Flow-mediated dilation; IL-6, Interleukin 6; SBP, Systolic blood pressure, DBP, Diastolic blood pressure; PWV, Pulse wave velocity 
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3.3.1 Study characteristics 
Fifteen studies used RCT design while seven were controlled trials using a non-randomised 
design. These 22 studies originated from the USA (n=4), UK (n=2), Greece (n=3), Israel 
(n=5), and single studies from Finland, Germany, Korea, Mexico, Iran, India, Australia and 
New Zealand.  
The pooled study population meta-analysed included 1197 participants who were followed-
up for 4 months on average (range from 1 day to 6 months). The mean ages of the samples 
in these studies ranged from 27 to 68 years. Three studies recruited women only (Ghavipour 
et al., 2013; Misra et al., 2006; Stangl et al., 2011). Mean BMI in these studies was 26.8 
kg/m2 (Table 3.1). Twelve of the included studies assessed tomato products alone as the 
intervention agent (Biddle et al., 2015; Blum et al., 2006; Blum et al., 2007; Burton-Freeman 
et al., 2012; Collins et al., 2004; Cuevas-Ramos et al., 2013; Ghavipour et al., 2013; Samaras 
et al., 2014; Silaste et al., 2007; Stangl et al., 2011; Tsitsimpikou et al., 2014; Xaplanteris et 
al., 2012), eight studies used lycopene alone (Devaraj et al., 2008; Engelhard et al., 2006; 
Gajendragadkar et al., 2014; Kim et al., 2011; Markovits et al., 2009; Misra et al., 2006; 
Paran et al., 2009; Ried et al., 2009) and one study used both tomato products and lycopene 
(Thies et al., 2012). The dose of tomato-products ranged from 70 to 400g/d, and lycopene 
dose ranged from 4 to 30 mg/d. 
Approximately half (n=13) of the reports included in the systematic review came from 
studies involving healthy participants (Table 3.1). The remaining studies reported the 
recruitment of participants with underlying cardiometabolic disorders (n=11), such as 
metabolic syndrome (1 study), CVD (1 study), heart failure (1 study), Type 2 diabetes (1 
study), overweight (3 studies), obesity (2 studies), hypertension (2 studies) and 
prehypertension (1 study). 
3.3.2 Meta-analysis of studies supplementing tomato 
 LDL-cholesterol 
Six studies, including 401 participants, evaluated the impact of tomato supplementation on 
LDL-cholesterol. Overall, tomato supplementation significantly reduced LDL-cholesterol 
by 0.22 mmol/L (95% CI -0.37 to -0.06, p=0.006). Heterogeneity levels assessed by the I2 
test were low at 0% (Figure 3.2). 
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Figure 3.2 Meta-analysis of effect of interventions supplementing tomato on LDL-cholesterol 
(mmol/L). 
 FMD  
Six studies, including 233 participants evaluated the impact of tomato supplementation on 
FMD. Three studies measured FMD acutely (≤24hours) and three studies evaluated FMD in 
the short-term (≥1 week). Overall, short-term tomato supplementation significantly 
increased FMD by 2.53% (95% CI 0.56 to 4.50, p=0.01). Heterogeneity levels assessed by 
the I2 test were low at 0%; however acute studies did not show any improvements (1.46%; 
95% CI -0.33 to 3.26, p=0.11) (Figure 3.3).  
 
Figure 3.3 Meta-analysis of effect of interventions supplementing tomato on FMD (%). 
 IL-6 
Three studies, including 288 participants, reported IL-6 showing tomato supplementation 
significantly reduced by 0.25 pg/mL (95% CI -0.49 to -0.02, p=0.03). Heterogeneity levels 
assessed by the I2 test were low at 1% (Figure 3.4). 
 
Figure 3.4 Meta-analysis of effect of interventions supplementing tomato on IL-6 (pg/mL). 
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There was only weak evidence that tomato interventions had an effect on other 
cardiovascular factors including SBP, DBP, Total- or HDL-cholesterol, triglycerides, 
oxLDL, PWV, or CRP and ICAM-1. 
 Resting blood pressure 
Three studies/arms, including 207 participants, reported resting SBP and DBP which showed 
no differences between interventions and controls, mean is -0.84mmHg (95% CI -5.10 to 
3.42, p=0.70) (Figure 3.5) and 1.12mmHg (95% CI -1.34 to 3.59, p=0.37) (Figure 3.6) 
respectively. Both heterogeneity levels assessed by the I2 test were low at 0%. 
 
Figure 3.5 Meta-analysis of effect of interventions supplementing tomato on resting SBP (mmHg).  
 
 
Figure 3.6 Meta-analysis of effect of interventions supplementing tomato on resting DBP 
(mmHg). 
 Total-cholesterol 
Nine studies/arms, including 421 participants, reported total cholesterol which showed no 
differences between interventions and controls, mean is -0.01mmol/L (95% CI -0.16 to -
0.13, p=0.87). Heterogeneity levels assessed by the I2 test were low at 0% (Figure 3.7). 
 
Figure 3.7 Meta-analysis of effect of interventions supplementing tomato on total-cholesterol 
(mmol/L). 
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 Triglycerides 
Seven studies/arms, including 379 participants, reported triglycerides which showed no 
differences between interventions and controls, mean is 0.05mmol/L (95% CI -0.07 to 0.17, 
p=0.41) (Figure 3.8). Heterogeneity levels assessed by the I2 test were low at 10%. 
 
Figure 3.8 Meta-analysis of effect of interventions supplementing tomato on triglyceride 
(mmol/L). 
 HDL-cholesterol 
Eight studies/arms, including 379 participants, reported HDL-cholesterol which showed no 
differences between interventions and controls, mean is 0.11mmol/L (95% CI -0.01 to 0.23, 
p=0.08). Heterogeneity levels assessed by the I2 test were high at 80% (Figure 3.9).  
 
Figure 3.9 Meta-analysis of effect of interventions supplementing tomato on HDL-cholesterol 
(mmol/L). 
 OxLDL  
One study, including 157 participants, reported oxLDL which showed no differences 
between interventions and controls, mean is 0.80mmol/L (95% CI -9.04 to 10.64, p=0.87) 
(Figure 3.10).  
 
Figure 3.10 Meta-analysis of effect of interventions supplementing tomato on oxLDL (mmol/L).  
  
   Chapter 3 
 87 
 PWV 
One study, including 157 participants, reported PWV which showed no differences between 
interventions and controls, mean is 0.93m/s (95% CI -0.20 to 2.06, p=0.11) (Figure 3.11).  
 
Figure 3.11 Meta-analysis of effect of interventions supplementing tomato on PWV (m/s). 
 CRP 
Four studies, including 404 participants, reported CRP which showed no differences 
between interventions and controls, mean is -0.14mg/L (95% CI -0.34 to 0.05, p=0.15). 
Heterogeneity levels assessed by the I2 test were low at 0% (Figure 3.12).  
 
Figure 3.12 Meta-analysis of effect of interventions supplementing tomato on CRP (mg/L). 
 ICAM-1 
Two studies, including 260 participants, reported ICAM-1 which showed no differences 
between interventions and controls, mean is 0.20pg/mL (95% CI -0.47 to 0.88, p=0.56). 
Heterogeneity levels assessed by the I2 test were high at 86% (Figure 3.13).  
 
Figure 3.13 Meta-analysis of effect of interventions supplementing tomato on ICAM-1 (pg/mL). 
3.3.3 Meta-analysis of studies supplementing lycopene 
 Resting SBP 
Seven studies/arms, including 492 participants, evaluated the impact of lycopene 
supplementation on resting SBP. Overall lycopene supplementation significantly reduced 
SBP by 5.66 mmHg (95% CI -9.31 to -2.01, p=0.002). Heterogeneity levels assessed by the 
I2 test were high at 65% (Figure 3.14). 
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Figure 3.14 Meta-analysis of effect of interventions supplementing lycopene on systolic blood 
pressure (mmHg). 
There was only weak evidence that lycopene interventions had an effect on other 
cardiovascular factors including DBP, Total- LDL- or HDL-cholesterol, triglycerides, 
oxLDL, PWV, CRP, IL-6 or ICAM-1. 
 Total-cholesterol 
Six studies/arms, including 363 participants, reported total-cholesterol which showed no 
differences between interventions and controls, mean is 0.14mmol/L (95% CI -0.06 to 0.34, 
p=0.16). Heterogeneity levels assessed by the I2 test were low at 0% (Figure 3.15). 
 
Figure 3.15 Meta-analysis of effect of interventions supplementing lycopene on total-cholesterol 
(mmol/L). 
 Triglyceride 
Six studies/arms, including 363 participants, reported triglyceride which showed no 
differences between interventions and controls, mean is -0.05mmol/L (95% CI -0.14 to 0.04, 
p=0.24). Heterogeneity levels assessed by the I2 test were low at 0% (Figure 3.16). 
 
Figure 3.16 Meta-analysis of effect of interventions supplementing lycopene on triglyceride 
(mmol/L). 
 HDL-cholesterol 
Eight studies/arms, including 435 participants, reported HDL-cholesterol which showed no 
differences between interventions and controls, mean is -0.02mmol/L (95% CI -0.12 to 0.09, 
p=0.76). Heterogeneity levels assessed by the I2 test were high at 64% (Figure 3.17). 
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Figure 3.17 Meta-analysis of effect of interventions supplementing lycopene on HDL-cholesterol 
(mmol/L). 
 LDL-cholesterol 
Eight studies/arms, including 441 participants, reported LDL-cholesterol which showed no 
differences between interventions and controls, mean is 0.04mmol/L (95% CI -0.08 to 0.16, 
p=0.54). Heterogeneity levels assessed by the I2 test were low at 0% (Figure 3.18). 
 
Figure 3.18 Meta-analysis of effect of interventions supplementing lycopene on LDL-cholesterol 
(mmol/L). 
 OxLDL 
Three studies/arms, including 216 participants, reported OxLDL which showed no 
differences between interventions and controls, mean is 5.20 mmol/L (95% CI -4.11 to 
14.51, p=0.27). Heterogeneity levels assessed by the I2 test were low at 0% (Figure 3.19). 
 
Figure 3.19 Meta-analysis of effect of interventions supplementing lycopene on OxLDL (mmol/L).  
 DBP 
Five studies/arms, including 376 participants, reported DBP which showed no differences 
between interventions and controls, mean is -1.45mmHg (95% CI -4.02 to 1.13, p=0.27). 
Heterogeneity levels assessed by the I2 test were high at 53% (Figure 3.20).  
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Figure 3.20 Meta-analysis of effect of interventions supplementing lycopene on DBP (mmHg). 
 PWV 
Three studies/arms, including 216 participants, reported PWV which showed no differences 
between interventions and controls, mean is 0.39m/s (95% CI -0.20 to 0.97, p=0.19). 
Heterogeneity levels assessed by the I2 test were low at 0% (Figure 3.21). 
 
Figure 3.21 Meta-analysis of effect of interventions supplementing lycopene on PWV (m/s). 
 CRP 
Six studies/arms, including 344 participants, reported CRP which showed no differences 
between interventions and controls, mean is -0.03mg/L (95% CI -0.28 to 0.23, p=0.83). 
Heterogeneity levels assessed by the I2 test were low at 17% (Figure 3.22). 
 
Figure 3.22 Meta-analysis of effect of interventions supplementing lycopene on CRP (mg/L). 
 IL-6 
Four studies/arms, including 232 participants, reported IL-6 which showed no differences 
between interventions and controls, mean is -0.02pg/mL (95% CI -0.42 to 0.37, p=0.90). 
Heterogeneity levels assessed by the I2 test were low at 0% (Figure 3.23).  
 
Figure 3.23 Meta-analysis of effect of interventions supplementing lycopene on IL-6 (pg/mL). 
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 ICAM-1 
Three studies/arms, including 260 participants, reported ICAM-1 which showed no 
differences between interventions and controls, mean is -0.05pg/ml (95% CI -0.30 to 0.20, 
p=0.71). Heterogeneity levels assessed by the I2 test were low at 0% (Figure 3.24). 
 
Figure 3.24 Meta-analysis of effect of interventions supplementing lycopene on ICAM-1 (pg/ml). 
 Subgroup analysis  
Subgroup analysis according to country of origin was undertaken. Studies originating from 
western countries with relatively similar dietary patterns such as the UK, USA, Australia, 
Germany, and Finland were combined and compared with studies originating from countries 
with non-western dietary patterns such as Mexico, Israel, Iran, India, Korea, and Greece. 
Results showed that tomato supplementation significantly increased HDL-cholesterol by 
0.19mmol/L (95% CI 0.04 to 0.33, p=0.01) in studies from non-western dietary patterns. 
Heterogeneity levels assessed by the I2 test were significant at 81% (Figure 3.25).  
 
Figure 3.25 Meta-analysis of effect of supplementing tomato on HDL-cholesterol (mmol/L) 
according to two dietary pattern groups. 
In addition, tomato supplementation significantly reduced LDL-cholesterol by -0.25mmol/L 
(95% CI -4.60 to -0.04, p=0.02) in studies from western dietary patterns. Heterogeneity 
levels assessed by the I2 test were low at 0% (Figure 3.26).  
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Figure 3.26 Meta-analysis of effect of supplementing tomato on LDL-cholesterol (mmol/L) 
according to two dietary pattern groups. 
 
Lycopene supplementation significantly reduced SBP and DBP by -5.78mmHg (95% CI -
10.31 to -1.38, p=0.01) (Figure 3.27) and -3.89mmHg (95% CI -6.10 to -1.68, p=0.0006) 
respectively in studies from non-western countries (Figure 3.28). Heterogeneity levels of 
SBP and DBP subgroup from non-western countries assessed by the I2 test were 74% and 
0% respectively (Figure 3.27 and Figure 3.28). 
 
Figure 3.27 Meta-analysis of effect of supplementing lycopene on SBP (mmHg) according to two 
dietary pattern groups. 
 
 
Figure 3.28 Meta-analysis of effect of supplementing lycopene on DBP (mmHg) according to two 
dietary pattern groups. 
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3.3.4 Publication bias 
Funnel plots of results were derived and are reported in Figure 3.29, Figure 3.30, Figure 
3.31 and Figure 3.32. These suggested absences of publication bias. Egger’s tests supported 
this for LDL-cholesterol (p=0.467), FMD (p=0.43) and SBP (p=0.62). Egger’s test was not 
calculated for IL-6 given that only 3 studies were identified.  
 
Figure 3.29 Funnel plot of standard error for the effect of interventions supplementing tomato on 
LDL. 
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Figure 3.30 Funnel plot of standard error for the effect of interventions supplementing tomato on 
FMD. 
 
 
Figure 3.31 Funnel plot of standard error for the effect of interventions supplementing tomato on 
IL-6. 
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Figure 3.32 Funnel plot of standard error for the effect of interventions supplementing lycopene 
on SBP. 
3.3.5 Quality of studies 
We assessed the methodological quality and risk bias of the studies included in this review. 
The average retention rate for the RCT included in this review was >90% for all studies and 
the reason for the dropouts were often not related to the interventions themselves. Therefore, 
the majority of the included studies satisfied the criteria of the quality assessment tool. 
Blinding of participants and researchers delivering the intervention was implemented in 
interventions testing lycopene supplements. In addition, the included studies provided an 
adequate description of methods and randomisation procedures, thus no studies were 
excluded from analysis based on quality assessment. 
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3.4 Discussion 
3.4.1 Principal findings 
This systematic review and meta-analysis assessed the effectiveness of tomato and lycopene 
supplementation on cardiovascular risk factors, including blood lipids (total-, HDL-, LDL-
cholesterol, triglycerides, oxLDL) vascular function (FMD, PWV), inflammatory factors 
(CRP, IL-6) and adhesion molecules (ICAM-1), among adult subjects >18 years of age 
within RCT. This systematic review revealed that there is strong evidence indicating that 
tomato supplementation is associated with significant reductions in LDL-cholesterol and 
improvements in FMD, but not on other blood lipids or measures of vascular function. In 
addition, lycopene supplementation was associated with significant reductions in SBP but 
not on any other cardiovascular marker. In subgroup analysis tomato supplementation 
improved HDL-cholesterol in non-western dietary patterns but not in western dietary 
patterns while LDL-cholesterol decreased in western dietary patterns but not in non-western 
dietary patterns. Lycopene supplementation significantly reduced SBP and DBP in non-
western diets. The reduction of SBP and DBP may due to the HDL-antiatherogenic 
properties. Thies et al. (2017) suggested that increased lycopene intake improvement in HDL 
functionality, as measured by the activity of HDL-associated enzymes such as paraoxonase 
1, lecithin cholesterol acyl transferase and cholesterol ester transfer protein, potentially 
enhancing HDL-antiatherogenic properties (Thies et al., 2017). It is noteworthy that the 
changes of the subgroup outcome reported in these studies could be due to the characteristics 
of the studied population. In addition, the heterogeneity of non-western diets in HDL-
cholesterol is high at 81% which showed there are high variability among the studies. More 
research needed to identify tomato supplementation that improved HDL-cholesterol. 
Together, these results indicate that consuming tomato products and/or supplementing 
lycopene may have important health implications. This systematic review has also revealed 
that current studies have mostly focused on studying well-established cardiovascular 
biomarkers such as blood lipids and blood pressure, with less evidence on FMD and other 
measures of vascular function, however the evidence on the effects of tomato products or 
lycopene supplementation on novel biomarkers of vascular risk is scarce at present and 
requires further investigation. The results are in agreement with earlier reports such as a 
meta-analysis carried out in 2010 showing that lycopene supplementation from different 
sources significantly reduced LDL-cholesterol (Ried and Fakler, 2011) and a meta-analysis 
carried out on 2012 indicating that lycopene supplementation significantly lowered SBP (Li 
and Xu, 2013). 
   Chapter 3 
 97 
3.4.2 Strengths and limitations  
The strengths of these findings include a rigorous methodology in the systematic review of 
the literature, the low levels of heterogeneity between the studies included in this meta-
analysis were very low, as well as the risk of publications bias was low, adding validity to 
the findings of this meta-analysis. It is of note that the intervention studies included in this 
review were consistently, and significantly, successful in modifying the outcomes above 
described. The overall quality of the studies was high. All studies were randomised, and 
double-blind in the case of lycopene supplementation. The studies reported a high 
compliance with the interventions, which may be explained by the relatively short duration 
of the studies. 
This study is not without limitations. Due to the limited number of studies available, the 
analysis focused on examining the overall effects of interventions on the pre-specified 
outcomes preventing us of exploring the effects of common moderator variables such as age, 
gender, or other aspects of the interventions. Overall, studies were characterised by a small 
sample size, short duration, and over-representation of young, healthy men. It is important 
to acknowledge that there might be important heterogeneity on the bioavailability and 
concentrations of lycopene given that the products used in these studies varied in the degree 
of processing. Furthermore, the present study was not able to conduct subgroup analysis due 
to the limited number of studies. Studies included in meta-analysis originated from different 
geographic regions, and the dietary patterns, ethnicity of participants, genetic and sensitivity 
to lycopene might be influenced by these factors. The present study limited the choice of 
databases to three and although there might be a risk to have overlooked some studies, the 
databases included were considered the most relevant to the topic of study. 
3.4.3 Scientific analysis of findings 
This meta-analysis showed that tomato products supplementation was associated with 
significant reductions in LDL-cholesterol and improvements in short-term FMD, while 
lycopene supplementations reduced SBP. The beneficial effects of these interventions 
support the epidemiological evidence indicating an association between lower CVD risk and 
tomato (Jacques et al., 2013; Sesso et al., 2003) and suggest that these epidemiological 
findings may be explained by a potential combination of improvements in blood lipids, BP, 
and vascular function an early marker of cardiovascular risk (Gonzalez and Selwyn, 2003). 
A number of potential mechanisms are probably responsible behind the findings of this 
systematic review. Lycopene, the major carotenoid in tomato, might be more important than 
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other carotenoids in preventing atherosclerosis and cardiovascular diseases, however the 
findings from supplementing lycopene this systematic review did not support a role in 
reducing LDL-cholesterol. This may be related to the fact that tomatoes contain also other 
compounds (e.g. antioxidants such as vitamin C) possessing lipid-lowering properties 
associated with increased faecal excretion and reduced intestinal absorption of cholesterol, 
in addition to increasing cellular LDL receptor activity (Ashor et al., 2016; Silaste et al., 
2007). 
In addition, the results of the present meta-analysis are comparable to those achieved by 
other nutritional interventions such as dietary nitrates modifying SBP and FMD. Two 
previous systematic reviews of the literature have shown that inorganic nitrate or beetroot 
juice consumption were associated with significant reductions in SBP (4.4 mmHg 95% CI -
5.9 to -2.8, p<0.01) (Siervo et al., 2013), and improvements in FMD (SMD 0.52; 95% CI 
0.15 to 0.68, p=0.002) (Lara et al., 2016).  
Evidence from the effects of lycopene supplementation on oxidative stress is scarce at 
present and suggests the possibility of a positive effect on DNA damage but not on markers 
such as lag-time of LDL (Chen et al., 2013a). The results of the present study on oxLDL are 
in line with this evidence.  
3.4.4 Implications for health and future research 
Our results showed a significant decline in vascular risk factors after short-term (1 day to 6 
months) tomato-products and lycopene (tomato-products doses from 70 to 400 g/d, and 
lycopene dose ranged from 4 to 30 mg/d) supplementation, which may potentially have 
important implications in primary and secondary prevention of atherosclerosis, 
cardiovascular diseases and cardiovascular mortality. The seventh report of the Joint 
National Committee on BP estimated that a systolic BP reduction of at least 5 mmHg (similar 
to the observed decline in SBP after Lycopene supplementation) could decrease the risk of 
mortality due to stroke by 13-14% (Chobanian et al., 2003; Reboldi et al., 2011) and 
mortality from cardiovascular diseases by 9% (Chobanian et al., 2003). In addition, 
reductions of 1 mmol in LDL-cholesterol have been associated with a 23% reduction in 
myocardial infarction or coronary death and 12% reduction in all-cause mortality (Baigent 
et al., 2005). In relation with the findings on FMD, several recent systematic reviews and 
meta-analysis indicate that increases in FMD of 1% increase, independently of confounding 
factors, are associated with reductions ranging from 10-13% in the risk of cardiovascular 
events (Inaba et al., 2010; Matsuzawa et al., 2015; Xu et al., 2014). 
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3.5 Conclusions 
The available evidence on the effects of tomato and lycopene supplementation on vascular 
risk factors supports the view that increasing the intake of these has positive effects on blood 
lipids, blood pressure, some inflammatory factors, and vascular function. These results have 
potential public health implications and support the development of promising 
individualised nutritional strategies to tackle cardiovascular diseases.  
3.6 Research Questions Raised from The Present Chapter 
The work described in this chapter raised the following questions: 
1. Does the carotenoid content vary in different varieties of tomato? 
2. Does the carotenoid content change during postharvest storage? 
These questions will be addressed in Chapter 4 by using HPLC to determine the lycopene 
content in different tomato varieties. We also investigate the effect of postharvest storage on 
carotenoid content. We hypothesised that carotenoid content varies in different tomato 
varieties. 
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Chapter 4 Method for Determine Lycopene Content in Tomato 
This study was designed to answer the research questions in section 3.6.  
4.1 Introduction 
Nutritional value and appearance of tomato fruit are primary determined by carotenoid 
content (Kang et al., 2014). Carotenoid biosynthesis pathway begins with formation of 
phytoene from geranylgeranyl pyrophosphate (GGPP) (Figure 4.1) (Kang et al., 2014). 
Phytoene is further metabolised through desaturations, cyclisation and hydroxylation to from 
other carotenoid such as lycopene, carotenes, lutein and xanthophyll. There are only two 
recessive mutation available in tomato, yellow-flesh and tangerine, affecting lycopene 
biosynthesis from GGPP (Fantini et al., 2013; Kachanovsky et al., 2012; Liu et al., 2015). 
Mutation yellow-flesh is a loss-of-function mutant of the phytoene synthase (PSY1) gene 
while tangerine is a mutation in carotenoid cis-trans isomerase (CRTISO) gene (Liu et al., 
2015). Fruits of tomato with the recessive mutation yellow-flesh appear pale yellow fruit 
(Liu et al., 2015). The tangerine phenotype of the mutant tomato fruits is associated with an 
orange fruit due to the accumulation of 7,9,9’,7’-tetra-cis-lycopene (prolycopene) as the 
result of mutation in the CRTISO (Kachanovsky et al., 2012). CRTISO, a specific enzyme, 
produces all-trans-lycopene from prolycopene (Figure 4.1).  
Lycopene is the predominant carotenoid in tomatoes and tomato products responsible for the 
red colour. It is a polyunsaturated hydrocarbon with 11 liner conjugated double bond and 
two non-conjugated double bond, which give lycopene antioxidant properties and singlet 
oxygen quenching ability (Agarwal and Rao, 2000; Bohm, 2012). During process of tomato 
product, it usually involves thermal treatment and/or homogenisation, which can release 
lycopene from the food matrix and initiates cis-isomerisation of lycopene (Cooperstone et 
al., 2015; Petyaev, 2016; Shi and Le Maguer, 2000; Story et al., 2010; Valderas-Martinez et 
al., 2016). Cis-isomerisation can also be facilitated under light and oxidation (Shi and Le 
Maguer, 2000; Story et al., 2010). In fruit and vegetables, lycopene is present predominately 
in the all-trans configuration (approximately 95%), while lycopene in human plasma and 
tissue consists of 50-90% cis-lycopene (Figure 4.2) (Cooperstone et al., 2015; Sinha and 
Dua, 2015; Unlu et al., 2007b). The observation has led to the hypothesis that isomerisation 
from all-trans-isomers to cis-isomers increases the bioavailability and enhance the lycopene 
biological benefits (Cooperstone et al., 2015; Gärtner et al., 1997; Stahl and Sies, 1992).  
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Figure 4.1 The carotenoid biosynthesis pathway in plants. 
Copyright (2012) National Academy of Sciences, Kachanovsky et al., 2012.  
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4.1.1 Determination of lycopene content using HPLC 
Studies have reported various assay methods for the determination of lycopene content in 
food products using HPLC, which is a technique in analytical chemistry used to separate, 
identify, and quantify a compound in a solution mixture (Lindsay, 1992). In addition to all-
trans-lycopene and cis-lycopene, tomato and its products contain other types of carotenoids 
such as β-carotene. Therefore, HPLC is used to separate the different carotenoid components 
of the tomato sample from each other so that they may be identified and/or quantified. 
There are two main objectives of this chapter. First, to analysis the lycopene content in both 
Piccolo (red cherry tomato) and Oranjstar (orange cherry tomato) tomatoes. Second, to 
variate the effect of storage time under darkness condition on carotenoids content of cherry 
tomato during postharvest storage.  
 
Figure 4.2 Structures of all-trans and cis isomers of lycopene. 
(Wang, 2012). 
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4.2 Method 
4.2.1 Measurement of carotenoids in tomato fruit 
All organic solvents (methanol (MeOH), methyl t-butyl ether (MTBE), butylated 
hydroxytoluene (BHT), ethyl acetate (EA), dichloromethane (DCM), acetonitrile (ACN), 
and hexane (Hex)) used for separation of tomato carotenoids were HPLC grade and 
purchased from Fisher Scientific (Pittsburgh, PA, USA). Lycopene standard was purchased 
from Sigma-Aldrich Chemicals (St Louis, MO, USA). To protect carotenoids from 
degradation and oxidation, all steps of extraction and determination were conducted under 
limited light and using amber Eppendorf.  
 Plant material sampling and experimental design 
A total of three varieties of tomatoes, Piccolo (red cherry tomato), Oranjstar (orange cherry 
tomato), and Red Comet (red cherry tomato), were submitted to this experiment. Two 
varieties of Piccolo and Oranjstar were provided by Thanet Earth (Figure 4.3). Healthy 
cherry tomato fruits provided by Thanet Earth were hand harvested from each plant when 
they had reached the mature ripe stage. Red cherry tomatoes purchased from supermarket 
(Marks & Spencer, Piccolo grown by Thanet Earth (Appendix C1) and by Andy Roe 
(Appendix C2) respectively, Sainsbury's, Piccolo grown by Thanet Earth (Appendix C3), 
and Tesco, Red Comet grown in Spain (Appendix C4)). Changes in carotenoids content 
were measured by HPLC on day zero and after 4, 7 and 10 days of storage in temperature 
controlled incubator (15 ℃) under darkness condition.  
Six biological replicates of tomatoes, Piccolo and Oranjstar, provided by Thanet Earth, were 
analysed on each day, (day of harvest (day 0), after 4, 7 and 10 days of storage). Position 1, 
4 and 8 of each tomato trusses were taken for analysis (Figure 4.3) to confirm the 
carotenoids content not vary in the different position. Tomato samples purchased from 
supermarkets, were analysed by randomly picking 3 tomatoes from each pack and the 
process was repeated twice for each supermarket.  
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Figure 4.3 Tomato samples provided by Thanet Earth, Piccolo (A) and Oranjstar (B). 
 
 Carotenoid extraction methods 
The micro-extraction technique was employed to extract the carotenoids from the samples 
(Serino et al., 2009). Tomatoes were washed, dried and cut into halves. Liquid nitrogen was 
used to snap-freeze the samples followed by pulverisation using a mechanical blender. 
Carotenoid extraction was performed in a 2 mL amber Eppendorf tube containing 400-600 
mg of accurately weighed tomato powder. Saturated aqueous NaCl solution (100 µL) and 
50 µL of hexane was added, followed by vortex mixing for 30s; addition of 200 µL of DCM, 
vortex for 30s; addition of 1 mL EA, vortex for 30s, and centrifugation for 5 minutes at 9800 
RCF to separate the organic and aqueous phase. The organic phase was recovered and 
filtered with a 0.2 µm PTFE microfilter. The detailed procedure for carotenoid extraction is 
shown in Figure 4.4.  
 Preparation of the lycopene and β-carotene standard 
The lycopene and β-carotene standard used in HPLC (100 µg/mL) was originally prepared 
in the lab and stored at -80 ℃ in DCM. Eight different concentrations of lycopene standard 
solutions were prepared from the 100 µg/mL lycopene and β-carotene stock solution as 
shown in Table 4.1. 
 
Position 1 Position 1
Position 4
Position 8
(A) (B)
Position 4
Position 8
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Figure 4.4 Carotenoids extraction procedures for analytical HPLC. 
(Serino et al., 2009). 
 
 
 
Table 4.1 Lycopene and β-carotene standard preparation. 
Lycopene and β-
carotene (µg/mL) 
Volume of lycopene and β-carotene 
standard stock solution (100 µg/mL) (µL) 
DCM added 
in vial (µL) 
100 No dilution needed  0 
75 375 125 
50 250 250 
25 125 375 
10 50 450 
5 25 475 
Lycopene and β-
carotene (µg/mL) 
Volume of lycopene and β-carotene 
standard stock solution (10 µg/mL) (µL) 
DCM added 
in vial (µL) 
2.5 125 375 
1 50 450 
 
  
Cherry tomatoes cut into halves 
Liquid nitrogen 
Mechanical blender 
Tomato powder 
Powder ~400-600 mg, put in 2 ml amber Eppendorf 
Agitation with 100 µl NaCl saturated aqueous solution and 50 µl 
Hexane (Vortex 30s, maxi speed) 
Agitation with 200 µl DCM (Vortex 30s, maxi speed) 
Agitation with 1 ml EA (Vortex 30s, maxi speed) 
Centrifugation (6 min at RT, 9800 RCF) 
Transfer the organic upper layer in a 5 ml syringe fitted with a 
microfilter (PTFE 0.2 µm) 
Directly recovered the filtrate in the amber Eppendorf and analysis 
immediately 
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4.2.3 Analytical HPLC 
A modified carotenoid determination method was used for lycopene and β-carotene 
quantification in this study (Müller et al., 2008). 
HPLC analysis was performed on an analytical HPLC Dionex Ultimate 3000 HPLC system 
(Thermo Fisher, Dreieich, Germany), consisting of a WPS-3000 TPL RSWell Plate 
autosampler, a HPG-3000 RS binary pump with online solvent degasser and a 3000 RS diode 
array detector (DAD). Separation was operated on a Sigma SUPLEX PKB-100 amide 
column (5 µm particle size, 250 mm length x 4.6 mm inner diameter) and connected to a 
SUPLEX PKB-100 Supelguard Cartridge (5 µm particle size, 20 mm length x 4.6 mm inner 
diameter). Isocratic elution was used at a flow rate of 1.5 mL/min. Injection volume was 5 
µL. Column temperature was set at 30 ℃ and the autosampler temperature was at 4 ℃. The 
presumptive peaks were identified based on HPLC retention times and published absorbance 
spectral data (Table 4.2) (Serino et al., 2009). Analysis was performed through the 
Chromeleon Chromatography Data System (CDS) Software (version 7.1.1) (Thermo Fisher 
Scientific, USA).  
Table 4.2 Presumptive peak identification of HPLC peaks in extracts of tomato. 
Carotenoids Peak retention time (min) Absorbance maxima (nm) 
All-trans-lycopene 5.78 474 
cis-lycopene  6.62 474 
β-Carotene 7.92 454 
 
 Preparation of mobile phases 
Mobile phase A: BHT (50 mg) dissolved in 20 mL of 2-propanol were added in a 1 L 
volumetric flask, followed by the addition of a 0.2 mL N-ethyldiisopropylamine and 50 mg 
of ammonium acetate dissolved in 25 mL of water. Acetonitrile (455 mL) and 450 mL of 
MeOH were added and the solution was diluted to volume with methanol and filtered 
through filter paper (0.2 µm). Mobile phases B was MTBE with BHT (50 mg/L). All 
solutions were used within 2 days of preparation (Müller et al., 2008). 
4.2.4 Statistical analysis 
All data are reported as mean (SD) of the average for two or six replications. One-way 
analysis of variance (ANOVA) was used to compare the means of all evaluated parameters. 
Differences were considered significant at p<0.05. T-test for two averages was also used to 
study the interactions between pure standards of antioxidants. 
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4.3 Result 
4.3.1 Carotenoid Content of different tomato varieties 
In Figure 4.5 and Figure 4.6, show the chromatograms of carotenoids standard and 
carotenoid extracted from Piccolo and Oranjstar under absorbance 484nm and 474nm 
respectively. The mean trans-lycopene content of Piccolo over 10 days were 8.32±0.14 
mg/100 g while trans-lycopene content of Oranjstar were untraceable (<0.05 mg/100 g) 
(Figure 4.7). The mean cis-lycopene content of Piccolo over 10 days were 0.42±0.01 
mg/100 g while cis-lycopene content of Oranjstar were 2.64±0.08 mg/100 g (Figure 4.7). 
The mean β-carotene content of Piccolo over 10 days were 0.89±0.02 mg/100 g while β-
carotene content of Oranjstar were 0.68±0.03 mg/100 g (Figure 4.7). The content of trans-
lycopene, cis-lycopene and β-carotene of the red tomato purchased in the supermarket were 
shown in Figure 4.8.  
 
Figure 4.5 HPLC chromatograms of carotenoids standard (A) and carotenoids extracted from 
Piccolo (B) and Oranjstar (C) under 448nm wavelength detection. 
 
Figure 4.6 HPLC chromatograms of carotenoids standard (A) and carotenoids extracted from 
Piccolo (B) and Oranjstar (C) under 448nm wavelength detection.  
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Figure 4.7 Trans-lycopene content (A), cis-lycopene content (B) and β-carotene (C) of different 
varieties of cherry tomato provided by Thanet Earth.  
 Piccolo (6 replications); Oranjstar (6 replications). 
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Figure 4.8 Trans-lycopene content (A), cis-lycopene content (B) and β-carotene (C) of different 
varieties of cherry tomato purchased from supermarket.  
 Piccolo, purchased from M&S grown by Andy Roe (2 replications); 
Piccolo, purchased from M&S grown by Thanet Earth (2 replications);  Piccolo, 
purchased from Sainsbury's grown by Thanet Earth (2 replications); Red Comet, 
purchased from Tesco grown in Spain (2 replications). 
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4.4 Discussion 
The carotenoid content of Piccolo and Oranjstar did not change significantly over the 10 
days of storage. The mean trans-lycopene content of Piccolo over 10 days were 8.32±0.14 
mg/100 g while the mean cis-lycopene content of Piccolo over 10 days were 0.42±0.01 
mg/100 g while cis-lycopene content of Oranjstar were 2.64±0.08 mg/100 g. Therefore, 
intake of 300 g of Piccolo and Oranjstar provided 26.22 mg and 7.92 mg of total lycopene 
respectively. Our analysis of the lycopene content showed no variations over time, therefore 
adding confidence that participants received a constant dose of lycopene throughout the 
study. Overall the carotenoid content of tomato used in the present study were in agreement 
with previous studies, as well as with tomatoes of the same variety available in supermarket 
(Table 4.3, Figure 4.7 and Figure 4.8). Therefore, population supplementing tomato 
purchased from supermarket could have the same beneficial effects as present study (in 
Chapter 5-7). Nutritional composition data obtained from the USDA Food Composition 
Databases, indicates that overall, the macronutrient content between different varieties of 
tomato is fairly similar as reported in Table 4.4. However, some differences at the 
micronutrient level can be observed. For example, the content of vitamin C in green tomato 
varieties is reportedly higher than other tomato varieties. In relation with the colour of 
tomatoes used in this study (i.e. red vs orange), only the content of vitamin A and sodium 
are reportedly higher in the orange variety (Table 4.4).  
4.5 Conclusion  
The Piccolo was rich in trans-lycopene while the Oranjstar was rich in cis-lycopene as well 
as low content of trans-lycopene.  
4.6 Research Questions Raised from The Present Chapter 
The work described in this chapter raised the following questions: 
1. What are the gaps in the literature in relation with RCT supplementing tomato on 
cardiovascular risk factors? 
2. Do different varieties of cherry tomato have the same extent of health beneficial 
effects? 
The following chapters present the work undertaken to answer this research question. A 
study protocol was designed to investigate whether red cherry tomatoes (Piccolo) and orange 
cherry tomatoes (Oranjstar), improve vascular function and other cardiovascular risk factors 
to the same extent. This trial has been registered in the National Library of Medicine 
(ClinicalTrials.gov identifier: NCT03209817). 
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Table 4.3 Carotenoid Content (mg/100 g fresh weight) of different tomato varieties 
  No. of varieties 
All trans-lycopene 
(mg/100 g fresh 
weight) 
SD 
Cis-lycopene 
(mg/100 g fresh 
weight) 
SD 
β-carotene 
(mg/100 g 
fresh weight) 
SD 
Tomato used in the clinical trial 
Red cherry tomato (Piccolo, provided by Thanet Earth) 1 8.32 0.14 (SEM) 0.42 0.01 (SEM) 0.89 0.02 (SEM) 
Orange cherry tomato (Oranjstar, provided by Thanet 
Earth) 1 <0.05 N/A 2.64 0.08 (SEM) 0.68 0.03 (SEM) 
Tomato purchased from supermarket 
Red cherry tomato (Piccolo, purchased from M&S 
grown by Andy Roe) 1 9.68 0.42 (SEM) 0.38 0.04 (SEM) 1.13 0.08 (SEM) 
Red cherry tomato (Piccolo, purchased from M&S 
grown by Thanet Earth ) 1 9.77 0.35 (SEM) 0.47 0.04 (SEM) 1.1 0.03 (SEM) 
Red cherry tomato (Piccolo, purchased from 
Sainsbury's grown by Thanet Earth) 1 10.21 0.49 (SEM) 0.45 0.03 (SEM) 1.15 0.05 (SEM) 
Red cherry tomato (Red Comet, purchased from Tesco 
grown in Spain) 1 7.85 0.52 (SEM) 0.39 0.03 (SEM) 1.13 0.04 (SEM) 
Data from previous studies 
Red salad tomato (including different varieties) 
(Abushita et al., 2000) 12 6.27 0.95 0.10 0.02 0.42 0.11 
Red tomato (including different varieties)  
(Kavitha et al., 2014) 14 8.60 2.24 N/A N/A N/A N/A 
Red cherry tomato (including different varieties) 
(Kavitha et al., 2014) 9 8.14 2.22 N/A N/A N/A N/A 
Red cherry tomato (including different varieties)  
(Kuti and Konuru, 2005) 4 8.69 1.59 0.50 0.43 N/A N/A 
Tangerine (Orange cherry tomato)  
(Unlu et al., 2007a) 1 0.10 0.01 (SEM) 3.15 0.05 (SEM) 2.32 0.24 (SEM) 
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Table 4.4 Nutrient Content (mg/100 g fresh weight) of different tomato varieties.  
Data obtained from USDA Food Composition Databases. 
Nutrient (unit) Red, ripe, raw, 
year round 
Green, 
raw 
Orange, 
raw 
Yellow, 
raw 
Red cherries, 
raw 
Macronutrients 
Water (g) 94.5 93.0 94.8 95.3 86.1 
Energy (kcal) 18.0 23.0 16.0 15.0 50.0 
Protein (g) 0.9 1.2 1.2 1.0 1.0 
Total fat (g) 0.2 0.2 0.2 0.3 0.3 
Carbohydrate (g) 3.9 5.1 3.2 3.0 12.2 
Fibre, total dietary (g) 1.2 1.1 0.9 0.7 1.6 
Sugars 
Sugars, total (g) 2.6 4.0 N/A N/A 8.5 
Sucrose (g) 0.0 N/A N/A N/A 0.8 
Glucose (dextrose) (g) 1.3 N/A N/A N/A 4.2 
Fructose (g) 1.4 N/A N/A N/A 3.5 
Minerals 
Calcium, Ca (mg) 10.0 13.0 5.0 11.0 16.0 
Iron, Fe (mg) 0.3 0.5 0.5 0.5 0.3 
Magnesium, Mg (mg) 11.0 10.0 8.0 12.0 9.0 
Phosphorus, P (mg) 24.0 28.0 29.0 36.0 15.0 
Potassium, K (mg) 237.0 204.0 212.0 258.0 173.0 
Sodium, Na (mg) 5.0 13.0 42.0 23.0 3.0 
Zinc, Zn (mg) 0.2 0.1 0.1 0.3 0.1 
Copper, Cu (mg) 0.1 0.1 0.1 0.1 0.1 
Manganese, Mn (mg) 0.1 0.1 0.1 0.1 0.1 
Selenium, Se (mg) 0.0 0.4 0.4 0.4 0.0 
Vitamins 
Vitamin C, total ascorbic 
acid (mg) 
13.7 23.4 16.0 9.0 10.0 
Thiamine (mg) 0.0 0.1 0.0 0.0 0.0 
Riboflavin (mg) 0.0 0.0 0.0 0.0 0.0 
Niacin (mg) 0.6 0.5 0.6 1.2 0.4 
Pantothenic acid (mg) 0.1 0.5 0.2 0.1 0.1 
Vitamin B-6 (mg) 0.1 0.1 0.1 0.1 0.0 
Folate, total (mg) 15.0 9.0 29.0 30.0 8.0 
Choline, total (mg) 6.7 8.6 
  
6.1 
Vitamin A (IU) 833.0 642.0 1496.0 0.0 1283.0 
Vitamin E (mg) 0.5 0.4 N/A N/A 0.1 
Vitamin K (µg) N/A 10.1 N/A N/A 2.1 
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Chapter 5 Protocol for A Randomised Controlled Trial on The Effects of Two 
Tomato Varieties on Cardiovascular Function in Young and Older Adults 
This study was designed to answer the research questions in section 4.6.  
5.1 Introduction  
In order to inform the design of this protocol, systematic reviews and meta-analysis of the 
relevant literature were undertaken. Overall, the analysis of epidemiological and 
experimental studies consistently showed that tomato consumption is associated with 
reduced CVD risk and mortality (Cheng et al., 2019) as well as CVD risk markers (Cheng 
et al., 2017). This evidence therefore supports the inclusion of tomato as an important food 
within dietary recommendations.  
The systematic reviews and meta-analyses in Chapter 2 and 3 revealed that previous 
controlled experimental studies on the effects of tomato consumption have focused on red 
tomatoes, red tomato products or lycopene supplementations. However, a comprehensive 
study examining different varieties of tomatoes and its effects on both traditional and novel 
CVD risk factors is currently lacking in the literature. With new varieties of tomatoes, 
Oranjstar (rich in cis-lycopene with low trans-lycopene content), available to the public, it 
is important to evaluate whether other varieties exert the same effect. 
Previous human trials have shown the protective effects of the tomato on blood lipid. 
However, there are numerous emergent circulating biomarkers including interleukin 6 (IL-
6), tumour necrosis factor alpha (TNF-α), intercellular adhesion molecules-1 (ICAM-1), 
vascular adhesion molecules-1 (VCAM-1), E-selectin and P-selectin. However, these 
inflammatory markers were less examined. We aimed to determine the beneficial effects of 
tomato on blood lipid profile as well as these inflammatory markers including TNF-α, IL-6, 
E-selectin, P-selectin, sICAM-1, and sVCAM-1. Furthermore, previous nutrition 
interventions were focused on BP and blood lipid while the impact of tomato on vascular 
function, especially on microvascular vasodilation and arterial stiffness were less evaluated.  
This chapter outlines the methods used throughout this tomato human trial study. Specific 
methods used in individual experimental chapters are discussed within the corresponding 
chapters. The present study investigated whether red cherry tomatoes (Piccolo) characterised 
by high content of trans-lycopene, and orange cherry tomatoes (Oranjstar) rich in cis-
lycopene, improve vascular function to the same extent (Table 4.3). A 4-week period of 
intervention was chosen to evaluate chronic effects of the interventions tested. This study 
included three arm treatments including 300 g fresh Piccolo and Oranjstar supplementation 
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and a washout period (without tomatoes supplementation). We aimed to compare the 
beneficial effects of two different varieties of tomato on blood pressure, vascular function, 
blood lipid and inflammatory markers in young and older adults.  
5.2 Method 
5.2.1 Subjects 
Thirty non-smoking healthy male volunteers aged 18-60 years of age, with a BMI between 
25 and 40kg/m2, were recruited and a total of 27 participants completed the intervention. 
The study participants were recruited from Northumbria University and the local community 
between January and May 2017.  
 Inclusion criteria  
Participants were selected if they met the following inclusion criteria: BP <150/90 mmHg; 
not on a weight-reducing diet or taking dietary supplements; not diagnosed with diabetes, 
high blood cholesterol and heart problems (e.g. arrhythmia, high-grade stenosis of the carotid 
artery or carotid sinus syndrome); alcohol intake <21 units/week for men; non-allergic to 
tomatoes or tomato products; and were healthy non-smokers. The study was subject to 
ethical review by the Northumbria University Ethics Committee (Project ref: 
PG02_Cheng_121216) and was given a favourable ethical opinion to proceed. Informed 
signed consent was provided by each participant. This trial has been registered in the 
National Library of Medicine (ClinicalTrials.gov identifier: NCT03209817).  
 Sample size 
Sample size calculation was performed for the primary endpoint: change in SBP response. 
Data for this calculation was derived from a previous systematic review of the literature 
carried out as part of this PhD program (Cheng et al., 2017). Sample size was calculated 
using G*Power version 3.1.3 (Program written, concept and design by Franz, Universitat 
Kiel, Germany; freely available windows application software) (Faul et al., 2007). The two-
tails t-test to compare the differences between two dependent means was used. Calculations 
considered a prior power of 0.8, a 0.05 significance level and a 0.5 correlation coefficient 
between groups. The estimated participants required to allow detection a difference of 6 
mmHg between the responses to the intervention and control, based on the systematic review 
in Chapter 3, was estimated to be 24 as shown in Figure 5.1. This sample size is a 
conservative one, given that in a cross-over study design, the correlation between the groups 
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would be higher which lower the sample size. For example, a correlation of 0.7 would result 
in a sample of 16. This study aimed to recruit 30 participants to allow for 20% drop out rate.  
 
Figure 5.1 Power calculation from change in SBP response considering a priori power of 0.8, a 
0.05 significance level and a 0.5 correlation coefficient between groups.  
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 Randomisation 
The randomisation plan was carried out using www.randomization.com by the principal 
supervisor, Dr Jose Lara. The randomisation sequence defined the order of the tomato 
interventions in counterbalance, half participants started with Piccolo and half participants 
started with Oranjstar. Participants were randomised either to consumed 300 g of fresh 
Piccolo or Oranjstar for a 4-week period. After a 4-week washout, they repeated the above 
process consuming the other tomato intervention (Figure 5.2). Participants were unaware of 
the randomisation sequence; but they were not blind to intervention, once they began each 
phase of the intervention, they were aware of the variety of tomato to be consumed. 
 
Figure 5.2 Flow diagram of tomato intervention. 
5.2.2 Study design 
Based on the systematic review in Chapter 3, a daily intake of 15 mg lycopene in 4-week 
would be sufficient to show the effect on the vascular function and cardiovascular factors 
(Cheng et al., 2017). In Chapter 4, intake of 300 g of Piccolo and Oranjstar provided 26.22 
mg and 7.92 mg of total lycopene respectively which inform the maximum does in order to 
increase the chances to observe effects of intervention. Therefore, a 4-week period of 
intervention was chosen to evaluate chronic effects of the interventions tested. According to 
Gustin et al. (2004), the half-life for the lycopene ranged between 1 day and 2.5 day. 
Therefore, in corporation of 4 week washout (non-tomato diet) could diminish the impact of 
carryover effects (Gustin et al., 2004). 
This study was designed as a 12-week, cross-over design, randomised controlled dietary 
interventional study. The study was conducted at the Northumbria University and it was 
undertaken according to the CONSORT guidelines (Figure 5.3 and Appendix D1) (Schulz 
et al., 2010). Participants completed a questionnaire including socio-demographic data at the 
beginning of the study. Participants were also asked to record their dietary intake for 2 non-
Week 0
Intervention 1
Visit 1
Intervention 2Washout
Visit 2 Visit 3 Visit 4
4 8 12
Randomise
Study population 
(screening)
Study population 
(Enrolled)
Washout (without 
tomato diet)
Washout (without 
tomato diet)
Red tomato
(Piccolo)
Orange tomato
(Oranjstar)
Red tomato
(Piccolo)
Orange tomato
(Oranjstar)
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consecutive days (i.e. type of foods, preparation and amount of food/drink consumed), one 
day on weekday and one day on weekend.  
During the 12 weeks of the study intervention, participants were asked to consume two 
different fresh cherry tomato varieties (Piccolo or Oranjstar, 300 g per day according to the 
randomisation order) for 4 weeks each and 4 weeks of non-tomato diet in between these 
tomato intervention periods. The participants were instructed to consume tomatoes anytime 
as snack or with meal and not to consume additional tomato sources. The researcher (HMC) 
weighted the tomatoes and packed them into in individual food bags the amount to be 
consumed each day (300g). As in Chapter 4, it had shown that the carotenoid content did not 
change significantly over 10 days storage, participants received 7 days portions of tomatoes 
every week and were asked to keep the tomatoes under cool condition.  
On each study day, participants arrived at either 0800 or 1000 at the research facility at 
Northumbria University, UK after a 12-hour fasting. Participants attended four 2-hour study 
visits (baseline, end of the first, second and last study period). Fasting plasma samples were 
collected on each of study visit. Additionally, anthropometric measurements, peripheral 
microvascular vasodilation using Laser Doppler Imaging (LDI) with iontophoresis, arterial 
stiffness using carotid-femoral pulse wave velocity (cf-PWV) and pulse wave analysis 
(PWA) and endothelium-dependent vasodilation using FMD were also assessed. During the 
study days, participants were asked to refrain from strenuous exercise. Participants returned 
at same time point for the study visit every 4 weeks and repeated all of the measurement 
mentioned above. 
In order to control for other dietary factors, participants were also asked to record food 
diaries throughout the first study period (4 weeks) and recommended to repeat their own 
dietary patterns for the washout period (4 weeks) and second study period to match up the 
food and nutrition intake throughout the whole study. Participants were encouraged to not 
alter their usual diet and exercise patterns when completing the food diary or study (in 
conjunction with daily consumption of tomatoes). Before and after each 4 weeks intervention 
or washout period, the participants attended the study visit for measurements. Compliance 
with interventions was assessed by asking participants to self-report consumption using daily 
checklist. In addition, body weight and body composition, and handgrip strength (see below) 
were measured on each study visit as indicators of evidence of maintenance of habitual 
lifestyles. Participants were also contacted regularly to discuss any problems related to the 
supplementation of tomato and to provide encouragement and support. 
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Figure 5.3 CONSORT Flow diagram for reporting of trials. 
5.2.3 Outcome measures 
The outcome measures of this study included resting (laboratory) blood pressure 
measurements, basic anthropometric measurements, and plasma samples, microvascular 
vasodilation by LDI with iontophoresis, endothelium dependent vasodilation by FMD, 
arterial stiffness by PWA and cf-PWV, 24-Hour ambulatory blood pressure (ABP) and home 
blood pressure (Table 5.1). All measurements were carried in a temperature-controlled room 
in which the ambient temperature was 23±1oC.  
To minimise inter-observer variability all outcome measures in this study were measured by 
the researcher (Ho Ming Cheng) every time.  
CONSORT 2010 Flow diagram 
Assessed for eligibility (n=31) Enrolment 
Excluded (n=2) 
Participants cannot fulfil the 
time for study visit  
Randomized (n=29) 
Allocation 
Lost to follow-up (n=0) 
Follow-Up 
Analysed (n=15) 
Analysis 
Allocated to Oranjstar (orange 
tomato) for the first interventional 
period (n=14) 
Lost to follow-up  
(Lag of time to complete study) 
(n=2) 
Analysed (n=12) 
Excluded from analysis  
(Participant only attended for the 
baseline, n=2) 
Allocated to Piccolo (red tomato) 
for the first interventional period 
(n=15) 
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Table 5.1 Outcome measure at baseline, 4, 8 and 12 weeks 
Primary Outcome Measures 
A. Vascular 
Function 
1. Peripheral microvascular vasodilation by Laser Doppler 
Imaging (LDI) 
2. Endothelium-dependent vasodilation by Flow-mediated dilation 
(FMD) 
3. Arterial stiffness by Carotid-femoral Pulse wave velocity (cf-
PWV) and Pulse wave analysis (PWA) 
B. Blood pressure 1. Resting (Laboratory) Blood pressure 
2. 24hr ambulatory blood pressure 
3. Home blood pressure 
C. Blood lipid 1. Total cholesterol 
2. HDL 
3. LDL 
4. Triglyceride 
D. New established 
biomarker 
1. Interleukin-6 
2. Tumour Necrosis Factor Alpha (TNF-α) 
3. E-Selectin  
4. P-Selectin  
5. Intercellular Adhesion Molecule 1 (ICAM-1) 
6. Vascular Cell Adhesion Molecules (VCAM-1) 
Secondary Outcome Measures 
Anthropometric measurements 
Body composition assessment  
Handgrip strength assessment 
 Resting blood pressure measurements 
Resting blood pressure was measured in a quiet room after participants have rested for 10 
minutes in a seated position with arm resting on a firm surface and feet flat on the floor, 
using a non-invasive digital automatic blood pressure monitor (Carescape™ V100: GE 
Healthcare, UK). Blood pressure measurements were taken in the non-dominant upper arm 
in triplicate, and the average of the last two measurements was used for subsequent analyses 
(Pickering et al., 2005).  
 Anthropometric measurements 
Anthropometric measurements were taken including: height and weight without shoes 
(World Health Organization, 1995), which were then used to calculate BMI by dividing body 
mass (kg) by body height2 (m) (kg/m2). A stadiometer was used to measure height to the 
nearest centimetre (cm). Participants were asked to remove their shoes and position their 
head in the Frankfurt plane position. Participants were positioned looking straight ahead with 
the lower border of the left orbit and the tragus of the ear lying on the horizontal plane (Raine 
and Twomey, 1994). Body weight was measured using Tanita scales after participants 
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removed outer garments and any personal objects affecting body weight (keys, coins, 
jewellery etc.). Participants were bare-foot for both height and weight measurements.  
 Body composition assessment  
Bioelectrical impedance analysis (BIA) was performed using a single frequency (50 kHz) 
device (Bodystat 1500, Bodystat Ltd; Isle of Man, UK). Estimations of fat in percentage (%) 
and in weight (kg), lean weight in percentage (%) and (kg), total water in percentage (%) 
and litre (L) were recorded. Before measurement, participants were rested in the supine 
position and have their limbs abducted to avoid current shunting. Bodystat electrode pads 
were placed in the middle of the dorsal surface of the left hand just proximal to the 
metacarpophalangeal joints and left foot proximal to the metatarsophalangeal joints; a 
second set of electrodes was placed between the distal prominence of the radius and the ulnar 
styloid and between the medial and lateral malleoli at the ankle (Figure 5.4) (Simpson et al., 
2001).  
 
Figure 5.4 Electrodes position on hand and foot.  
 Handgrip strength 
Handgrip strength was measured using a CAMRY-EH101 hand dynamometer (range 0 to 
90 kg; accuracy 0.1 kg) (EH101; Camry, Guangdong Province, China). In a standing 
position, participants held the dynamometer in their dominant hand (Meng et al., 2015). The 
handle of the dynamometer was adjusted if required. When participants were ready, they 
were instructed to squeeze the dynamometer with maximum effort and hold for 
approximately 5 seconds without other body movements. The participants were strongly 
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encouraged by the researcher to give a maximum effort. Handgrip strength was assessed in 
triplicate and the average of all readings were taken as the final score.  
 Fasting blood sample collection  
Fasting blood samples were collected using a butterfly needle inserted into the antecubital 
vein in right arm; blood was drawn into separate 6 mL Lithium Heparin vacutainer tubes 
(Becton Dickinson). Tubes were inverted 10 times to mix the blood and anticoagulant inside 
the tube, and were centrifuged immediately for 10 min at 1200rpm. Plasma samples were 
immediately stored at -80 ℃ until analysis. Analyses of plasma samples were commenced 
after the intervention study was completed and all samples for each participant were analysed 
without knowledge of the treatments, within one batch to reduce inter-batch variation. 
 Measurement of vascular function 
Peripheral microvascular vasodilation – Laser Doppler Imaging (LDI) 
Peripheral microvascular vasodilation was assessed by Laser Doppler Imaging (LDI) with 
iontophoresis using a moorLDI2-IR Laser Doppler Imager (Moor Instruments Ltd, 
Axminster, UK). All measurements were carried out on the left arm after a 30-min rest in a 
supine position in a quiet room. 
 
Figure 5.5 Iontophoresis set-up for LDI. 
  
1% Acetylcholine chloride 
(ACh) 
1% Sodium nitroprusside  
(SNP) 
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Two Perspex iontophoresis chambers (MIC-ION6; Moor Instruments) with an internal 
platinum wire electrode were attached to the skin with the use of double sided adhesive discs 
(MIC-1AD; Moor Instruments) on the ventral aspect of the left forearm of the participants 
avoiding hair, broken skin, scar tissue, skin blemishes and superficial veins (Figure 5.5). 
Both Perspex iontophoresis chambers were connected to the iontophoresis controller (MIC2; 
Moor Instruments) (Keane et al., 2016). The iontophoresis method of Ferrell et al. (2002) 
was used to administer acetylcholine chloride, ACh (2.5 mL; 1%; Sigma-Aldrich) in 0.5% 
NaCl solution at the anodal chamber and sodium nitroprusside, SNP (2.5 mL of 1%; Sigma-
Aldrich) in 0.5% NaCl solution at the cathedral chamber, to assess endothelium-dependent 
and endothelium-independent vasodilation, respectively (Ferrell et al., 2002). Circular glass 
coverslips were placed over each chamber after addition of the corresponding solution to 
ensure there is no air bubbles within the chambers and prevent the evaporation of solutions 
(Figure 5.5). Current delivery was controlled by moorLDI Review software version 6.1 
(Moor Instruments). Skin perfusion was measured with the use of a moorLDI2-IR Laser 
Doppler Imager (Moor Instruments). The LDI scanner head was sited 30cm above the 
chambers and the laser beam was directed via a moving mirror to execute a raster pattern 
across. A total of twenty repeat scans were measured, the first without current to act as a 
control, then four scans at 5 µA, four at 10 µA, four at 15 µA and two at 20 µA, giving a 
total charge of 8 mC; the final five scans were recorded without any current (Figure 5.6) 
(George et al., 2012a). All twenty scans were performed on the left arm after a 30min rest in 
the supine position in a quiet. The flux compared with time area under the curve over the 20 
scans was calculated as a measure of microvascular response to ACh (endothelium-
dependent vasodilation) and SNP (endothelium-independent vasodilation) (George et al., 
2012a). During the measurement, participants were not allowed to speak or sleep. 
 
Figure 5.6 Flux images acquired with the moorLDI2-IR Laser Doppler Imager in young healthy 
man.  
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Endothelial-dependent vasodilation – Flow mediated dilation (FMD) 
Endothelium-dependent vasodilation, as partly nitric oxide mediated dilation, was assessed 
by noninvasively high-resolution ultrasonography as the percentage of flow-mediated 
dilation (FMD %) of the brachial artery in the right arm. Participants rested in the supine 
position for at least 15 minutes to facilitate baseline assessment of heart rate and blood flow 
(Corretti et al., 2002). To examine brachial artery FMD, the right arm was extended and 
positioned at an angle of ~90° from the torso (Figure 5.7) (Schreuder et al., 2014). Rapid 
inflation and deflation of the sphygmomanometer cuff is fitted on the right forearm to create 
a blood flow stimulus in the brachial artery (Corretti et al., 2002). 
 
Figure 5.7 Ultrasound imaging of the brachial artery with upper versus lower cuff placement and 
transducer position above the antecubital fossa. 
A 10-MHz multifrequency linear array probe (L12-5 38 mm Linear Array: Bavaria, 
Germany) connected to a high-resolution ultrasound machine, ATL HDI 5000 ultrasound 
system (ATL, Philips Medical Systems, Bothell, Washington, USA), was used to image the 
brachial arteries in the distal one-third of the upper arm (Corretti et al., 2002). The ultrasound 
parameters were set to optimise the longitudinal, B-mode images of lumen brachial arterial 
wall interface. Continuous doppler velocity assessment was simultaneously obtained using 
the ultrasound machine, and was collected using the lowest possible insonation angle 
(always <60°), which did not vary during each study (Figure 5.7) (Corretti et al., 2002). The 
brachial artery was imaged above the antecubital fossa in the longitudinal plane (Corretti et 
al., 2002). When an optimal image was obtained, the probe was held stable with a mechanical 
4.5 mm 5.0 mm, FMD =11.1%
Baseline diameter Diameter after inflation
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arm (Figure 5.7). Images of baseline diameter and blood flow were recorded 1 frame per 
second for 1 minute, using the software Vascular Imager version 6.0.3 (Medical Imaging 
Applications LLC, USA) (Figure 5.8A). The forearm cuff was then inflated to 200 mmHg 
for 5 minutes, to create forearm ischemia, and images were recorded 1 flame per 10 second. 
Subsequently, the rapid deflation and image of diameter, to allow reactive hyperaemia, and 
blood flow were recorded 1 flame per second for 5 minutes (Figure 5.8B). 
 
Figure 5.8 Diameter of brachial artery diameter baseline (A) and deflation (B) acquired with the 
ultrasound in a young healthy man. 
 
(A)
(B)
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Brachial arterial diameter was analysed and measured from the recorded image using the 
Brachial Analyzer for Research version 5.10.9 (Medical Imaging Applications LLC, USA). 
During the measurement, participants were not allowed to speak or sleep. 
The FMD were all taken by the same researcher for every visit to reduce the possibility of 
bias. Evaluation of FMD reproducibility prior to the study showed low variability within and 
between days. Intra-researcher reproducibility for FMD was good with a coefficient of 
variation (CV) of 5.22% (n= 20). There was no systematic bias between the first and second 
reading of the same researcher. The reproducibility was in agreement with previous study 
(Corretti et al., 2002). 
Arterial stiffness – Pulse Wave Velocity (cf-PWV) and Pulse Wave Analysis (PWA) 
Arterial stiffness was assessed by carotid-femoral pulse wave velocity (cf-PWV) and pulse 
wave analysis (PWA) using a tonometer of SphygmoCor® CPV System (AtCor Medical 
Pty. Ltd., Australia) by a single trained researcher (HMC). All measurements were carried 
out after a 15-min rest in the supine position in a quiet. During the measurement, participants 
not allowed to speak or sleep.  
cf-PWV 
The carotid pulse (on the neck) and femoral pulse (on the groin) were located with both 
middle and index fingers by the researcher (HMC) and their position were highlighted with 
a marker. The distance from the sternal notch (the “V” in their chest) to the carotid and 
femoral arteries were measured using measuring tape. The researcher measured the distance 
from the sternal notch to the mark on the neck in a straight-line and the distance from the 
sternal notch straight down to the umbilicus (belly button) and then diagonally across to the 
mark on the groin. Three electrocardiogram (ECG) lead were placed at the sternal notch, 
sternum and left-hand side of the patient halfway down the rib cage (Figure 5.9).  
 
Figure 5.9 Position of ECG lead for PWV measurement. 
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Pressure wave form in carotid and femoral arteries were measured by a sensitive tonometer. 
The transit time was calculated as the time between the R-spike in the ECG and the arrival 
of the pulse wave at the carotid and femoral recording site respectively. After the pulse wave 
of both sites were captured, the SphygmoCor® software (version 9.0, AtCor Medical, 
Sydney, Australia) automatically calculated the carotid-femoral PWV (cf-PWV) (Figure 
5.10). 
 
Figure 5.10 ECG signal (yellow line) and arterial pulse wave at carotid and femoral artery 
acquired with the SphygmoCor CPV System, in a young health man. 
PWA 
The atrial pressure (Figure 5.11A) in the right radials was recorded using the same 
tonometer as cf-PWV (SphygmoCor, AtCor Medical) and transformed to central aortic 
pressure waveform (Figure 5.11B) by the general transfer function in a validated software, 
SphygmoCor® (version 9.0, AtCor Medical, Sydney, Australia) (Bressendorff et al., 2016). 
The augmentation index (AIx) was calculated as the pressure difference between the second 
(P2) and first (P1) systolic peak as a percentage of the central pulse pressure (PP, difference 
between central SBP and DBP) (Figure 5.11B). All AIx data in this trial were corrected for 
heart rate at 75bpm (AIx@HR75) (Figure 5.12). 
Both cf-PWV and PWA were measured in duplicate and averaged. The SphygmoCor® 
(version 9.0, AtCor Medical, Sydney, Australia) software provides a quality control of the 
recorded pressure waveforms. If the measurement did not meet these control criteria, it was 
discarded and replaced by a new measurement.  
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Figure 5.11 Pulse pressure waveforms from the radial artery (A) and the derived waveform in the 
central aorta by SphygmoCor software (B). PP, Pulse pressure (Sp-Dp); P1, first 
systolic peak/shoulder; P2, systolic peak/shoulder; AIx= (P2-P1)/PP. 
 
 
Figure 5.12 Pulse pressure waveforms from the radial artery and the derived waveform in the 
central aorta acquired with the SphygmoCor CPV System in a young healthy man. 
 24-Hour ambulatory blood pressure (ABP) 
24-Hour ABP was recorded by a non-invasive ABP device (Medical 90217-1Q: Spacelabs, 
Inc. Richmond, Washington, USA). After completing all other measurements, an ABP cuff 
was fitted by researcher and participants were asked to wear the monitors on for a period of 
24-Hours. All readings were performed on the non-dominant upper arm of the participant on 
each study day. The monitor was programmed (ABP Report Management System version 
(A) (B)
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3.0.3 Spacelabs, Inc. Richmond, Washington, USA) to inflate automatically, at 30-min 
intervals during 0800-2200 and 60-min intervals during 2200-0800, for a total period of 24-
Hours. Participants were instructed to act and work as normal between 08:00 and 22:00 and 
rest or sleep between 22:00 and 08:00 and avoid any strenuous cardiovascular exercise 
during the 24 hour period. Participants were instructed to keep their arm relaxed down the 
side of their body, and keep still until the end of each subsequent measurement. While in 
walking, the participants were asked to stop and stand still for a minute until the 
measurement finished (Hobbs et al., 2012). Separate averages were obtained for the 24-
Hour, daytime (10:00 to 20:00) and nighttime (00:00 to 06:00) values.  
 Home blood pressure 
All participants were asked to measure their blood pressure at home in the morning every 
day during the last week of each study period. Blood pressure and HR were measured in the 
non-dominant upper arm in triplicate with the use of fully automatic blood pressure recorder 
(Omron® M3: HEM-7200-E, Omron Healthcare, Kyoto, Japan) while sitting and after 
having rested for 10 minutes. 
 Plasma samples analysis 
All plasma samples were frozen at -80 ℃ and kept until analysis.  
Plasma soluble vascular and intracellular adhesion molecules (sVCAM-1 and sICAM-1), 
were analysed by commercial ELISA kits for Human sVCAM-1 (Cat. No.: DDVC00) 
(Appendix D2) and sICAM-1 (Cat. No.: DCD540) (Quantikine®, R&D Systems, Inc., 
USA) (Appendix D3), respectively according to the manufacturer’s specifications. Plasma 
soluble E-selectin (sE-selectin) and P-selectin (sP-selectin) were measured by ELISA kits 
for Human E-selectin (Cat. No.: RAB0422) and P-selectin (Cat. No.: RAB0426) (Sigma-
Aldrich, St Louis, MO, USA) (Appendix D4). Plasma pro- and anti-inflammatory cytokines, 
IL-6 and TNF-α, were measured by commercial ELISA kits for human IL-6 (Cat. No.: 
KHC0061) (Appendix D5) and TNF-α (Cat. No.: KHC3012) (Invitrogen®, Camarillo, CA) 
(Appendix D6), respectively following the procedures of the manufacturers. 
Lipid profile, (including total cholesterol, triglycerides, HDL and LDL), insulin and glucose 
content in plasma were measured by The Laboratories of the Integrated Laboratory Medicine 
in Freeman Hospital at Newcastle Upon Tyne. Plasma triglycerides were measured by an 
enzymatic, colorimetric method with glycerol phosphate oxidase and peroxidase (Trigl, 
Cobas Roche Diagnostics, Indianapolis, IN, USA). Total plasma cholesterol was obtained 
by an enzymatic, colorimetric method through the cholesterol esterase/cholesterol 
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oxidase/peroxidase reaction (CHOL2, Cobas Roche Diagnostics, Indianapolis, IN, USA). 
The plasma concentration of HDL-cholesterol was determined by a homogeneous enzymatic 
colorimetric assay through the cholesterol esterase/cholesterol oxidase/peroxidase reaction 
(HDLC3, Cobas Roche Diagnostics, Indianapolis, IN, USA). Plasma glucose concentrations 
were determined with a colorimetric assay (GLUC3, Cobas, Roche Diagnostics GmbH, 
Mannheim, Germany). Commercial enzyme-linked immunosorbent assay (ELISA) kits were 
used to measure insulin (Iso-Insulin ELISA, Mercodia AB, Uppsala, Sweden) according to 
the manufacturer’s specifications. 
 Nutritional analysis 
Participants were asked to record their dietary intake for 2 non-consecutive days (i.e. type of 
foods, preparation and amount of food/drink consumed), one day on week day and one day 
on weekend. The record of the dietary intake allowed a nutritional analysis with the aid of 
the ‘‘Microdiet’’ software (Microdiet System, Version 6.4, Salford University, UK). In 
addition, Participants were required to keep record of their dietary intake during the first 4 
weeks of the study and then asked to repeat their food consumption during the next 8 weeks. 
5.2.4 Statistical analysis 
Participant data and recorded measurements were inputted into and statistically analysed 
using IBM SPSS Statistics version 24. Data were evaluated for normality of distribution 
using the Shapiro-Wilk test. 
The General Linear Model (GLM) for repeated measures was used to compare treatments. 
Unadjusted results (mean±SEM) as well as results adjusting for covariates including baseline 
values, results obtained after the washout period, and randomisation order are presented with 
Bonferroni correction test for multiple comparisons. Paired t-tests were used to compare 
changes from baseline.  
Analysis was carried out on the participants as a whole as well as subgrouped by age: <30 
(AgeCat=1) and >30 (AgeCat=2), to identify patterns in data.  
A p value less than 0.05 was classified as significant. 
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5.3 Result  
The study was completed at 9th August 2018. Overall, 27 participants completed the entire 
trial (93.2%) after baseline assessment. Self-reported daily checklist of tomato 
supplementation showed a good acceptability and compliance with tomato supplementation. 
No side-effect of interventions was reported about supplementation of tomato. The results 
of the study were reported in detail in Chapter 6 and 7. 
5.4 Discussion 
The study outcomes were discussed in detail in Chapter 6 and 7. 
5.5 Conclusion 
The present protocol for RCT showed the consumption of 300 g cherry tomato on the health 
effects on the vascular function, blood pressure, blood lipid and CVD risk biomarker.  
5.6 Research Questions Raised from The Present Chapter 
The work described in this chapter raised the following questions: 
1. Do different varieties of cherry tomato have the same extent of beneficial effects on 
BP and vascular function? 
2. Do these health benefits differ according to age? 
This question will be addressed in Chapter 6 by examining the effects of Piccolo and 
Oranjstar on blood pressure and vascular function. We also aimed to assess whether different 
varieties of cherry tomato would have same extent of beneficial effects on different age 
groups.  
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Chapter 6 The Effects of Piccolo and Oranjstar on Vascular Function and 
Cardiovascular Factors 
This study was designed to answer the research questions in section 5.6.  
6.1 Introduction 
Cardiovascular disease is a multifactorial disease, which is a result of interactive effects of 
different combinations of risk factors such as high blood pressure, high blood cholesterol, 
smoking, obesity, diabetes and lack of physical activity. The systematic reviews and meta-
analyses in Chapter 3 showed that previous RCT on the effects of tomato on resting BP, 
however only few studies have evaluated 24-Hour BP, a more accurate marker of BP (Cheng 
et al., 2017). In contrast, less is known on whether there are beneficial effects of tomato on 
vascular function especially on microvascular vasodilation and arterial stiffness (Cheng et 
al., 2017). We aimed to determine the beneficial effects of tomato on BP measured using 
different methods and outcomes of vascular function. We also aimed to compare whether 
two varieties of cherry tomato, Piccolo and Oranjstar, have the same extent of beneficial 
effects on BP and vascular function. 
6.2 Method  
6.2.1 Measurement of BP and vascular function 
The method of measuring BP and non-invasive assessment of vascular function were 
described in detail in Chapter 5 (section 5.2.3.1 and 5.2.3.6-5.2.3.8). 
6.2.2 Statistical analysis 
The statistical analysis was described in detail in Chapter 5 (section 5.2.4). 
6.3 Results 
6.3.1 Participants baseline characteristic  
The characteristics of the sample studied are shown in Table 6.1. In total 27 participants 
completed the intervention study, ranging from an age of 19 to 60 years. The participants 
were statistically analysed as a full sample size as well as being split into two different age 
groups. These were categorised as below 30 years of age, which included 16 participants, 
and above 30 years of age, including 11 participants. BMI values ranged from 16.5 kg/m2 to 
32.5 kg/m2 among all participants, but the mean BMI difference between the two age groups 
was small (2 kg/m2) (Table 6.1).  
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Table 6.1 Participants baseline characteristic. 
Baseline 
characteristics 
All participants 
(n=27) 
Below 30yrs 
(n=16) 
Above 30yrs 
(n=11) 
Mean SEM Mean SEM Mean SEM 
Age (year) 32.1 2.64 21.9 0.68 46.9 2.54 
Height (m) 1.8 0.01 1.8 0.02 1.8 0.02 
Weight (kg) 72.2 2.28 69.4 3.22 76.1 2.83 
BMI (kg/m2) 23.3 0.65 22.5 0.88 24.5 0.88 
Resting SBP (mmHg) 116.2 2.15 118.2 3.11 113.4 2.63 
Resting DBP (mmHg) 71.1 1.51 70.1 2.09 72.6 2.16 
HR (bpm) 68.4 1.62 68.4 2.21 68.4 2.50 
24-Hour BP 
 SBP (mmHg) 123.7 1.88 124.5 2.46 122.6 3.04 
 DBP (mmHg) 74.3 1.20 73.0 1.45 76.1 2.01 
Daytime BP 
 SBP (mmHg) 128.0 1.94 129.1 2.64 126.5 2.91 
 DBP (mmHg) 78.3 1.34 76.8 1.79 80.6 1.89 
Nighttime BP 
 SBP (mmHg) 112.6 2.10 113.9 2.69 110.8 3.41 
 DBP (mmHg) 64.2 1.23 63.9 1.71 64.6 1.81 
Handgrip strength (kg) 42.76 1.33 41.52 2.03 44.56 1.34 
Body fat (%) 17.13 0.82 14.68 0.80 20.68 0.90 
Body fat (kg) 12.65 0.90 10.43 0.99 15.87 1.13 
Lean (kg) 59.52 1.62 59.01 2.41 60.26 2.00 
Water (%) 59.22 0.83 60.11 1.24 57.94 0.91 
Water (L) 42.36 0.96 41.24 1.29 43.99 1.35 
Impedance 50KHz 525.52 12.06 541.06 16.95 502.91 14.66 
LDI-ACh 158.50 10.36 168.25 12.86 144.31 17.02 
LDI-SNP 187.02 12.73 175.62 14.78 203.60 22.60 
Baseline brachial artery diameter (mm) 4.03 0.11 3.89 0.13 4.23 0.20 
Post-release brachial artery diameter 
(mm) 4.23 0.11 4.11 0.13 4.41 0.20 
FMD% 5.26 0.68 5.85 1.02 4.40 0.78 
cf-PWV (m/s) 6.15 0.18 5.71 0.18 6.80 0.25 
PWA (AIx, %) 4.49 2.63 -4.31 2.34 17.30 2.16 
PWA@75bpm (AIx, %) -2.22 2.60 -10.75 2.36 10.18 2.27 
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6.3.2 Study compliance 
The average energy intake of participants from 2-d diet diaries were in line with the DRV 
(Table 6.2). The weight, BMI, handgrip strength and body composition, including body fat, 
water mass and impedance of the participants did not differ significantly between baseline, 
washout period and after intake of both Piccolo and Oranjstar (Table 6.3). 
Table 6.2 The average daily intakes of nutrients by participants from 2-d diet diaries comparable 
with the RNI’s. 
Nutrients Reference Nutrient intake (RNIs) Mean SD 
Protein (g) 50 107.6 35.4 
Fat (g) <70 86.6 29.0 
Carbohydrate (g) >260 253.1 76.3 
Energy (kcal) 2000 2201.0 574.8 
Energy (kJ)  9249.5 2401.0 
Total Sugars (g) 90 78.1 42.2 
Total Saturates (g) <20 30.5 14.3 
Total Monounsaturate (g)  23.3 10.7 
Total Polyunsaturate (g)  9.6 4.0 
Tot Trans Fatty Acid (g)  0.9 0.9 
Total n3 fatty acid (g)  0.5 0.4 
Total n6 fatty acid (g)  4.8 5.2 
Non-starch Polysacch (g)  9.6 5.8 
Starch (g)  116.5 59.1 
Potassium (mg)  2181.9 840.2 
Calcium (mg)  512.6 269.8 
Magnesium (mg)  229.7 137.0 
Iron (mg)  7.9 3.3 
Copper (mg)  1.0 0.4 
Zinc (mg)  8.1 3.9 
Thiamin (B1) (mg)  26.0 13.6 
Riboflavin (B2) (mg)  4.3 1.7 
Vitamin B6 (mg)  15.0 6.8 
Vitamin B12 (µg)  168.5 90.8 
Vitamin C (mg)  8.6 43.3 
Vitamin D (µg)  334.0 700.4 
Vitamin E (alpha-t) (mg)  1329.5 2328.1 
Beta-carotene (µg)  0.8 1.6 
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Table 6.3 Effects of Piccolo and Oranjstar on anthropometric data in healthy men. 
  Unadjusted Adjustment for baseline and washout 
Adjustment for baseline, washout and 
randomisation order 
Variable N 
Piccolo Oranjstar 
P 
Piccolo Oranjstar 
P† 
Piccolo Oranjstar 
P‡ 
Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
Grip strength (kg) 27 44.69 1.29 45.14 1.38 0.51 44.69 0.57 45.14 0.48 0.50 44.69 0.58 45.14 0.48 0.49 
Body fat (%) 27 17.16 0.89 17.25 0.86 0.69 17.16 0.16 17.25 0.18 0.66 17.16 0.17 17.25 0.18 0.66 
Body fat (kg) 27 12.68 0.98 12.74 0.98 0.78 12.68 0.17 12.74 0.27 0.78 12.68 0.17 12.74 0.28 0.78 
Water (%) 27 59.12 0.90 59.13 0.84 0.97 59.12 0.16 59.13 0.22 0.97 59.12 0.16 59.13 0.22 0.96 
Water (It) 27 42.11 0.91 42.01 0.91 0.55 42.11 0.15 42.01 0.19 0.55 42.11 0.15 42.01 0.20 0.56 
Impedance (50KHz) 27 527.81 10.49 529.00 9.64 0.73 527.82 3.38 529.00 4.13 0.72 527.82 3.45 52.00 4.20 0.72 
†Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline and washout as covariate. 
‡Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline, washout and randomisation order as covariate with Bonferroni correction test. 
LSM= Least Squared Means (Marginal means). 
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6.3.3 Blood pressure 
 Resting BP 
The resting SBP was significantly reduced by 3.3 mmHg (p=0.021) after consumption of 
Piccolo, and no change was observed after consumption of Oranjstar in the group of all 
participants when compared to the baseline. There was no significant difference in resting 
SBP between Piccolo and Oranjstar intervention in either the younger or older groups, or 
when these were combined (Table 6.4, Table 6.5 and Table 6.6). 
After the consumption of Piccolo and Oranjstar, there were no change in resting DBP in the 
group of all participants when compared to the baseline. However, there was no significant 
difference in resting DBP changes between Piccolo and Oranjstar intervention in either the 
younger or older groups, or when these were combined (Table 6.4, Table 6.5 and Table 
6.6).  
 Ambulatory blood pressure (ABP) 
After the consumption of Piccolo and Oranjstar, there were no change in the 24-Hour 
ambulatory SBP in the group of all participants when compared to the baseline. There was 
no significant difference in the 24-Hour ambulatory SBP between Piccolo and Oranjstar 
intervention in either the younger or older groups, or when these were combined (Table 6.4, 
Table 6.5 and Table 6.6). 
After the consumption of Piccolo and Oranjstar, the 24-Hour ambulatory DBP was 
significantly reduced by 2.33 mmHg (p=0.006) and 1.56 mmHg (p=0.049) respectively in 
the group of all participants when compared to the baseline. After adjusting for covariate 
(baseline, washout and randomisation order), 24-Hour ambulatory DBP was significantly 
lower 1.8 mmHg (p=0.029) after Piccolo consumption compared with Oranjstar in the age 
group above 30 years of age (Table 6.6). The age group below 30 years of age showed no 
significant differences in the comparison of unadjusted or adjusted results.  
After the consumption of Piccolo and Oranjstar, there were no change in the daytime 
ambulatory SBP in the group of all participants when compared to the baseline. In age group 
above 30 years of age, daytime ambulatory SBP was significantly lower 3.3 mmHg 
(p=0.043) after Piccolo consumption compared with Oranjstar and the significance remained 
after adjusting for covariate (Table 6.6). Age group below 30 years of age showed no 
significant differences in the comparison of unadjusted or adjusted results. 
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After consumption of Piccolo, the daytime ambulatory DBP was significantly reduced by 
1.78 mmHg (p=0.047) and no change was observed after consumption of Oranjstar in the 
group of all participants when compared to the baseline. In age group above 30 years of age, 
daytime ambulatory DBP was significantly lower 3.0 mmHg (p=0.025) followed by Piccolo 
consumption compared with Oranjstar and the significance remained after adjusting for 
covariate (Table 6.6). Age group below 30 years of age showed no significant differences 
in the comparison of unadjusted or adjusted results. 
The nighttime ambulatory SBP was significantly reduced by 4.52 mmHg (p=0.039) after 
consumption of Piccolo and no change was observed after consumption of in the group of 
all participants when compared to the baseline. Nighttime ambulatory SBP was significantly 
lower 2.9 mmHg (p=0.042) followed by Piccolo consumption in the group of all participants, 
compared with Oranjstar and the significance remained after adjusting for covariate (Table 
6.4). 
After the consumption of Piccolo and Oranjstar, the nighttime ambulatory DBP was 
significantly reduced 3.82 mmHg (p=0.016) and 2.63 mmHg (p=0.026) respectively in the 
group of all participants when compared to the baseline. However, there were no significant 
differences in nighttime ambulatory DBP changes between Piccolo and Oranjstar 
intervention groups in either the younger or older groups, or when these were combined 
(Table 6.4, Table 6.5 and Table 6.6). 
 Home BP 
After the consumption of Piccolo and Oranjstar, the home SBP did not change in the group 
of all participants when compared with washout period. There were no significant 
differences in the home SBP between Piccolo and Oranjstar intervention in either the 
younger or older groups, or when these were combined (Table 6.4, Table 6.5 and Table 
6.6). 
After the consumption of Piccolo and Oranjstar, the home DBP did not change in the group 
of all participants when compared with washout period. There were no significant 
differences in the home DBP between Piccolo and Oranjstar intervention in either the 
younger or older groups, or when these were combined (Table 6.4, Table 6.5 and Table 
6.6).
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Table 6.4 Effects of Piccolo and Oranjstar on blood pressure in all healthy men. 
  Unadjusted Adjustment for baseline and washout 
Adjustment for baseline, washout 
and randomisation order 
Variable N Piccolo Oranjstar P Piccolo Oranjstar P† Piccolo Oranjstar P‡ Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
Resting SBP (mmHg) 27 112.9 1.58 113.6 1.72 0.44 112.9 0.75 113.6 1.08 0.46 112.9 0.75 113.6 1.10 0.46 
Resting DBP (mmHg) 27 68.2 1.33 68.8 1.38 0.46 68.2 0.97 68.8 0.89 0.47 68.2 0.99 68.8 0.90 0.48 
24-Hour ABP 
 SBP (mmHg) 27 121.7 1.85 122.6 1.86 0.32 121.7 1.07 122.6 0.80 0.33 121.7 1.02 122.6 0.80 0.33 
 DBP (mmHg) 27 71.9 1.31 72.7 1.46 0.32 71.9 0.80 72.7 0.73 0.30 71.9 0.80 72.7 0.74 0.30 
Daytime ABP 
 SBP (mmHg) 27 126.8 2.00 128.0 1.82 0.34 126.8 1.12 128.0 0.99 0.35 126.8 1.10 128.0 1.01 0.34 
 DBP (mmHg) 27 76.6 1.38 78.0 1.46 0.17 76.6 0.78 78.0 0.86 0.17 76.6 0.71 78.0 0.88 0.15 
Nighttime ABP 
 SBP (mmHg) 27 108.1 2.24 111.0 1.91 0.042* 108.1 1.92 111.0 1.45 0.048* 108.1 1.93 111.0 1.48 0.049* 
 DBP (mmHg) 27 60.4 1.42 61.6 1.33 0.27 60.4 1.36 61.6 1.08 0.27 60.4 1.36 61.6 1.10 0.27 
Home BP 
 SBP (mmHg) 27 116.9 2.02 117.7 2.05 0.41 116.9 0.91 117.7 0.94 0.42 116.9 0.93 117.7 0.89 0.39 
  DBP (mmHg) 27 73.5 1.11 72.3 1.23 0.08 72.3 0.64 73.5 0.54 0.08 72.3 0.64 73.5 0.52 0.06 
†Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline and washout as covariate. 
‡Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline, washout and randomisation order as covariate with Bonferroni 
correction test. 
LSM= Least Squared Means (Marginal means). 
*p<0.05. 
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Table 6.5 Effects of Piccolo and Oranjstar on blood pressure in healthy men below 30 years of age. 
  Unadjusted Adjustment for baseline and washout 
Adjustment for baseline, washout 
and randomisation order 
Variable N 
Piccolo Oranjstar 
P 
Piccolo Oranjstar 
P† 
Piccolo Oranjstar 
P‡ 
Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
Resting SBP (mmHg) 16 113.1 2.14 113.7 2.39 0.68 113.1 0.91 113.7 1.55 0.70 113.1 0.95 113.7 1.58 0.70 
Resting DBP (mmHg) 16 65.9 1.38 65.9 1.28 1.00 65.9 1.26 65.9 0.99 1.00 65.9 1.31 65.9 0.99 1.00 
24-Hour ABP 
 SBP (mmHg) 16 122.2 2.62 122.3 2.27 0.92 122.2 1.61 122.3 1.12 0.94 122.2 1.64 122.3 1.16 0.92 
 DBP (mmHg) 16 69.7 1.69 69.8 1.49 0.95 69.7 1.13 69.8 0.99 0.96 69.7 1.15 69.8 1.03 0.96 
Daytime ABP 
 SBP (mmHg) 16 127.9 2.89 127.6 2.09 0.86 127.9 1.57 127.6 1.38 0.85 127.9 1.60 127.6 1.41 0.84 
 DBP (mmHg) 16 74.4 1.90 74.8 1.54 0.81 74.4 1.22 74.8 1.26 0.81 74.4 1.11 74.8 1.30 0.78 
Nighttime ABP 
 SBP (mmHg) 16 109.3 3.09 111.1 2.64 0.29 109.3 2.74 111.1 1.75 0.31 109.3 2.85 111.1 1.76 0.31 
 DBP (mmHg) 16 59.6 1.90 59.1 1.55 0.66 59.6 1.64 59.1 0.97 0.67 59.6 1.70 59.1 1.00 0.69 
Home BP 
 SBP (mmHg) 16 117.3 3.00 118.7 2.94 0.28 117.3 1.17 118.7 0.98 0.30 117.3 1.20 118.7 0.91 0.26 
  DBP (mmHg) 16 71.8 1.16 70.4 1.14 0.15 70.4 0.78 71.8 0.80 0.17 70.4 0.80 71.8 0.68 0.14 
†Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline and washout as covariate. 
‡Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline, washout and randomisation order as covariate with 
Bonferroni correction test. 
LSM= Least Squared Means (Marginal means). 
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Table 6.6 Effects of Piccolo and Oranjstar on blood pressure in healthy men above 30 years of age. 
  Unadjusted Adjustment for baseline and washout 
Adjustment for baseline, washout and 
randomisation order 
Variable N Piccolo Oranjstar P Piccolo Oranjstar P† Piccolo Oranjstar P‡ Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
Resting SBP (mmHg) 11 112.6 2.42 113.4 2.53 0.22 112.6 0.80 113.4 1.28 0.26 112.6 0.84 113.4 1.37 0.30 
Resting DBP (mmHg) 11 71.6 2.29 73.0 2.37 0.28 71.5 1.43 73.0 1.68 0.24 71.5 1.42 73.0 1.79 0.25 
24-Hour ABP 
 SBP (mmHg) 11 121.1 2.62 123.1 3.30 0.13 121.1 1.12 123.1 0.90 0.08 121.1 1.01 123.1 0.76 0.10 
 DBP (mmHg) 11 75.2 1.71 77.0 2.36 0.10 75.2 0.73 77.0 0.78 0.02* 75.2 0.71 77.0 0.73 0.029* 
Daytime ABP 
 SBP (mmHg) 11 125.3 2.61 128.6 3.39 0.043* 125.3 1.15 128.6 1.09 0.011* 125.3 1.16 128.6 1.08 0.017* 
 DBP (mmHg) 11 79.6 1.61 82.6 2.20 0.025* 79.6 0.71 82.6 1.00 0.026* 79.6 0.61 82.6 1.02 0.038* 
Nighttime ABP 
 SBP (mmHg) 11 106.5 3.27 110.9 2.84 0.08 106.5 2.70 110.9 1.90 0.12 106.5 2.57 110.9 1.91 0.14 
 DBP (mmHg) 11 61.6 2.19 65.2 1.95 0.07 61.5 1.96 65.2 0.97 0.09 61.5 1.90 65.2 1.00 0.10 
Home BP 
 SBP (mmHg) 11 116.4 2.50 116.3 2.73 0.90 116.4 0.82 116.3 1.26 0.90 116.4 0.84 116.3 1.29 0.90 
  DBP (mmHg) 11 76.0 1.97 75.2 2.34 0.35 75.2 1.15 76.0 0.69 0.36 75.2 1.10 76.0 0.72 0.34 
†Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline and washout as covariate. 
‡Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline, washout and randomisation order as covariate with Bonferroni 
correction test. 
LSM= Least Squared Means (Marginal means). 
*p<0.05. 
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6.3.4 Vascular function 
 FMD 
After consumption of Piccolo and Oranjstar, FMD did not change in the group of all 
participants when compared to the baseline. In the age group above 30 years, FMD was 
significantly improved by 3.43% (p=0.026) after intake of Piccolo when compared with 
Oranjstar and the significant change remained after the covariate adjustment (Table 6.9). 
Age group below 30 years of age showed no significant differences in the comparison of 
unadjusted or adjusted results (Table 6.8). 
 Arterial stiffness 
After the consumption of Piccolo and Oranjstar, cf-PWV did not change in the group of all 
participants when compared to the baseline. There were no significant differences in cf-PWV 
between Piccolo and Oranjstar intervention in either the younger or older groups, or when 
these were combined (Table 6.7, Table 6.8 and Table 6.9).  
After the consumption of Piccolo and Oranjstar, PWA did not change in the group of all 
participants when compared to the baseline. In the age group above 30 years, consumption 
of Piccolo significantly improved PWA by 2.48% (p=0.013) and no change was observed 
after intake of Oranjstar, when compared to the baseline. There were no significant 
differences in PWA between Piccolo and Oranjstar intervention in either the younger or 
older groups, or when these were combined (Table 6.7, Table 6.8 and Table 6.9).  
 LDI 
After the consumption of Piccolo and Oranjstar, LDI-ACh did not change in the group of all 
participants when compared to the baseline. There were no significant differences in LDI-
ACh between Piccolo and Oranjstar intervention in either the younger or older groups, or 
when these were combined (Table 6.7, Table 6.8 and Table 6.9). After the consumption of 
Piccolo and Oranjstar, LDI-SNP did not change in the group of all participants when 
compared to the baseline. There were no significant differences in LDI-SNP between Piccolo 
and Oranjstar intervention in either the younger or older groups, or when these were 
combined (Table 6.7, Table 6.8 and Table 6.9).  
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Table 6.7 Effects of Piccolo and Oranjstar on non-invasive assessment in all healthy men. 
  Unadjusted Adjustment for baseline and washout 
Adjustment for baseline, washout and 
randomisation order 
Variable N Piccolo Oranjstar P Piccolo Oranjstar P† Piccolo Oranjstar P‡ Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
FMD (%) 27 6.38 0.70 5.48 0.69 0.26 6.38 0.72 5.48 0.68 0.24 6.38 0.72 5.48 0.68 0.25 
PWV (m/s) 27 6.03 0.17 5.91 0.17 0.26 6.03 0.09 5.91 0.12 0.26 6.03 0.92 5.91 0.12 0.26 
PWA (AIx, %) 27 3.62 2.22 3.58 2.69 0.98 3.62 0.80 3.58 1.06 0.98 3.62 0.82 3.58 1.06 0.98 
PWA@75bpm (AIx, %) 27 -3.34 2.30 -3.72 2.74 0.78 -3.34 0.80 -3.72 1.13 0.77 -3.34 0.82 -3.72 1.15 0.78 
LDI-Ach (PU) 27 160.00 10.06 168.49 10.90 0.39 160.00 9.86 168.49 10.09 0.40 160.00 9.90 168.49 10.28 0.41 
LDI-SNP (PU) 27 191.39 15.81 209.42 15.01 0.21 191.39 11.04 209.42 12.76 0.22 191.39 10.58 209.42 12.49 0.23 
†Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline and washout as covariate. 
‡Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline, washout and randomisation order as covariate with Bonferroni correction test. 
LSM= Least Squared Means (Marginal means). 
 
 
 
Table 6.8 Effects of Piccolo and Oranjstar on non-invasive assessment in healthy men below 30 years of age. 
  Unadjusted Adjustment for baseline and washout Adjustment for baseline, washout and randomisation order 
Variable N Piccolo Oranjstar P Piccolo Oranjstar P† Piccolo Oranjstar P‡ Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
FMD (%) 16 5.61 0.75 6.44 1.01 0.25 5.61 0.81 6.44 1.03 0.26 5.61 0.76 6.44 0.98 0.27 
PWV (m/s) 16 5.48 0.13 5.35 0.14 0.32 5.48 0.11 5.35 0.12 0.32 5.48 0.11 5.35 0.12 0.31 
PWA (AIx, %) 16 -4.09 1.82 -5.10 2.76 0.65 -4.09 1.27 -5.10 1.65 0.61 -4.09 1.28 -5.10 1.68 0.62 
PWA@75bpm (AIx, %) 16 -11.44 1.76 -12.64 2.74 0.58 -11.44 1.14 -12.64 1.80 0.57 -11.44 1.15 -12.64 1.85 0.58 
LDI-Ach (PU) 16 165.30 10.51 169.97 12.56 0.64 165.30 10.91 169.97 13.02 0.64 165.30 11.35 169.97 12.89 0.61 
LDI-SNP (PU) 16 171.13 16.43 179.41 14.08 0.28 171.13 12.26 179.41 12.83 0.20 171.13 12.40 179.41 13.20 0.22 
†Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline and washout as covariate. 
‡Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline, washout and randomisation order as covariate with Bonferroni correction test. 
LSM= Least Squared Means (Marginal means). 
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Table 6.9 Effects of Piccolo and Oranjstar on non-invasive assessment in healthy men above 30 years of age. 
  Unadjusted Adjustment for baseline and washout Adjustment for baseline, washout and randomisation order 
Variable N 
Piccolo Oranjstar 
P 
Piccolo Oranjstar 
P† 
Piccolo Oranjstar 
P‡ 
Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
FMD (%) 11 7.51 1.30 4.08 0.73 0.026* 7.51 1.33 4.08 0.73 0.042* 7.51 1.38 4.08 0.66 0.035* 
PWV (m/s) 11 6.83 0.20 6.72 0.18 0.59 6.83 0.15 6.72 0.18 0.57 6.83 0.16 6.72 0.20 0.59 
PWA (AIx, %) 11 14.82 1.76 16.21 1.63 0.19 14.82 0.68 16.21 0.94 0.23 14.82 0.63 16.21 0.99 0.21 
PWA@75bpm (AIx, %) 11 8.44 1.90 9.26 1.81 0.45 8.44 0.94 9.26 1.13 0.49 8.44 0.91 9.26 1.19 0.51 
LDI-Ach (PU) 11 152.30 19.86 166.33 20.32 0.49 152.30 18.67 166.34 10.69 0.38 152.30 16.61 166.34 10.70 0.36 
LDI-SNP (PU) 11 220.86 29.30 253.07 26.15 0.35 220.86 22.77 253.07 24.91 0.39 220.86 22.06 253.07 24.98 0.43 
†Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline and washout as covariate. 
‡Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline, washout and randomisation order as covariate with Bonferroni correction test. 
LSM= Least Squared Means (Marginal means). 
*p<0.05. 
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6.4 Discussion 
The aim of this study was to evaluate the impact of a 4-week dietary intervention of two 
varieties of tomato on BP and vascular function in healthy male subjects.  
6.4.1 Principle findings 
 Blood pressure 
The present study showed that the consumption of 300 g of Piccolo (containing 26.22 mg of 
total lycopene) and Oranjstar (7.92 mg of total lycopene) over a 4-week period produced a 
positive effect on BP. The resting SBP was significantly reduced by 3.3 mmHg (p=0.021) 
after consumption of Piccolo when compared to the baseline. After the consumption of 
Piccolo and Oranjstar, the 24-Hour ambulatory DBP was significantly reduced by 2.33 
mmHg (p=0.006) and 1.56 mmHg (p=0.049) respectively when compared to the baseline. 
However, Piccolo showed a greater reduction in BP. Specifically in the age group above 30 
years of age, there was a significant reduction in daytime ambulatory SBP and DBP 
compared with Oranjstar. In addition, a substantial decrease in nighttime ambulatory SBP 
by 4.52 mmHg (p=0.039) and nighttime ambulatory DBP reduced by 3.82 mmHg (p=0.016) 
and a significant decrease in daytime ambulatory DBP by 1.78 mmHg (p=0.047) following 
the consumption of Piccolo for group of all participants when compared to the baseline. No 
significant differences in the younger group, or in any other BP measurements were 
observed. These results indicate that consuming tomato as part of an overall diet brings 
benefits that in the long-term may translate into reducing the risk of CVD. These results 
remained after adjustments for baseline values.  
 Vascular function 
The present study showed that the consumption of 300 g of Piccolo and Oranjstar over a 4-
week period produced a positive effect on EF. However, Piccolo showed greater 
improvements in EF. In the age group above 30 years, consumption of Piccolo significantly 
improved PWA by 2.48% (p=0.013) from baseline and a borderline-significant trend to 
improvement of FMD by 3.11% (p=0.054) was observed when compared to the baseline. 
No significant differences in the younger group, or in any other vascular measurements were 
observed. These results indicate that consuming tomato as part of an overall diet brings 
benefits that in the long-term may translate into reducing the risk of CVD. In the age group 
above 30 years, consumption of Piccolo significantly improved FMD by 3.43% (p=0.026) 
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when compared to intake of Oranjstar. These results were robust and statistical significance 
remained after adjustments for baseline FMD values.  
6.4.2 Meaning of the current findings 
The results of BP reduction were significant given the fact that high BP remains ranked 1st 
among the leading 30 level-3 global risk factors for DALYs (Figure 1.13) (GBD 2015 Risk 
Factors Collaborators, 2016). The results from the Framingham Heart Study (in 1948-1966) 
showed that a 2 mmHg decrease in DBP could reduce the prevalence of hypertension by 
17% and reduce the risk of CHD by 6% (Hardy et al., 2015). Furthermore, a meta-analysis 
has shown a reduction in SBP by 10 mmHg and 5 mmHg DBP can reduce the risk of stroke 
by around 41% (33-38%) (Gaciong et al., 2013). A similar study reported that a 10 mmHg 
SBP and 5 mmHg DBP reduction also reduces chance of stroke by a third, CHD events by 
a quarter and heart failure by a quarter, regardless of the health of the patient prior to 
reduction (Law et al., 2009). In addition, one third of CHD and all-cause mortality can be 
attributed to elevated SBP (Hardy et al., 2015). These previous studies provide evidence on 
the significant effect of lowering BP on reducing prevalence of hypertension, CVD, CHD, 
heart failure, stroke and therefore a reduction in mortality. Consequently, the results of this 
dietary intervention indicate that a higher intake of trans-lycopene found in Piccolo was 
associated with causing a significant reduction in both SBP and DBP. Therefore, if Piccolo 
is included in the diet regularly, it could help to prevent BP related conditions and in the 
long-term reduce the levels of mortality. The cis-lycopene in the Oranjstar showed non-
significant reduction on BP. It may be due to the lower total lycopene content compared to 
that of Piccolo.  
As several methods of BP measurement were used during this study, comparisons between 
BP measurements can be made. For example, the highest measurement recorded was 
daytime 24hr ambulatory SBP/DBP (126.8/76.6 mmHg). This is expected and in agreement 
with other data available as measurements taken during this time are when the subject is 
awake and active during the day when the BP is likely to be at its highest. The lowest values 
recorded were nighttime SBP/DBP (108.1/60.4 mmHg), which would be expected as during 
the nighttime when participants were inactive BP would be lower. The second lowest 
measurement was resting office BP (112.9/68.2 mmHg) while home SBP/DBP (116.9/73.5 
mmHg) was higher than resting office BP. This is not expected as commonly under clinical 
settings patient’s BP tends to be slightly higher due to the uncomfortable and unfamiliar 
environment (white coat hypertension); while under relaxed environment (at home), the 
patient’s BP was expected to be lower. 
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FMD in the present study also have significant health implications. A recent systematic 
review reporting continuous risk estimates, CVD risk was RR 0.90 per 1% higher FMD 
(95% CI 0.86 to 0.94, p<0.01) (Ras et al., 2013). Regarding health status, the observed 
association between FMD and CVD risk was stronger for diseased populations RR 0.87 
(95% CI 0.83 to 0.92, p<0.01) than for asymptomatic populations RR 0.96 (95% CI 0.92 to 
1.00, p>0.03) (Ras et al., 2013). The RR for every 10% increase in AIx was 1.51 (95% CI 
1.23 to 1.86, p<0.0001) for all-cause mortality and 1.48 (95% CI 1.16 to 1.90, p<0.0001) for 
CV mortality (London et al., 2001). Another systematic review showed that age- and sex-
adjusted HR per 1-SD change in loge PWV were 1.35 (95% CI 1.22 to 1.50; p<0.001) for 
CHD, 1.54 (95% CI 1.34 to 1.78, p<0.001) for stroke, and 1.45 (95% CI 1.30 to 1.61, 
p<0.001) for CVD (Ben-Shlomo et al., 2014). Additionally, an increase in every 1 m/s in 
PWV was associated with a 15% higher CVD risk (Verbeke et al., 2011).  
6.4.3 Comparison to previous studies  
The systematic review in Chapter 3 showed that, lycopene supplementation significantly 
reduced SBP by 5.66 mmHg, but no significant reduction in DBP (Cheng et al., 2017). When 
comparing these results to the findings of the present study where there was a significant 
reduction in daytime SBP by 4.52 mmHg as well as in DBP by 3.82 mmHg. This could be 
due to the splitting of age groups in the present study. The significant changes were only 
found in the older group whereas the systematic review covered all different ages.  
A study into the effect of tomato products on CVD resulted in a significant reduction in DBP 
after a 6 week high tomato diet when compared to a low tomato diet but no significance in 
SBP reduction (Burton-Freeman et al., 2015). Again, with non-significant reduction in SBP 
and DBP, this difference could be due to the splitting into age categories in this study. There 
were not many current studies regarding tomatoes and BP. Therefore, comparing the results 
overall with the studies available, this study seems to be in line with the data.  
In Chapter 3, it has shown that, chronic (>1 week) tomato supplementation significantly 
increased FMD by 2.53% (95% CI 0.56 to 4.50, p=0.01, I2=0%) (Cheng et al., 2017). 
However acute studies (<24 hours) did not show any improvements (1.46%; 95% CI -0.33 
to 3.26, p=0.11) (Cheng et al., 2017). Previous results were compared to the findings of the 
present study where there was a non-significant trend to improvement of FMD by 3.11% 
(p=0.054) after Piccolo supplementation when compared to the baseline and FMD was 
significantly improved by 3.43% (p=0.026) after intake of Piccolo when compared with 
Oranjstar. The significant change remained after the covariate adjustment. In addition, the 
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meta-analysis in Chapter 3 showed that PWV did not differ between high intake of tomato 
interventions and washout period, mean difference was 0.93 m/s (95% CI -0.20 to 2.06, 
p=0.11) (Cheng et al., 2017). This result was in line with the findings of the present study 
where Piccolo and Oranjstar non-significantly reduced PWV by 0.12 m/s (p=0.357) and 0.25 
m/s (p=0.161) respectively when compared to the baseline. 
6.4.4 Retrospective power calculation for future study 
The retrospective sample size calculation was derived from the changes in nighttime SBP 
response after consumption of Piccolo and Oranjstar. The two-tails t-test to compare the 
differences between two dependent means was used. Calculations considered a Post hoc, a 
0.05 significance level and a 0.8 correlation coefficient between groups. The estimated 
participants required to allow detection a difference of 3 mmHg between the responses to 
the Piccolo and Oranjstar intervention, based on current study, was estimated to be 37 to 
give power of 0.8 as shown in Figure 6.1.  
However, if retrospective sample size calculation was derived from the changes in FMD 
response after consumption of Piccolo and Oranjstar, the estimated participants required to 
allow detection a difference of 3.42%, was estimated to be 15 to give power of 0.8 as shown 
in Figure 6.2. The two-tails t-test to compare the differences between two dependent means 
was used. Calculations considered a Post hoc, a 0.05 significance level and a 0.263 
correlation coefficient between groups. 
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Figure 6.1 Retrospective power calculation from changes in night time SBP response considering 
a Post hoc, a 0.05 significance level, a correlation coefficient between groups of 0.47.  
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Figure 6.2 Retrospective power calculation from the changes in FMD response considering a Post 
hoc, a 0.05 significance level, a correlation coefficient between groups of 0.47. 
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6.4.5 Strengths  
This study has a number of strengths. Firstly, the improvements observed in SBP and FMD 
reported in this study were documented using robust methodology. BP changes were 
documented using ambulatory 24-hr BP rather than resting BP (more likely to be affected 
by external factors to the intervention).  
The fact that the amount/dose of tomato to be consumed in this study was accurately weighed 
by the researcher and provided as separate parcels, and the fact that the two tomato varieties 
were provided by Thanet earth, reduces the risk of variability in consumption and 
composition of the tomato. Our analysis of the lycopene content showed no variations over 
time, therefore adding confidence that participants received a constant dose of lycopene 
throughout the study. The lycopene content and β-carotene content of cherry tomato used in 
present study were in line with previous studies (Table 4.3). In addition, Piccolo purchased 
from supermarket had similar carotenoid content to the Piccolo used in this study (Table 
4.3). Therefore, population supplementing Piccolo purchased from supermarket could have 
the same beneficial effects as present study.  
The measurements were all taken by the same researcher, so it would be consistent for every 
visit and reduce the possibility of bias. Furthermore, evaluation of FMD reproducibility prior 
to the study showed low variability within and between days. Intra-researcher reproducibility 
for FMD was good with a coefficient of variation (CV) of 5.22% (n= 20). Moreover, there 
was low systematic bias between the measurements from the same the researcher. This study 
implemented randomised allocation achieving a balanced order of interventions across 
groups which would reduce the influence of order effects. Subjects were not screened or 
selected on the basis of metabolic risk factors, so regression to the mean could not have 
confounded the results. 
As mentioned in Chapter 5, of the 31 enrolled subjects, 29 completed attended the baseline 
assessment and 27 completed the entire trial (93.2%); drop outs were due to inability to fulfil 
the time for study visits (Figure 5.3). Participants were contacted regularly to discuss any 
problems related to the supplementation of tomato. Self-reported daily checklist of tomato 
supplementation showed a good acceptability and compliance with tomato supplementation. 
No side-effect of interventions was reported about supplementation of tomato. In addition, 
the fact that BMI, body composition and handgrip strength remained unchanged during the 
whole clinical trial, supports the presence of good compliance with maintaining usual diet 
and physical activity patterns. 
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The fact that only men were studied, excludes the confounding associated with hormonal 
changes during menstrual cycles affecting outcome measures in women.  
6.4.6 Limitations  
This study is, however, not without limitations. For example, only males took part in the 
study, and results cannot be extrapolated to women. Although that is the case, female BP 
can vary through their menstrual cycle, therefore conducting the study with females could 
produce skewed results. This study was an “open label” study that could not blind 
participants and researchers. However, this is a common situation in dietary interventions. 
Although, participants were taking the same amount of tomato for both varieties, the total 
lycopene content of both tomatoes were not the same. This could be the reason Oranjstar 
showed lower improvement in BP and FMD. This level of tomato intake in this study was 
not intended to represent an amount to be recommended but to show that consumption of 
tomatoes was clearly sufficient to induce significant risk factor improvements.  
6.4.7 Possible mechanisms and implications for clinicians or policymakers. 
Tomatoes are not only rich in essential vitamins and minerals but also very low in fats, 
cholesterol or sodium, and thus, are great for cardiovascular health (Table 4.4) (Willcox et 
al., 2003). Lycopene is one of the most powerful antioxidants and free radical quenchers. 
Our results indicate that the role of lycopene in lowering SBP might be attributed to its role 
as an antioxidant and free radical quencher, which could inhibit oxidative stress, indirectly 
stimulate production of NO in the endothelium and improve vascular function. The 
antioxidant nature of lycopene found in tomatoes can act as an anticarcinogenic, 
chemopreventive agent helping to inhibit development of cancer cells. There has been 
research into the effects of lycopene and specifically prostate cancer prevention (Sporn and 
Liby, 2013; Zu et al., 2014). Therefore, this intervention could have also had other possible 
health benefits on the participants but have not been monitored. Lycopene could also help to 
reduce synthesis of cholesterol and increase low-density lipoprotein degradation (Cheng et 
al., 2017; Story et al., 2010). LDL-cholesterol builds up in the arteries and contributes to the 
development of atherosclerosis. The results of this study are important to health-related 
professionals. Nutritionists and dietitians should encourage a diet with an increased lycopene 
intake through tomato consumption to reduce BP and further reduce the risk of CVD, and 
also potentially decrease the risk of cancer, specifically prostate cancer. Especially for 
patients with hypertension or borderline hypertension, the intake of fruit and vegetables 
should be encouraged and the positive effects of Piccolo consumption should be highlighted.  
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6.4.8 Unanswered questions and future research 
In this study, only raw tomato was used for the dietary intervention, rather than tomato 
products such as tomato paste, juice or cooked tomatoes, which are associated with enhanced 
bioavailability of lycopene. These other forms of tomato products and lycopene supplements 
could be evaluated and ascertain the effects of varying lycopene doses and their effects on 
BP. Cooking vegetables changes their chemical composition and could affect the 
bioaccessibility of the vitamins and minerals (Chan et al., 2014). Future studies could also 
alter the dose (e.g. lower doses) of tomato supplemented and the length of intervention 
(longer periods). The possibility of combining another food with the lycopene rich tomatoes 
is also an attractive approach to test whether additional effects could be observed from food 
combinations such as beetroots alongside tomato. Beetroots have been shown to help lower 
BP but have never been trialled alongside tomato consumption and this could have a positive 
effect on the body (Hobbs et al., 2013a; Lara et al., 2016; Siervo et al., 2013). This study 
was conducted with only male participants, and so there would be room for further research 
with lycopene supplementation and effects on female BP. 
6.5 Conclusion  
In conclusion, this study provided evidence on the benefits of the consumption Piccolo, for 
four weeks, which had a significant impact on reducing both ambulatory SBP and DBP, and 
improving FMD, therefore lowering the risk of cardiovascular disease in healthy, 
particularly in older, adult males.  
6.6 Research Questions Raised from The Present Chapter 
The work described in this chapter raised the following questions: 
1. Do different varieties of cherry tomato have the same extent of beneficial effects on 
blood-borne biomarkers of vascular function? 
2. Do these health benefits differ according to age? 
3. Are changes in FMD associated with improvements on blood-borne biomarkers of 
vascular function? 
These questions will be addressed in Chapter 7 by examining the effects of Piccolo and 
Oranjstar on blood-borne cardiovascular biomarkers. We also aimed to assess whether 
different varieties of cherry tomato would have the same extent of beneficial effects.  
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Chapter 7 The Effects of Piccolo and Oranjstar on Blood-Borne Circulating 
Biomarkers and Other Cardiovascular Factors 
This study was designed to answer the research questions in section 6.7.  
7.1 Introduction 
In addition to vascular function and BP, a large number of traditional and emergent 
circulating biomarkers are significant predictors of CVD. A number of biomarkers have 
become well-established (also called traditional) markers of atherosclerosis, CVD, 
disability, and mortality. The traditional circulating biomarkers include blood lipid profile 
(total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein 
(HDL) cholesterol, and triglyceride (TG)). Some of these have been included in a number of 
algorithms, such as the Framingham Risk Score and the German Prospective Cardiovascular 
Münster (PROCAM) model, to calculate estimated risks of CHD and CVD.  
Previous human trials have shown the protective effects of tomato on blood lipid. There are 
numerous emergent circulating biomarkers including interleukin 6 (IL-6), tumour necrosis 
factor alpha (TNF-α), soluble intercellular adhesion molecules (sICAM-1), soluble vascular 
adhesion molecules (sVCAM-1), E-selectin and P-selectin. However, these inflammatory 
markers have been less studied. We aimed to determine the beneficial effects of tomato on 
blood lipid profile including TG, TC, LDL-cholesterol, HDL-cholesterol and inflammatory 
markers including TNF-α, IL-6, E-selectin, P-selectin, sICAM-1, and sVCAM-1. We also 
aimed to assess whether different varieties of cherry tomato would have the same extent of 
beneficial effects. 
7.2 Method 
7.2.1 Blood sample collection and measurement of blood circulating CVD risk 
markers 
The method of the collection of blood samples and the measurement of blood circulating 
CVD risk markers were described in detail in Chapter 5 (section 5.2.3.9). 
7.2.2 Statistical analysis 
The statistical analysis was described in detail in Chapter 5 (section 5.2.4). 
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7.3 Result 
7.3.1 Participants baseline characteristic  
In total 27 participants completed the intervention study, ranging from an age of 19 to 60 
years. The participants were statistically analysed as a full sample size as well as being split 
into two different age groups. These were categorised as below 30 years of age, which 
included 16 participants, and above 30 years of age, including 11 participants. BMI values 
ranged from 16.5 kg/m2 to 32.5 kg/m2 among all participants, but the mean BMI difference 
between the two age groups was small (2 kg/m2) (Table 6.1). The baseline blood-borne 
biomarkers characteristics of the participants are shown in Table 7.1. The blood-borne 
marker level of all participants was in normal range.  
Table 7.1 Participants baseline characteristic of blood-borne biomarkers. 
Baseline 
characteristics 
All participants 
(n=27) 
Below 30yrs 
(n=16) 
Above 30yrs 
(n=11) 
Mean SEM Mean SEM Mean SEM 
Fasting glucose (mmol/L) 5.46 0.20 5.23 0.08 5.78 0.46 
Total-cholesterol (mmol/L) 4.53 0.14 4.51 0.16 4.55 0.25 
HDL-cholesterol (mmol/L) 1.26 0.06 1.31 0.07 1.18 0.10 
LDL (mmol/L) 3.42 0.16 3.21 0.17 3.72 0.28 
Triglycerides (mmol/L) 1.06 0.09 1.07 0.14 1.05 0.11 
Interleukin 6 (ng/mL) 3.35 0.36 3.56 0.55 3.06 0.39 
TNF-α (pg/mL) 25.01 1.76 27.35 2.52 21.51 1.88 
sICAM (ng/mL) 210.38 14.63 189.09 16.72 239.41 24.18 
sVCAM (ng/mL) 432.75 25.56 445.48 39.12 416.55 31.36 
P-selectin (ng/mL) 45.08 1.72 41.95 1.73 49.34 2.93 
E-selectin (ng/mL) 30.45 2.63 26.46 2.57 35.88 4.79 
7.3.2 Blood lipid profile 
 Triglyceride 
After the consumption of Piccolo and Oranjstar, TG did not change in the group of all 
participants when compared to the baseline. There were no significant differences in TG 
between Piccolo and Oranjstar intervention in either the younger or older groups, or when 
these were combined (Table 7.2, Table 7.3 and Table 7.4). 
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 Total cholesterol 
After the consumption of Piccolo and Oranjstar, TC did not change in the group of all 
participants when compared to the baseline. In the age group above 30 years, consumption 
of Piccolo and Oranjstar significantly increased TC by 0.423 mmol/L (p=0.013) and 0.45 
mmol/L (p=0.02) respectively, when compared to the baseline. There were no significant 
differences in TC between Piccolo and Oranjstar intervention in either the younger or older 
groups, or when these were combined (Table 7.2, Table 7.3 and Table 7.4). 
 LDL-cholesterol 
After the consumption of Piccolo and Oranjstar, LDL-cholesterol did not change in the group 
of all participants when compared to the baseline. There were no significant differences in 
LDL-cholesterol between Piccolo and Oranjstar intervention in either the younger or older 
groups, or when these were combined (Table 7.2, Table 7.3 and Table 7.4). 
 HDL-cholesterol 
After the consumption of Piccolo and Oranjstar, HDL-cholesterol did not change in the 
group of all participants when compared to the baseline. After adjusting for baseline, HDL-
cholesterol was significantly increase 0.04 mmol/L (p=0.048) followed by Piccolo 
consumption compared with Oranjstar in the group of all participants (Table 7.2). 
7.3.3 Blood glucose level 
After the consumption of Piccolo and Oranjstar, blood glucose level did not change in the 
group of all participants when compared to the baseline. There were no significant 
differences in blood glucose level between Piccolo and Oranjstar intervention in either the 
younger or older groups, or when these were combined (Table 7.2, Table 7.3 and Table 
7.4). 
7.3.4 Blood insulin level 
Insulin was only measured after each tomato intervention. There were no significant 
differences in blood insulin level between Piccolo and Oranjstar intervention in either the 
younger or older groups, or when these were combined (Table 7.2, Table 7.3 and Table 
7.4). 
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Table 7.2 Effects of Piccolo and Oranjstar on blood-borne biomarkers in healthy men. 
 Unadjusted Adjustment for baseline and washout Adjustment for baseline, washout and randomisation order 
Variable N 
Piccolo 
N 
Oranjstar 
P 
Piccolo Oranjstar 
P† 
Piccolo Oranjstar 
P‡ 
Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
Glucose (mmol/l) 16 5.25 0.08 16 5.14 0.12 0.14 5.25 0.07 5.14 0.11 0.16 5.25 0.06 5.14 0.08 0.10 
Total cholesterol (mmol/l) 16 4.40 0.17 16 4.53 0.22 0.33 4.40 0.11 4.53 0.11 0.30 4.40 0.11 4.53 0.10 0.14 
HDL (mmol/l) 16 1.31 0.05 16 1.26 0.07 0.09 1.31 0.03 1.26 0.04 0.05 1.31 0.03 1.26 0.03 0.06 
Non-HDL (mmol/l) 16 3.09 0.18 16 3.21 0.19 0.26 3.09 0.10 3.21 0.10 0.27 3.10 0.10 3.26 0.11 0.06 
Triglycerides (mmol/l) 16 1.04 0.09 16 1.28 0.29 0.32 1.04 0.07 1.28 0.26 0.30 1.04 0.62 1.28 0.25 0.28 
 Unadjusted Adjustment for baseline Adjustment for baseline and randomisation order 
Variable N 
Piccolo 
N 
Oranjstar 
P 
Piccolo Oranjstar 
P❖ 
Piccolo Oranjstar 
P▲ 
Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
Insulin (pmol/l) 16 30.65 4.72 16 28.90 3.44 0.59      30.65 4.873 28.96 3.56 0.60 
IL-6 (pg/ml) 16 2.73 0.68 16 2.78 0.61 0.90 2.66 0.73 2.89 0.69 0.60 2.66 0.73 2.89 0.70 0.61 
TNF-α (pg/ml) 16 23.40 2.22 16 22.67 1.88 0.81 23.86 2.40 22.60 2.05 0.71 23.86 2.10 22.60 1.96 0.63 
sICAM-1 (ng/ml) 15 141.56 13.28 15 152.96 15.37 0.39 144.99 11.85 158.55 12.29 0.35 144.99 11.53 158.55 12.67 0.32 
sVCAM-1 (ng/ml) 15 357.81 29.39 15 364.69 29.73 0.74 369.04 20.21 373.11 25.81 0.85 369.04 20.58 373.11 26.51 0.84 
P-selectin (ng/ml) 16 44.82 2.36 16 46.13 2.34 0.54 44.71 2.58 46.02 2.57 0.58 44.71 2.68 46.02 2.39 0.52 
E-selectin (ng/ml) 16 25.01 28.01 16 20.14 2.59 0.77 22.56 4.09 20.52 2.59 0.71 22.56 4.25 20.52 2.69 0.72 
†Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline and washout as covariate. 
‡Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline, washout and randomisation order as covariate with Bonferroni correction test. 
❖Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline value as covariate. 
▲Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline and randomisation order as covariate with Bonferroni correction test. 
LSM= Least Squared Means (Marginal means). 
Insulin levels were only measured in post-intervention. 
IL-6, TNF-α, sICAM-1, sVCAM-1, P-selectin and E-selectin level were only measured in baseline and post-intervention. 
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Table 7.3 Effects of Piccolo and Oranjstar on blood-borne biomarkers in healthy men below 30 years of age. 
  Unadjusted Adjustment for baseline and washout Adjustment for baseline, washout and randomisation order 
Variable N Piccolo N Oranjstar P Piccolo Oranjstar P† Piccolo Oranjstar P‡ Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
Glucose (mmol/l) 16 5.25 0.08 16 5.14 0.12 0.14 5.25 0.07 5.14 0.11 0.16 5.25 0.06 5.14 0.08 0.10 
Total cholesterol (mmol/l) 16 4.40 0.17 16 4.53 0.22 0.33 4.40 0.11 4.53 0.11 0.30 4.40 0.11 4.53 0.10 0.14 
HDL (mmol/l) 16 1.31 0.05 16 1.26 0.07 0.09 1.31 0.03 1.26 0.04 0.05 1.31 0.03 1.26 0.03 0.06 
Non-HDL (mmol/l) 16 3.09 0.18 16 3.21 0.19 0.26 3.09 0.10 3.21 0.10 0.27 3.10 0.10 3.26 0.11 0.06 
Triglycerides (mmol/l) 16 1.04 0.09 16 1.28 0.29 0.32 1.04 0.07 1.28 0.26 0.30 1.04 0.62 1.28 0.25 0.28 
  Unadjusted Adjustment for baseline Adjustment for baseline and randomisation order 
Variable N Piccolo N Oranjstar P Piccolo Oranjstar P❖ Piccolo Oranjstar P▲ Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
Insulin (pmol/l) 16 30.65 4.72 16 28.90 3.44 0.59      30.65 4.873 28.96 3.56 0.60 
IL-6 (pg/ml) 16 2.73 0.68 16 2.78 0.61 0.90 2.66 0.73 2.89 0.69 0.60 2.66 0.73 2.89 0.70 0.61 
TNF-α (pg/ml) 16 23.40 2.22 16 22.67 1.88 0.81 23.86 2.40 22.60 2.05 0.71 23.86 2.10 22.60 1.96 0.63 
sICAM-1 (ng/ml) 15 141.56 13.28 15 152.96 15.37 0.39 144.99 11.85 158.55 12.29 0.35 144.99 11.53 158.55 12.67 0.32 
sVCAM-1 (ng/ml) 15 357.81 29.39 15 364.69 29.73 0.74 369.04 20.21 373.11 25.81 0.85 369.04 20.58 373.11 26.51 0.84 
P-selectin (ng/ml) 16 44.82 2.36 16 46.13 2.34 0.54 44.71 2.58 46.02 2.57 0.58 44.71 2.68 46.02 2.39 0.52 
E-selectin (ng/ml) 16 25.01 28.01 16 20.14 2.59 0.77 22.56 4.09 20.52 2.59 0.71 22.56 4.25 20.52 2.69 0.72 
†Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline and washout as covariate. 
‡Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline, washout and randomisation order as covariate with Bonferroni correction test. 
❖Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline value as covariate. 
▲Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline and randomisation order as covariate with Bonferroni correction test. 
LSM= Least Squared Means (Marginal means). 
Insulin levels were only measured in post-intervention. 
IL-6, TNF-α, sICAM-1, sVCAM-1, P-selectin and E-selectin level were only measured in baseline and post-intervention. 
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Table 7.4 Effects of Piccolo and Oranjstar on blood-borne biomarkers in healthy men above 30 years of age. 
    Unadjusted Adjustment for baseline and washout Adjustment for baseline, washout and randomisation order 
Variable N Piccolo N Oranjstar P Piccolo Oranjstar P† Piccolo Oranjstar P‡ Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM  
Glucose (mmol/l) 11 5.75 0.42 11 5.73 0.39 0.81 5.75 0.08 5.73 0.13 0.79 5.75 0.87 5.73 0.13 0.78 
Total cholesterol (mmol/l) 11 4.98 0.22 11 5.00 0.24 0.87 4.98 0.13 5.01 0.16 0.87 4.98 0.05 5.01 0.10 0.84 
HDL (mmol/l) 11 1.24 0.10 11 1.21 0.09 0.36 1.24 0.04 1.21 0.02 0.39 1.24 0.02 1.21 0.03 0.14 
Non-HDL (mmol/l) 11 3.74 0.23 11 3.80 0.25 0.66 3.74 0.13 3.80 0.08 0.66 3.74 0.67 3.80 0.96 0.63 
Triglycerides (mmol/l) 11 1.13 0.14 11 1.25 0.20 0.31 1.13 0.09 1.26 0.13 0.29 1.13 0.87 1.26 0.13 0.22 
    Unadjusted Adjustment for baseline Adjustment for baseline and randomisation order 
Variable N Piccolo N Oranjstar P Piccolo Oranjstar P❖ Piccolo Oranjstar P▲ Mean SEM Mean SEM LSM SEM LSM SEM LSM SEM LSM SEM 
Insulin (pmol/l) 11 32.89 6.69 11 37.00 5.23 0.49      32.89 6.86 37.00 5.44 0.52 
IL-6 (pg/ml) 11 2.55 0.32 11 1.73 0.24 0.026* 2.54 0.34 1.84 0.24 0.027* 2.54 0.35 1.84 0.25 0.034* 
TNF-α (pg/ml) 11 20.54 1.29 11 22.36 1.60 0.46 20.98 1.40 21.99 1.67 0.69 20.98 1.16 21.99 0.89 0.25 
sICAM-1 (ng/ml) 11 184.69 21.07 11 147.78 18.77 0.14 184.70 16.40 147.78 16.87 0.15 184.70 17.38 147.78 17.76 0.18 
sVCAM-1 (ng/ml) 11 444.58 42.78 11 356.27 27.01 0.08 444.58 37.04 356.72 25.21 0.09 444.58 38.52 356.27 24.48 0.09 
P-selectin (ng/ml) 11 50.41 3.02 11 46.91 3.11 0.42 50.41 2.95 46.91 3.01 0.44 50.41 2.15 46.91 2.84 0.46 
E-selectin (ng/ml) 11 25.01 28.01 11 28.26 4.56 0.82 30.08 5.38 28.26 4.25 0.82 30.08 4.11 28.26 4.50 0.81 
†Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline and washout as covariate. 
‡Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline, washout and randomisation order as covariate with Bonferroni correction test. 
❖Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline value as covariate. 
▲Estimated from repeated measures ANOVA of the Piccolo and Oranjstar with baseline and randomisation order as covariate with Bonferroni correction test. 
LSM= Least Squared Means (Marginal means). 
*p<0.05. 
Insulin levels were only measured in post-intervention. 
IL-6, TNF-α, sICAM-1, sVCAM-1, P-selectin and E-selectin level were only measured in baseline and post-intervention. 
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7.3.5 Other circulating biomarkers 
 Inflammatory cytokines 
After the consumption of Piccolo and Oranjstar, IL-6 did not change in the group of all 
participants when compared to the baseline. The age group above 30 years of age showed 
significant reduction in IL-6 by 1.22 pg/mL (p=0.035) after intake of Oranjstar when 
compared to the baseline. IL-6 was significantly reduced by 0.82 pg/mL (p=0.026) following 
Oranjstar consumption compared with Piccolo in age group above 30 years of age and the 
significant change remained after the covariate adjustment (Table 7.4). Age group below 30 
years of age showed no significant change after adjusting for covariate (Table 7.3). 
After the consumption of Piccolo and Oranjstar, TNF-α did not change in the group of all 
participants when compared to the baseline. There were no significant differences in TNF-α 
between Piccolo and Oranjstar intervention in either the younger or older groups, or when 
these were combined (Table 7.2, Table 7.3 and Table 7.4). 
 Adhesion molecules  
E-selectin was significantly reduced by 6.651 ng/mL (p=0.016) after consumption of 
Oranjstar and no change was observed after consumption of Piccolo in the group of all 
participants when compared to the baseline. There were no significant differences in E-
selectin between Piccolo and Oranjstar intervention in either the younger or older groups, or 
when these were combined (Table 7.2, Table 7.3 and Table 7.4). 
After the consumption of Piccolo and Oranjstar, P-selectin did not change in the group of all 
participants when compared to the baseline. There were no significant differences in P-
selectin between Piccolo and Oranjstar intervention in either the younger or older groups, or 
when these were combined (Table 7.2, Table 7.3 and Table 7.4). 
After the consumption of Piccolo and Oranjstar, sICAM-1 was significantly reduced by 
49.56 ng/mL (p<0.001) and 59.14 ng/mL (p<0.001) respectively in the group of all 
participants when compared to the baseline. There were no significant differences in sICAM-
1 between Piccolo and Oranjstar intervention in either the younger or older groups, or when 
these were combined (Table 7.2, Table 7.3 and Table 7.4). 
sVCAM-1 was significantly reduced by 67.35 ng/mL (p=0.003) after consumption of 
Oranjstar and no change was observed after consumption of Piccolo in the group of all 
participants when compared to the baseline. There were no significant differences in 
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sVCAM-1 between Piccolo and Oranjstar intervention in either the younger or older groups, 
or when these were combined (Table 7.2, Table 7.3 and Table 7.4). 
7.4 Discussion 
Previous interventional studies have focused on explaining the effects of tomatoes, tomato 
by-products, or lycopene supplementations on blood lipid profile and inflammatory 
biomarkers (Blum et al., 2006; Collins et al., 2004; Cuevas-Ramos et al., 2013; Devaraj et 
al., 2008; Engelhard et al., 2006; Misra et al., 2006). In this study, we measured the blood 
lipid profile and a wide range of molecules that involved in the initiation and progression of 
atherosclerosis, such as the inflammatory cytokines TNF-α and IL-6, as well as adhesion 
molecules sICAM-1, and sVCAM-1, after 4-week interventions with different varieties of 
tomatoes. We also elucidated the role of major carotenoids in tomatoes.  
7.4.1 Principle findings 
The present study showed that the consumption of 300 g of Piccolo (containing 26.22 mg of 
total lycopene) and Oranjstar (7.92 mg of total lycopene) over a 4-week period produced a 
positive effect on inflammatory biomarkers. Supplementation of Piccolo and Oranjstar 
significantly reduced sICAM-1 by 49.56 ng/mL (p<0.001) and 59.14 ng/mL (p<0.001) 
respectively from baseline values for all participants. After the consumption of Oranjstar, all 
participants showed a significant reduction of sVCAM-1 and E-selectin by 67.35 ng/mL 
(p=0.003) and 6.65 ng/mL (p=0.016) respectively, when compared to the baseline.  
In the age group above 30 years of age, supplementation of Oranjstar was a significant 
reduction in IL-6 by 1.22 pg/mL (p=0.035) when compared with baseline values; Oranjstar 
consumption was also significantly lower (by 0.82 pg/mL, p=0.026) than the changes 
observed with Piccolo.  
Moreover, these effects were unrelated to differences in blood lipid profile, body fats and 
BMI.  
7.4.2 Meaning of the current findings 
The adhesion molecules ICAM-1 and VCAM-1 were well recognised for their role in the 
development of atherosclerotic plaque. Its expression was related to pro-inflammatory 
stimuli such as oxidised LDL and CRP (Galkina and Ley, 2007; Ley and Huo, 2001). A 
prospective study and meta-analysis showed a significant increase in the incidence of CHD 
among individuals within the top third of sICAM-1 levels (338 ng/mL) when compared with 
those in the bottom third of sICAM-1 levels (261 ng/mL) (OR 1.49, 95% CI 1.14 to 1.94) 
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after adjustments for age, town, smoking and risk factors (Malik et al., 2001). In addition, 
this study also reported a significant increase in the incidence of CHD among individuals in 
the top third of sVCAM-1 levels (516 ng/mL) when compared with those in the bottom third 
of sVCAM-1 levels (37 ng/mL) (OR 1.35, 95% CI 1.05 to 1.75) after adjustments for age, 
town, smoking and risk factors (Malik et al., 2001). Consequently, the results of the present 
dietary intervention study indicated that a higher intake of Oranjstar was associated with 
significant reductions in both ICAM-1 and VCAM-1, independent to the changes in blood 
lipids.  
7.4.3  Comparison to previous studies  
Human intervention trials that have evaluated the effects of lycopene on inflammatory 
biomarker were scarce. In agreement with our results, Colman-Martinez et al. (2017) showed 
a 10-fold reduction in sICAM-1 (Colman-Martinez et al., 2017) after tomato juice 
supplementation for 2 weeks. In addition, García-Alonso et al. (2012) observed a reduction 
of sVCAM-1 after tomato juice supplementation for 2 weeks (García-Alonso et al., 2012). 
It is noteworthy that the differences in magnitudes of the changes reported in these studies 
when compared to our study could be due to the characteristics of the studied population. 
Both trials mentioned above included participants with high cardiovascular risks (Colman-
Martinez et al., 2017; García-Alonso et al., 2012). 
In contrast, two previous studies showed no significant changes in sICAM-1 after dietary 
intervention with tomatoes, tomato by-products or lycopene supplements (Blum et al., 2007; 
Cheng et al., 2017; Thies et al., 2012).  
The present study also showed a reduction of plasma IL-6 after consumption of Oranjstar 
when compared with baseline (1.22 pg/mL, p=0.035) in age group above 30 years. In line 
with our results, previously reviewed studies supplementing tomato were also associated 
with significant reductions in IL-6 (SMD -0.25; p=0.03) (Cheng et al., 2017). 
The evidence of the impact of tomato or lycopene on blood lipids is contrasting. Several 
studies have shown an improvements on lipid parameters such as TC (Li et al., 2015; Silaste 
et al., 2007; Vinha et al., 2014), TG (Vinha et al., 2014), HDL-cholesterol (Bohn et al., 2013; 
Cuevas-Ramos et al., 2013; Madrid et al., 2006) and LDL-cholesterol (Silaste et al., 2007) 
after tomato consumption. However, other studies such as the one conducted by Petyaev et 
al. (2018) showed that tomato did not significantly affect parameters of lipid profile in 
patients with coronary vascular disease (Petyaev et al., 2018). The systematic review and 
meta-analysis in Chapter 3 showed that overall, interventions supplementing tomato were 
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associated with significant reductions in LDL-cholesterol (-0.22 mmol/L; p=0.006) but no 
significant changes were observed in other lipid parameters (Cheng et al., 2017). 
7.4.4 Strengths  
Cis-lycopene isomers were well recognised for their better bioavailability and greater 
proportion in human plasma and tissues when compared with the trans-lycopene. It was 
therefore suggested that cis-lycopene has a more important effect than trans-lycopene on 
reducing risk factors of CVD (Böhm and Bitsch, 1999; Rao and Agarwal, 1999; Unlu et al., 
2007b). One of the strong points of the present study was the elucidation of the beneficial 
effects of both trans-lycopene and cis-lycopene on the decrease of adhesion molecules after 
tomato consumption, which were in agreement with a previous study (Colman-Martinez et 
al., 2017). These beneficial effects were independent to blood lipids. A possible mechanism 
is that lycopene may modulate the concentration of adhesion molecules, and probably other 
inflammatory molecules. This is achieved through inhibiting the translocation of the nuclear 
factor kappa B (NF-κB) (Hung et al., 2008; Yang et al., 2017). NF-κB is involved in the 
activation of the inflammatory cascade that could stimulate adhesion molecule and 
inflammatory molecules expression (Hung et al., 2008; Yang et al., 2017). In addition, 
lycopene may increase the intracellular glutathione (GSH) level and glutamate-cysteine 
ligase expression. Subsequently, lycopene induces nuclear factor-erythroid 2 related factor 
2 (Nrf2) activation, leading to the increased expression of downstream heme oxygenase-1 
(HO-1). The use of siRNA to target HO-1 blocks the inhibitory effects of lycopene on IκB 
degradation and sICAM-1 expression. The inhibitory effects of lycopene thus appear to be 
mediated through its induction of Nrf2-mediated HO-1 expression (Yang et al., 2017). 
7.4.5 Limitations  
In the present study, we did not have a control arm but previous studies have proven that 
tomato intervention has improved cardiovascular risk factors when compared against control 
or placebo groups (Cheng et al., 2017). We did not involve a control arm because the purpose 
of the present intervention is to compare the effects of two tomato varieties on cardiovascular 
risk factors. Furthermore, the volunteers enrolled in this trial were perhaps too healthy to 
allow detection of significant changes in blood lipid. In 2013, 67% of men were measured 
as overweight (BMI>25kg/m2) and 26% of men were defined as obese (BMI>30kg/m2) in 
England (Townsend et al., 2015), which is higher than the mean BMI (23.3kg/m2) of 
participants in this study. Although not all previous intervention studies carried out in obese 
individuals and/or patients with disease with lycopene/tomato-based products showed 
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beneficial effects on blood lipid (Cheng et al., 2017), recruiting participants with established 
elevated risk markers for CVD and/or with a higher BMI may increase the probability of 
detecting such changes. 
7.4.6 Unanswered questions and future research 
To the best of our knowledge, no previous studies have compared the two different varieties 
of tomato (rich in trans-lycopene and cis-lycopene). The positive impacts of lycopene on 
inflammatory biomarkers encourage further studies with a larger population to investigate 
the effects of carotenoid consumption. In addition, influences of other components present 
in tomato, such as vitamin C, polyphenols or other micronutrients, which could act in a 
synergistic/antagonistic way in regulating the activity of these molecules, could also be 
studied. This dietary intervention was conducted with only healthy male participants, and so 
there would be room for further research with lycopene supplementation and effects on high 
CVD risk groups as well as patients with CVD and diabetes. 
7.5 Conclusion  
In conclusion, this study has proven that the consumption of Piccolo and Oranjstar for four 
weeks has a significant impact on reducing adhesion molecules, such as sICAM-1 and 
sVCAM-1, and therefore lowers the risk of developing cardiovascular disease in healthy 
males. 
7.6 Research Questions Raised from The Chapter 5  
Regarding the result of Chapter 5, tomato supplementation significantly improved BP and 
FMD but showed less beneficial effects on other non-invasive methods assessing vascular 
function. Microvascular vasodilation and arterial stiffness assessing vascular function are 
still novel markers for estimating the risks of developing CVD. Both techniques are 
increasingly being adopted as clinical measures of vascular function but the evidence on the 
impact of food interventions on vascular function are scattered and has not been 
systematically reviewed nor meta-analysed. This raised the following questions: 
1. What is the evidence for nutritional interventions enhancing microvascular 
vasodilation and arterial stiffness? 
This question will be addressed in the Chapter 8 where the evidence from the literature on 
the effectiveness and impact of nutritional intervention on microvascular vasodilation and 
arterial stiffness will be evaluated. 
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Chapter 8 The Effects of Food Interventions on Measures of Arterial Stiffness and 
Microvascular Vasodilation: Systematic Review and Meta-Analysis 
This study was designed to answer the research questions in section 7.6.  
8.1 Introduction 
The tomato clinical trial in Chapter 5 showed that although FMD and SBP improved after 
tomato supplementation, but other vascular function, such as microvascular vasodilation and 
arterial stiffness, showed no effect. Given the fact that the systematic searches of the 
literature identified no interventional studies evaluating the effects of tomato or lycopene on 
these outcomes, the work presented in this chapter intended to identify dietary and nutritional 
interventions affecting arterial stiffness and microvascular blood flow.  
Recent research studies showed clear benefits of specific foods and dietary patterns in 
improving cardiovascular function. There is evidence that supplementation with inorganic 
nitrates, or foods rich in inorganic nitrate can increase NO and improve risk factors such as 
BP and endothelial dysfunction (Siervo et al., 2013). Reduction in NO production is thus a 
proposed mechanism of endothelial dysfunction and a contributor to atherosclerosis. NO 
prevents oxidative modification of low-density lipoprotein (LDL) cholesterol; this oxidation 
process is proposed as a major mechanism of the atherosclerotic process (Rubbo et al., 2002; 
Steinberg and Witztum, 2002). Increased blood LDL can be linked to a high fat diet and 
through this, a link between diet and vascular function can be made.  
Traditionally, FMD has been the golden method to evaluate vascular function (Greyling et 
al., 2016; Ras et al., 2013). A recent systematic review of 8 interventional studies (involving 
652 participants) has shown that nut consumption significant improved FMD (Mean 
different 0.79% (95% CI 0.35 to 1.23)) (Neale et al., 2017). Each 1% increase of FMD 
significantly reduces the risk of CVD events (Inaba et al., 2010). In comparison, Neale et al. 
2017 study found an effect estimate of 0.79% for nut consumption compared with controls 
suggesting these results are likely to be of clinical relevance in predicting future CVD risk 
(Neale et al., 2017). The assessments for microvascular vasodilation and arterial stiffness are 
non-invasive methods to measure vascular function that have been developed in the past two 
decades. Both techniques are increasingly being adopted as clinical measures of vascular 
function. However, the evidence of the impact of dietary and nutritional interventions on 
these methods has not been systematically reviewed nor meta-analysed. Systematic reviews 
allow us to establish the effectiveness of interventions, which is done by thoroughly 
reviewing primary research for a focussed question. In this particular case, previous 
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nutritional interventions and their impact on arterial stiffness and microvascular vasodilation 
as assessed through reviewing their methodological quality and execution (Pearson et al., 
2005). Along with this, performing meta-analysis allows us to combine the results from 
many interventions, thus determines whether there is significant correlation between the 
testing methods in nutritional interventions. This helps to clarify the position of these 
methods in the effect of nutritional interventions on vascular function. It is important to 
systematically review primary articles in this field, as there is uncertainty and a lack of clarity 
in the effectiveness of PWV, PWA and LDI as testing methods. Here, a systematic review 
and meta-analysis will be reported on the current literature surrounding effects of on 
nutritional interventions vascular function assessed by PWV, PWA and LDI. 
8.2 Methods 
This systematic review was undertaken following standard guidance by the Cochrane 
collaboration (Higgins and Green, 2011) and the Centre for Reviews and Dissemination 
(Centre for Reviews and Dissemination, 2009). This review is reported according to the 
PRISMA guidelines (Figure 8.1 and Appendix E1) (Moher et al., 2010). The protocol of 
this systematic review has been previously registered with PROSPERO, the International 
Prospective Register of Systematic Reviews (Registration number CRD42016042092). 
In March 2019, three databases including PubMed, Medline, and Web of Science were 
searched from inception. In addition, reference lists of identified publications were screened 
in an attempt to identify further relevant studies. The searches included the following 
terms/keywords related to the exposures and outcomes of interest: 1) “PWV”; 2) “Pulse 
Wave Velocity”; 3) “PWA”; 4) “Pulse Wave Analysis”; 5) “Augmentation Index”; 6) 
“Arterial Stiffness”; 7) “Microvascular blood flow”; 8) “ LDI”; 9) “ Laser Doppler Imaging”; 
10) “ Endothelial Function”; 11) “Vascular Function”; 12) “Microcirculation”; 13) 
“Iontophoresis”; 14) “Nutrition”; 15) “Diet”; 16) “Potassium”; 17) “Trial”. The terms related 
to outcome measures of vascular function, based on nutritional interventions. Data for each 
of these outcomes was extracted if explicitly reported in the original papers. The present 
systematic review was restricted to articles published in English. Two authors (AOR, HMC) 
screened articles independently for eligibility. The decision to include/ exclude studies was 
hierarchical and consisted on screening firstly the titles and abstracts of studies; if the authors 
were unable to reach decision at this stage, then the full-text of the article was evaluated. 
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8.2.2 Inclusion/Exclusion Criteria 
The following specific inclusion criteria were used to identify eligible articles: 1) Study 
Design: Intervention Studies; 2) Subjects: Adult subjects >18 years of age; 3) Interventions: 
Nutritional/dietary interventions; 4) Outcomes: Vascular function. Exclusion criteria 
included: 1) Study design: Non-intervention studies; 2) Subjects: Subjects <18 years of age; 
3) Interventions: Non-Nutritional dietary interventions; 4) Outcomes: Non-vascular 
function.  
8.2.3 Data extraction 
A standardised, pre-piloted form was used to extract data from the included studies for 
assessment of study quality and evidence synthesis. Extracted information included: Study 
design (country, method of recruitment, follow-up length); participants (population and 
sample size, health status, mean age, body mass index and ethnicity); measurement 
description (PWV (m/s), augmentation index (%), LDI (PU)); outcome measure (vascular 
function); features of intervention (controlled conditions, study methodology, completion 
rates, outcomes and times of measurement). 
8.2.4 Outcome measures and exposures 
The primary outcome of interest was changes in arterial stiffness and microvascular blood 
flow with varying dietary compounds believed to be linked to improved vascular function. 
This included a high nitrate diet, fish oil and flavones.  
8.2.5 Statistical analysis 
Meta-analysis of results was undertaken using the Review Manager (RevMan Version 5.1 
for Windows Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 
2011). Random effects models, accounting for inter-study variation and minimizing 
potential bias due to methodological differences between studies, were used. For outcomes 
measured with the same technique and same units (pulse wave velocity, m/s), results were 
expressed as mean difference between groups with 95% confidence intervals and with two-
sided P-values. For comparisons where dissimilar units (LDI and augmentation index (AIx, 
%)) were reported, results were expressed as standardized mean difference (SMD). In 
addition, we undertook subgroup analysis to explore the impact of intervention type.  
A random effects model accounting for inter-study variation was used. Multiple dietary 
intervention arms from three studies were included in the meta-analysis. Following previous 
guidance (Higgins and Green, 2011), excessive weightings from “double counts” arising 
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from the “shared” group (in this case, the control group) were controlled by splitting the 
sample size of the shared group into approximately equal smaller groups for the 
comparisons. In this analysis, reviewers sought to extract and analyse adjusted results from 
multivariate models, if reported in the studies.  
Statistical heterogeneity was evaluated using the I2 statistic (Centre for Reviews and 
Dissemination, 2009; Higgins and Green, 2011), with I2 values greater than 50% 
representing high levels of heterogeneity. Publication bias was assessed by inspecting the 
funnel plot , and supplemented with calculations of the Egger’s regression test (Egger et al., 
1997). Quality of studies was assessed using the Jadad system (Jadad et al., 1996). 
8.3 Results 
A total of 1774 publications after de-duplication and results of the screening process are 
described in Figure 8.1. One hundred and thirteen publications met our inclusion criteria 
were included in the present systematic reviews (Table 8.1) and 93 of those publications 
were included in the meta-analysis.  
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Figure 8.1 PRISMA flow diagram of selection of studies on food intervention and vascular 
function.  
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Table 8.1 Characteristics of studies included in systematic review.  
Ref (Country 
of origin) 
Study 
design 
Age±SD Sex 
(%male) 
BMI±SD Healthy status Sample size Period Intervention type Dose Control/ 
comparator 
Outcome 
Ahuja et al., 
2007 (Australia) 
RCT, 
Cross-
over 
46±12 100% 26.4±4.8 Healthy N= 14 4 wk Chilli blend 30 g/d Without chilli 
blend 
AIx_HR75 
0% N= 20 
Al-Solaiman et 
al., 2010 (USA) 
RCT, 
Cross-
over 
40.3±1.7 
(SEM) 
20% 34.5±1.2 
(SEM) 
Obese/ HTN N= 15 3 wk Usual diet, with 
average of one 
fruit and one 
vegetable 
supplemented with 
potassium, 
magnesium and 
fibre 
Potassium 4100 
mg/d, magnesium 
500 mg/d, fibre-31 
mg/d  
Usual diet, 
with average of 
one fruit and 
one vegetable  
AIx 
DASH 2 Fruit/Veg/d - 
Dash 
36.7±1.8 
(SEM) 
22.8±0.4 
(SEM) 
Healthy N= 15 Usual diet, with 
average of one 
fruit and one 
vegetable 
supplemented with 
potassium, 
magnesium and 
fibre 
Potassium 4100 
mg/d, magnesium 
500 mg/d, fibre-31 
mg/d  
DASH 2 Fruit/Veg/d - 
Dash 
Al-Solaiman et 
al., 2009 (USA) 
RCT, 
Cross-
over 
44.1±1.4 
(SEM) 
22% 26.5±1.6 
(SEM) 
Healthy, salt 
sensitive 
N= 9 3 wk DASH 3000 mg Na/d Usual low 
fruits and 
vegetables diet 
AIx 
Low sodium-
DASH 
1500 mg Na/d 
34.3±2.5 
(SEM) 
30% 30.1±2.7 
(SEM) 
Healthy, salt 
resistant 
N= 10 DASH 3000 mg Na/d 
Low sodium-
DASH 
1500 mg Na/d 
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Armah et al., 
2008 (UK) 
RCT, 
Cross-
over 
46±4 100% 25.5±0.8 Healthy N= 25 4 hr Fish oil meal 31 g of mixed fat 
and 9 g of fish oil 
Placebo oil LDI in ACh 
LDI in SNP 
Babar et al., 
2018 (Canada) 
RCT, 
Parallel 
Intervention= 
28.7±3.76 
Control= 
28.5±3.46 
0% Intervention= 
23.57±4.46 
Control= 
23.55±3.89 
Healthy 
pregnant 
Intervention= 
66 
Control= 65 
12 wk High flavanol 
chocolate 
171 mg of 
flavanols 
Low flavanol 
chocolate 
AIx 
AIx_HR75 
Berry et al., 
2008 (UK) 
RCT, 
Cross-
over 
27.1±5.3 100% 24.3±3.0 Healthy N= 17 3 hr Shea butter blend 
rich in stearic acid 
meal 
50 g shea butter Oleic acid PAIx 
CAIx 
cf-PWV 
Blanch et al., 
2014 (Australia) 
RCT, 
Cross-
over 
31±11 26% 21.7±3.0 Healthy N= 35 6 d High potassium 
diet 
5690 mg/d Usual 
potassium 
AIx 
cf-PWV 
Blumenthal et 
al., 2010 (USA) 
RCT, 
Parallel 
Intervention= 
51.8±10 
Control= 
51.8±9 
33% Intervention= 
32.8±3.4 
Control= 
33±3.9 
HTN Intervention= 
46 
Control= 49 
16 wk DASH / Usual diet cf-PWV 
Bondonno et al., 
2014 (Australia) 
RCT, 
Cross-
over 
60±7.0 32% 27.1±3.8 Healthy N= 38 1 wk High-nitrate diet 
by consuming 
spinach and other 
green leafy 
vegetable 
400 mg/d of 
nitrate  
Low nitrate 
diet 
AIx_HR75 
cf-PWV 
Breslavsky et 
al., 2013 (Israel)  
RCT, 
Parallel 
Intervention= 
66.8±9.2 
Control= 
65.8±9.7 
Interventio
n= 46% 
Control= 
48% 
Intervention= 
27.9±5.2 
Control= 
30.5±5.1 
T2D Intervention= 
24 
Control= 23 
12 m Oral daily 
supplementation 
with 
cholecalciferol 
1000 u/d Placebo 
capsules 
AIx 
Bressendorff et 
al., 2016 
(Denmark) 
RCT, 
Parallel 
Intervention= 
41±9.05 
Control= 
44.5±8.5 
58% Intervention= 
24.7±3.8 
Control= 
25.1±4.3 
Healthy Intervention= 
22 
Control= 18 
16 wk Vitamin D 
precursors 
(Cholecalciferol) 
3000 IU/d Placebo AIx_HR75 
cf-PWV 
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Chen et al., 
2015a (USA) 
RCT, 
Cross-
over 
61.8±8.6 40% 30.2±5.1 CAD N= 45 6 wk Almonds 85 g/d No Nuts cf-PWV 
cr-PWV 
Chong et al., 
2010 (UK) 
RCT, 
Cross-
over 
48±18 48% 24.7±3.2 Healthy N= 25 4 hr Milkshake with 
EPA and DHA oil 
2 g EPA and 2.7g 
DHA 
Milkshake 
with Palm oil 
AIx_HR75 
Chuengsamarn 
et al., 2014 
(Thailand) 
RCT, 
Parallel 
Intervention= 
59.16±1.067 
(SEM) 
Control= 
59.58±1.04 
(SEM) 
45% Intervention= 
27.09±0.52 
(SEM) 
Control= 
26.84±0.42 
(SEM) 
T2D Intervention= 
107 
Control= 106 
6 m Curcuminoid 
capsule 
250 mg/d Placebo 
capsules 
ba-PWV 
(Right) 
  
ba-PWV 
(Left) 
Coombes et al., 
2016 (Australia) 
RCT, 
Parallel 
Intervention= 
49.1±11.2 
Control= 
50.9±13.4 
74% Intervention= 
26.2±4.1 
Control= 
27.7±7.6 
Renal transplant 
patients 
Intervention= 
33 
Control= 28 
12 m Astaxanthin 
capsules 
12 mg/d Placebo 
capsules 
AIx 
AIx_HR75 
cf-PWV 
Curtis et al., 
2013 (UK) 
RCT, 
Parallel 
Intervention= 
62.1±0.7 
(SEM) 
Control= 
63±0.8 (SEM) 
0% Intervention= 
32.7±1.1 
(SEM) 
Control= 
31.9±0.9 
(SEM) 
T2D Intervention= 
47 
Control= 46 
12 m 27 g flavonoid-
enriched 
chocolate/d 
90 mg epicatechin 
(850 mg total 
flavan-3-ols) and 
100 mg isoflavone 
Placebo 
chocolate 
AIx_HR75 
cf-PWV 
Dalan et al., 
2016 
(Singapore) 
RCT, 
Parallel 
Intervention= 
52.2±8.2 
Control= 
54.8±10.8 
Interventio
n= 14% 
Control= 
19% 
Intervention= 
27.3±5.8 
Control= 
28.9±6 
T2D Intervention= 
33 
Control= 31 
16 wk Cholecalciferol Cholecalciferol 
2000-4000 IU 
daily depending 
om baseline 
25(OH)D and 
response 
Placebo AIx_HR75 
Dickinson et al., 
2014a 
(Australia) 
RCT, 
Cross-
over 
18-70 44% N/A Healthy N= 16 2 hr Low sodium soup 5 mmol Na/d High sodium 
soup (65mmol 
Na /d) 
AIx 
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Dickinson et al., 
2014b 
(Australia) 
RCT, 
Cross-
over 
N/A 32% 27-40 Overweight N= 25 6 wk Salt reduction diet 6 g Na/d Usual salt diet 
(9 g/d) 
AIx 
cf-PWV 
Din et al., 2011 
(UK) 
RCT, 
Cross-
over 
23±3 100% 24.5±2.3 Healthy N= 30 4 wk Walnut 15 g/d Normal diet AIx 
Dower et al., 
2016 
(Netherlands) 
RCT, 
Cross-
over 
61.8±9.3 100% 25.1±2.1 Healthy N= 20 2 hr Dark chocolate 150 mg 
epicatechin /d 
75g white 
chocolate 
AIx_HR75 
Epicatechin 
capsules 
100 mg 
epicatechin /d 
Dreyer et al., 
2014 (UK) 
RCT, 
Parallel 
Intervention= 
45.8±10 
Control= 
48.8±12.2 
Interventio
n= 14% 
Control= 
14% 
Intervention= 
30.4±7.1 
Control= 
29.2±3.4 
CKD Intervention= 
20 
Control= 18 
6 m Ergocalciferol 5000 IU weekly 
for 1 m and then 
monthly for 5 m 
Placebo cf-PWV 
Duthie et al., 
2018 (UK) 
RCT, 
Parallel 
Intervention= 
48.3±5.6 
Control= 
48.5±4.8 
42% Intervention= 
26.6±3.9 
Control= 
26.0±3.4 
Healthy Intervention= 
21 
Control= 24 
12 wk Additional 480 g 
of fruit and 
vegetables and 
fruit juice (300 
mL) daily 
 
Usual diet PWV 
Esser et al., 
2013 
(Netherlands) 
RCT, 
Cross-
over 
61.8±5.9 100% 23.8±0.8 Lean N= 18 4 hr Milkshake rich in 
MUFA 
95 g/d Milkshake rich 
in SFA 
AIx 
Milkshake rich in 
PUFA 
62.6±3.2 32.4±3.0 Obese N= 11 Milkshake rich in 
MUFA 
Milkshake rich in 
PUFA 
Fahs et al., 2009 
(USA) 
RCT, 
Cross-
over 
24.2±0.7 
(SEM) 
100% 27±1.2 (SEM) Healthy N= 17 1 hr L-Arginine capsule 7 g/d Placebo 
capsule 
AIx 
AIx_HR75 
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Feresin et al., 
2017 (USA) 
RCT, 
Parallel 
Intervention= 
59±1 (SEM) 
Control= 58±1 
(SEM) 
0.0% Intervention= 
32.7±1.1 
(SEM) 
Control= 
32.1±0.7 
(SEM) 
Healthy Intervention= 
20 
Control= 20 
8 wk Freeze-dried 
strawberry powder 
50 g Placebo 
powder 
ba-PWV 
Intervention= 
61±1 (SEM) 
Control= 58±1 
(SEM) 
Intervention= 
31.0±1.0 
(SEM) 
Control= 
32.1±0.7 
(SEM) 
Intervention= 
20 
Control= 20 
25 g 
Figueroa et al., 
2011 (USA) 
RCT, 
Cross-
over 
54±3 (SEM) 44% 28.4±0.9 
(SEM) 
Healthy N= 9 6 wk Watermelon 
powder 
4 g L-Citrulline/L-
Arginine /d 
Placebo AIx 
AIx_HR75 
cf-PWV 
Figueroa et al., 
2012 (USA) 
RCT, 
Cross-
over 
58±1 (SEM) 21% 37.3±1.8 
(SEM) 
HTN N= 14 6 wk Watermelon 
extract 
6 g L-Citrulline/L-
Arginine /d 
Placebo CAIx 
Figueroa et al., 
2014 (USA) 
RCT, 
Cross-
over 
57.4±1.4 
(SEM) 
23% 36.8±2.1 
(SEM) 
HTN, Obese N= 13 6 wk Watermelon 
powder 
6 g L-Citrulline/L-
Arginine /d 
Placebo AIx 
AIx_HR75 
Forouhi et al., 
2016 (UK) 
RCT, 
Parallel 
Intervention= 
52.5±8.2 
Control= 
52.4±8.5 
Interventio
n= 51% 
Control= 
58% 
Intervention= 
29±5.5 
Control= 
28.3±5 
elevated risk of 
T2D 
Intervention= 
114 
Control= 114 
16 wk Vigantol oil Cholecalciferol 
20000 IU/ m 
Miglyol oil cf-PWV 
Intervention= 
52.5±8.2 
Control= 
52.4±8.5 
Interventio
n= 50% 
Control= 
58% 
Intervention= 
28.9±5.5 
Control= 
28.3±5 
Intervention= 
112 
Control= 114 
Sterogyl Ergocalciferol 
20000 IU/ m 
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Fulton et al., 
2016 (UK) 
RCT, 
Parallel  
76±4.4 53% N/A Diabetes/ HTN Intervention= 
38 
Control= 39 
6 m Vitamin K2 
capsule 
500 mg/d Placebo 
capsule 
cf-PWV 
AIx 
Garg et al., 
2015 (India) 
RCT, 
Parallel 
Intervention= 
22±4.61 
Control= 
22.8±4.56 
0% Intervention= 
26.8±4.56 
Control= 
26.7±6.11 
PCOS Intervention= 
15 
Control= 17 
6 m 1.5 g Metformin 
and vitamin D 
4000 IU/d 1.5 g 
Metformin and 
placebo 
AIx_75HR 
cf-PWV 
George et al., 
2012a (UK) 
RCT, 
Cross-
over 
45±10 38% 24.4±3.2 Healthy N= 39 6 wk Fruit and vegetable 
puree based drink 
2 x 100 mL/d 2x100 mL/d 
fruit-flavoured 
cordial 
LDI in ACh 
LDI in SNP 
George et al., 
2013 (UK) 
RCT, 
Cross-
over 
M= 46±11 
F= 49±4 
84% M= 25.6±3.2 
F= 24±2.6 
Healthy N= 24 6 hr Fruit and vegetable 
puree based drink 
400 mL 400 mL fruit-
flavoured 
cordial 
LDI in ACh 
Gepner et al., 
2012 (USA) 
RCT, 
Parallel  
64.1±3.0 0% 27.1±4.7 Healthy Intervention= 
38 
Control= 37 
16 wk Cookies rich in 
vitamin D 
2500 IU vitamin 
D3/d 
Placebo 
cookies 
cf-PWV 
AIx 
Gijsbers et al., 
2015 
(Netherlands) 
RCT, 
Cross-
over 
M= 66±9.3 
F= 65.4±8.2 
66% M= 27.3±4.8 
F= 27.0±4.6 
Pre-HTN M= 24 
F= 12 
4 wk Placebo capsule Cellulose Sodium 
capsule 
(371mg of 
Na/d) 
AIx 
cf-PWV 
Potassium capsule 353 mg/d Placebo 
capsule 
AIx 
cf-PWV 
Hazim et al., 
2016 (UK) 
RCT, 
Cross-
over 
62±2 (SEM) 100% 25±1 (SEM) Healthy-Non 
EP 
N= 14 1 d Isoflavone 
Supplement 
80 mg/d Placebo AIx 
57±1 (SEM) 26±1 (SEM) Healthy-Equol 
Producer (EP) 
62±2 (SEM) 25±1 (SEM) Healthy-Non 
EP 
cf-PWV 
57±1 (SEM) 26±1 (SEM) Healthy-Equol 
Producer (EP) 
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He et al., 2010 
(UK) 
RCT, 
Cross-
over 
51±10 71% 29.7±4.8 HTN N= 42 4 wk 10 Potassium 
chloride capsules 
6.4 mmol 
potassium per 
capsule/d 
Placebo 
capsule 
cf-PWV 
10 Potassium 
bicarbonate 
capsules 
He et al., 2009 
(UK) 
RCT, 
Cross-
over 
52±12 79% 28±5 HTN N= 71 6 wk Sodium matching 
capsule 
90 mmol Slow sodium 
capsule 
cf-PWV 
50±9 49% 31±5 N= 69 
47±10 79% 27±5 N= 29 
Hewitt et al., 
2013 (Australia) 
RCT, 
Parallel 
Intervention= 
60 
Control= 67 
Interventio
n= 53% 
Control= 
43% 
Intervention= 
26.6±6.4 
Control= 
31.3±9.5 
Haemodialysis Intervention= 
30 
Control= 30 
6 m Cholecalciferol 50000 IU/ wk Placebo PWV 
Hin et al., 2017 
(UK) 
RCT, 
Parallel 
Intervention= 
71±6 
Control= 72±6 
Interventio
n= 51% 
Control= 
51% 
Intervention= 
27±5 
Control= 28±5 
Healthy Intervention= 
193 
Control= 95 
12 m Cholecalciferol  4000 IU/d or 2000 
IU/d 
Placebo AIx 
cf-PWV 
Hobbs et al., 
2013b (UK) 
RCT, 
Cross-
over 
31±2 (SEM) 100% 23.3±0.5 
(SEM) 
Healthy N= 24 6 hr Beetroot bread 1.1 mmol nitrate/d White bread AIx 
AIx_HR75 
cf-PWV 
LDI in SNP 
LDI in ACh 
Hollands et al., 
2018a (UK) 
RCT, 
Cross-
over 
52.2±13.6 50.0% 29±5.1 Healthy 
overweight 
N= 41 4 wk Anthocyanin-rich 
blood orange juice 
500 mL (50 mg 
anthocyanins) 
blonde orange 
juice (without 
anthocyanins 
cf-PWV 
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Hollands et al., 
2018b (UK) 
RCT, 
Cross-
over 
63±7 35.7% 25.9±3.1 Healthy N= 42 4 wk Apple flavanol 
extract 
70 mg monomeric 
flavanols, 65 mg 
PCs 
Placebo 
capsules 
AIx_HR75 
cf-PWV 
Apple flavanol 
extract 
140 mg 
monomeric 
flavanols, 130 mg 
PCs 
AIx_HR75 
cf-PWV 
Apple PC extract 130 mg PCs, 6.5 
mg monomeric 
flavanols 
AIx_HR75 
cf-PWV 
Hu et al., 2009 
(China) 
RCT, 
Parallel 
59±10 46% 27±3.9 Vascular 
disease/ T2D 
Intervention= 
93 
Control= 94 
12 m Salt substitute 65% sodium 
chloride, 25% 
potassium chloride 
and 10% 
magnesium sulfate 
Normal salt AIx 
Jablonski et al., 
2013(USA) 
RCT, 
Cross-
over 
60±2 (SEM) 73% 81.8±5.4 
(SEM) 
HTN N= 11 5 wk Low sodium intake 2.5 g/d Normal diet cf-PWV 
Jauhiainen et 
al., 2010 
(Finland) 
RCT, 
Parallel 
49±5 60% 27.6±3.6 HTN Intervention= 
45 
Control= 44 
12 wk 200 mL 
lactobacillus 
helveticus 
fermented milk 
Ile-Pro-Pro 5.8 
mg/ 100 mL and 
Val-Pro-Pro 6.6 
mg/ 100 mL 
Placebo milk 
drink 
AIx 
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Jennings et al., 
2019 (European 
Multi-Centre) 
RCT, 
Parallel 
Intervention= 
70.7±14 
Control= 
71±3.9 
Interventio
n= 55.7% 
Control= 
53.1% 
Intervention= 
70.7±14 
Control= 
71±3.9 
Healthy Intervention= 
114 
Control= 116 
12 m Mediterranean-
Style Diet 
 
Usual diet AIx_HR75 
Intervention= 
115 
Control= 122 
cf-PWV 
Jin et al., 2011 
(UK) 
RCT, 
Cross-
over 
M= 44±5.2 
(SEM) 
F= 45±5.2 
(SEM) 
45% M= 24±0.83 
(SEM) 
F= 23±0.91 
(SEM) 
Healthy M= 9 
F= 11 
2 hr Blackcurrant Juice 250 mL/d Placebo Juice LDI in ACh 
LDI in SNP 
Johnson et al., 
2015 (UK) 
RCT, 
Parallel 
Intervention= 
59.7±4.58 
Control= 
57.3±4.76 
0% Intervention= 
30.1±5.94 
Control= 
32.7±6.79 
HTN Intervention= 
20 
Control= 20 
8 wk Freeze-dried 
blueberry powder 
22 g/d (Phenolics 
845 mg, 
Anthocyanins 470 
mg) 
Control 
powder 
cf-PWV 
ba-PWV 
Joris et al., 2016 
(Netherlands) 
RCT, 
Parallel 
Intervention= 
62±5 
Control= 62±6 
37% 29.6±2.8 Overweight Intervention= 
26 
Control= 25 
6 m Magnesium 
capsules 
350 mg/d Placebo 
capsules 
AIx_HR75 
cf-PWV 
Jovanovski et 
al., 2014 
(Canada) 
RCT, 
Cross-
over 
25±2 39% 22±0.6 Healthy N= 23 3 hr Ginsenoside Rg3-
Korean red 
ginseng extract 
400 mg/d Wheat bran 
control 
AIx_HR75 
Jovanovski et 
al., 2015 
(Canada) 
RCT, 
Cross-
over 
24.5±11 41% 22.8±3.7 Healthy N= 27 2 wk Spinach 845 mg Nitrate /d Asparagus AIx_HR75 
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Jovanovski et 
al., 2010 
(Canada) 
RCT, 
Cross-
over 
30±9 59% 25±3 Healthy N= 17 3 hr Korean red 
ginseng rootlet 
extract 
3 g of dried 
Korean red 
ginseng  
3 g of 
cornstarch 
control 
AIx 
Ginsenoside 
extract 
1.22 g of 
ginsenoside 
extract delivering 
105 mg total 
saponin-equivalent 
to the total 
ginsenosides from 
3 g of KRG 
rootlets 
Polysaccharide 
extract 
0.21 g of 
polysaccharide 
extract delivering 
172 mg of 
polysaccharide 
equivalent 
to the 
polysaccharide 
content of 3 g of 
KRG rootlets 
Karatzi et al., 
2013 (Greece) 
RCT, 
Cross-
over 
28.5±5.2 100% 24.4±2.5 Healthy N= 17 2 hr Beer 20 g alcohol Dealcohol beer AIx 
Vodka 
Beer cf-PWV 
Vodka 
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Karatzi et al., 
2005 (Greece) 
RCT, 
Cross-
over 
52.4±9.7 100% 28.3±1.8 Mix N= 15 1.5 hr Red wine 250 mL Dealcohol red 
wine 
AIx 
AIx_HR75 
Kasliwal et al., 
2015 (India) 
RCT, 
Parallel 
Intervention= 
40.4±8.2 
Control= 
37.7±7.6 
74% Intervention= 
27.8±4.7 
Control= 
26.1±2.9 
Dyslipidaemia Intervention= 
21  
Control= 21 
12 wk Pistachio 80 g No nuts ba-PWV 
cf-PWV 
Keane et al., 
2016 (UK) 
RCT, 
Cross-
over 
31±9 100% 27.0±3.8 Early HTN N= 15 8 hr Montmorency tart 
cherry 
60 mL Placebo AIx 
cf-PWV 
LDI in ACh 
LDI in SNP  
Keheyan et al., 
2011 (UK) 
RCT, 
Cross-
over 
22±5 100% 22±3.2 T2D/ CVD/ 
Thrombosis 
N= 14 6 hr 6 Ginkgo biloba 
extract capsules 
Each capsule 
contains 60 mg 
GBE 
Placebo 
capsules 
AIx 
Kendall et al., 
2014 (Canada) 
RCT, 
Cross-
over 
54±8 40% 37.5±7.9 Metabolic 
Syndrome 
N= 20 3 hr Pistachio 3 oz/d White bread AIx 
Kouguchi et al., 
2013 (Japan) 
RCT, 
Parallel 
Intervention= 
54.3±9.2 
Control= 
51.2±7.8 
52% Intervention= 
24.6±2.9 
Control= 
24.8±3 
HTN Intervention= 
29 
Control= 29 
12 wk 120 mL lactic acid 
drink 
Contain 2.9 g 
Chicken collagen 
hydrolysate 
120 mL lactic 
acid drink 
ba-PWV 
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Krantz et al., 
2015 (USA) 
RCT, 
Parallel 
60.2±10.8 37% 31.5±7.1 CVD Risk Intervention= 
27  
Control= 35 
12 wk 4 Omega 3 fatty 
acids capsules 
Each capsule 
contains 465 mg 
of EPA and 375 
mg of DHA 
Placebo 
capsules 
ba-PWV 
Kristensen et 
al., 2016 
(Denmark) 
RCT, 
Parallel 
Intervention= 
53.2±11.4 
Control= 
50.7±11.5 
60% Intervention= 
28.6±5.7. 
Control= 
28.0±5 
Patients 
psoriatic 
arthritis 
Intervention= 
58 
Control= 56 
6 m 6 omega 3 fatty 
acids capsules 
3 g of n-3 PUFA 
(50% EPA and 
50% DHA) 
Olive oil 
capsules 
AIx 
cr-PWV 
Kumar et al., 
2017 (Australia) 
RCT, 
Parallel 
Intervention= 
43.2±11.8 
Control= 
45.2±11.6 
Interventio
n= 67.8% 
Control= 
70.7% 
Intervention= 
23.6±2.7 
Control= 
23.5±2.9 
CKD Intervention= 
59 
Control= 58 
16 wk Cholecalciferol 300000 IU single 
dose 
Placebo cf-PWV 
Larijani et al., 
2013 (USA) 
RCT, 
Parallel 
Intervention= 
54±5 
Control= 55±6 
100% Intervention= 
29±4 
Control= 28±3 
Healthy Intervention= 
32 
Control= 33 
12 m 4 Ageing garlic 
extract capsules 
4 capsules contain 
300 mg/AGE and  
30 mg/CoQ10 
Placebo 
capsules 
cr-PWV 
Larsen et al., 
2012 
(Denmark) 
RCT, 
Parallel 
Intervention= 
60±12 
Control= 61±9 
Interventio
n= 32% 
Control= 
30% 
Intervention= 
27.7±4.2 
Control= 
28.3±3.7 
HTN Intervention= 
55 
Control= 57 
6 m Cholecalciferol 3000 IU (75 µg)/d Placebo AIx 
cf-PWV 
Levin et al., 
2017 (Canada)  
RCT, 
Parallel 
Intervention= 
65.9±15.3 
Control= 
64.5±12.2 
Interventio
n= 70% 
Control= 
73% 
Intervention= 
29±5 
Control= 
28.8±5.3 
CKD Intervention= 
29 
Control= 30 
6 m Calcifediol 5000 IU thrice 
weekly 
Placebo AIx 
PWV 
Intervention= 
66.9±11.7 
Control= 
64.5±12.2 
Interventio
n= 72% 
Control= 
73% 
Intervention= 
29.7±5.9 
Control= 
28.8±5.3 
Intervention= 
28 
Control= 30 
Calcitriol 0.5 µg thrice 
weekly 
AIx 
cf-PWV 
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comparator 
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Lithander et al., 
2013 (Ireland)  
RCT, 
Cross-
over 
38.7±14.4 100% 24.1±2.3 Healthy N= 20 4 hr Monounsaturated 
fat meal  
MUFA meal and 
SFA meal  
SFA Meal AIx 
cf-PWV 
Liu et al., 2013 
(Australia)  
RCT, 
Cross-
over 
58.8±7.6 23% 25.4±3.3 Healthy N= 26 3.5 hr Nitrate rich meal 
(spinach) 
High nitrate 220 
mg twice/d 
Low nitrate AIx 
cf-PWV 
Lucey et al., 
2018 (UK)  
RCT, 
Cross-
over 
56.9±5.2 56.9% 28.3±3.5 Healthy N= 65 6 wk Powdered egg 
ovalbumin-derived 
protein hydrolysate 
3 g/d Maltodextrin 
powder 
AIx_HR75 
cf-PWV 
Lundwall et al., 
2015 (Sweden) 
RCT, 
Parallel 
Intervention= 
70.8±10 
Control= 
59.1±11.6 
Interventio
n= 67% 
Control= 
75% 
Intervention= 
28.1±2.4 
Control= 
26.8±2.8 
CKD Intervention= 
12 
Control= 12 
12 wk Paricalcitol 2 µg/d Placebo AIx 
PWV 
Intervention= 
66.1±7.9 
Control= 
59.1±11.6 
Interventio
n= 92% 
Control= 
75% 
Intervention= 
26.4±3.5 
Control= 
26.8±2.8 
Intervention= 
12 
Control= 12 
1 µg/d LDI in ACh 
LDI in SNP 
Lynn et al., 
2012 (UK)  
RCT, 
Parallel  
Intervention= 
39.0±1.24 
Control= 
36.1±0.92 
33% Intervention= 
24.99±1.26 
Control= 
24.99±1.06 
Healthy Intervention= 
24 
Control= 24 
4 wk Pomegranate juice 
drink  
330 mL/d  Placebo bf-PWV 
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BMI±SD Healthy status Sample size Period Intervention type Dose Control/ 
comparator 
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Macready et al., 
2014 (UK)   
RCT, 
Parallel 
Intervention= 
52±1 (SEM) 
Control= 53±1 
(SEM) 
0% Intervention= 
28.2±0.6 
(SEM) 
Control= 
27±0.6 (SEM) 
Healthy Intervention= 
22 
Control= 21 
6 wk High flavonoid 
Diet  
>15 mg/100 g 
flavonoid food 
Habitual diet AIx_HR75 
cf-PWV 
Intervention= 
47±1 (SEM) 
Control= 50±2 
(SEM) 
100% Intervention= 
26.8±0.6 
(SEM) 
Control= 
27.9±0.6 
(SEM) 
Intervention= 
36 
Control= 36 
AIx_HR75 
cf-PWV 
Intervention= 
52±2 (SEM) 
Control= 53±1 
(SEM) 
0% Intervention 
(LF, F)= 
28.4±0.5 
(SEM) 
Control (F)= 
27±0.6 (SEM) 
Intervention= 
25 
Control= 21 
Low flavonoid 
Diet  
>5 mg/100 g of 
total flavonoids 
AIx_HR75 
cf-PWV 
Intervention= 
49±1 (SEM) 
Control= 50±2 
(SEM) 
100% Intervention= 
27.5±0.5 
(SEM) 
Control= 
27.9±0.6 
(SEM) 
Intervention= 
34 
Control= 36 
AIx_HR75 
cf-PWV 
Marckmann et 
al., 2012 
(Danmark)  
RCT, 
Parallel 
Intervention= 
71 
Control= 68 
Interventio
n= 73% 
Control= 
77% 
Intervention= 
25.9 
Control= 24.6 
CKD Intervention= 
13 
Control= 17 
8 wk Cholecalciferol 40000 UI/wk Placebo AIx_HR75 
Intervention= 
14 
Control= 17 
cf-PWV 
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comparator 
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Marques et al., 
2018 (Brazil) 
RCT, 
Cross-
over 
54±1SEM 42% 30±2 HTN 24 1.5 hr Trans-resveratrol 
capsule 
300 mg Placebo AIx 
AIx_HR75 
Martins et al., 
2014 (USA)  
RCT, 
Parallel 
18-60 Interventio
n= 63.1% 
Control= 
58.5% 
25-30 HTN Intervention= 
60 
Control= 55 
12 wk Vitamin D 100000 IU/m Placebo AIx 
McAnulty et al., 
2014 (USA)  
RCT, 
Parallel  
Intervention= 
46.15±11.92 
Control= 
24.23±3.44 
N/A Intervention= 
27.8±5.46 
Control= 
24.23±7.79 
Healthy 
(sedentary) 
Intervention= 
13 
Control= 12 
6 wk Whole blueberry 
powder 
38 g/d of 
dehydrated 
blueberry powder 
Placebo  AIx 
cf-PWV 
McGreevy et 
al., 2015 
(Ireland)  
RCT, 
Parallel  
Intervention= 
79.3±7 
Control= 
80.5±6.6 
Interventio
n= 55% 
Control= 
51% 
Intervention= 
26.6±6.4 
Control= 
26.9±9.5 
Vitamin D 
insufficient 
patients 
Intervention= 
51 
Control= 51 
8 wk Vitamin D 
(Cholecalciferol) 
supplementation 
100,000 IU 
Vitamin D/d 
50,000 IU 
Vitamin D /d 
AIX 
cf-PWV 
Mose et al., 
2014 
(Denmark)  
RCT, 
Parallel 
Intervention= 
68±9 
Control= 
67±13 
Interventio
n= 60% 
Control= 
68% 
Intervention= 
24±4.5 
Control= 
23.8±4.4 
Haemodialysis Intervention= 
25 
Control= 25 
6 m Cholecalciferol 3000 IU (75 µg)/d Placebo AIx 
cf-PWV 
Mucalo et al., 
2013 (USA)  
RCT, 
Parallel 
Intervention= 
62.1±8.8 
Control= 
63.910.93 
Interventio
n= 54% 
Control= 
50% 
Intervention= 
33.4±5.6 
Control= 
29.9±4.95 
T2DM, HTN Intervention= 
30 
Control= 34 
6 wk American ginseng 
extract capsules 
6 capsules /d Placebo 
capsules 
AIx 
Mullan et al., 
2016 (UK)  
RCT, 
Parallel 
Intervention= 
60.3±4.60 
Control= 
62.21±4.26 
Interventio
n= 50% 
Control= 
53% 
Intervention= 
33.08±6.68 
Control= 
31.49±4.38 
Overweight Intervention= 
20 
Control= 19 
4 wk 250 mL Beverage 
rich in polyphenol 
361 mg of 
(poly)phenols and 
120 mg of vitamin 
C 
Placebo drink cf-PWV 
AIx 
Mullan et al., 
2004 (UK)  
RCT, 
Cross-
over 
25.2±4.1 100% 24.4±2.8 Healthy N= 12 2 hr Hyperglycaemia 
meal, with Vitamin 
C 
2 g Vitamin C Hyperglycaemi
a meal, without 
ascorbic acid 
AIx_HR75 
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Mullan et al., 
2002 (UK)  
RCT, 
Parallel  
Intervention= 
61±6.5 
Control= 
57.9±6.6 
Interventio
n= 80% 
Control= 
67% 
Intervention= 
28.6±4.4 
Control= 28.6 
4.2 
T2DM Intervention= 
15 
Control= 15 
4 wk Vitamin C 500 mg/d Placebo AIx_HR72 
Muth et al., 
2017 (USA)  
RCT, 
Cross-
over 
27±1 (SEM) 61.2% 23.6±0.4 
(SEM) 
Healthy N= 49 1 wk Low Sodium 20 mmol/d High Sodium 
(300 mmol/d) 
AIx_HR75 
cf-PWV 
52±1 (SEM) 36% 25.1±0.5 
(SEM) 
N= 36 AIx_HR75 
cf-PWV 
Noad et al., 
2016 (UK)  
RCT, 
Parallel 
Intervention= 
54.0±6.7 
Control= 
55.6±6.8 
25% Intervention= 
31.6±6.5 
Control= 
29.8±5 
HTN Intervention= 
48 
Control= 47 
8 wk High Polyphenol 
diet 
6 portions of fruit 
and vegetables/d 
Low 
polyphenol 
diet 
LDI in ACh 
LDI in SNP 
Ochiai et al., 
2012 (Japan)  
RCT, 
Parallel 
Intervention= 
58.5±5.0 
Control= 
58±3.9 
100% Intervention= 
25.2±2.4 
Control= 
24.9±2.2 
Healthy Intervention= 
8 
Control= 7 
1 wk L-Citrulline L-Citrulline 5.6 
g/d 
Placebo ba-PWV 
Otsuki et al., 
2015 (Japan)  
RCT, 
Parallel 
Intervention= 
62.2±1.5 
(SEM) 
Control= 
63.1±2.3 
(SEM) 
40% Intervention= 
23.6±0.6 
(SEM) 
Control= 
22.8±0.8 
(SEM) 
Healthy Intervention= 
15 
Control= 17 
4 wk Chlorella-derived 
supplementation 
200 mg Chlorella Placebo ba-PWV 
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Pal and Ellis, 
2010 (Australia)  
RCT, 
Parallel 
Intervention= 
48.0±2.1 
(SEM) 
Control= 
48.4±1.5 
(SEM) 
N/A Intervention= 
31.3±0.9 
(SEM) 
Control= 
30.6±0.8 
(SEM) 
Healthy Intervention= 
20 
Control= 25 
12 wk Casein supplement Two sachets in 
250 mL of water - 
twice a day 
Glucose 
control 
AIx 
Intervention= 
48.5±2.0 
(SEM) 
Control= 
48.4±1.5 
(SEM) 
Intervention= 
32.0±0.8 
(SEM) 
Control= 
30.6±0.8 
(SEM) 
Intervention= 
25 
Control= 25 
Whey supplement Two sachets in 
250 mL of water - 
twice a day 
Pilz et al., 2015 
(Denmark)  
RCT, 
Parallel 
60.1±11.3 53.0% N/A HTN Intervention= 
100 
Control= 100 
8 wk Cholecalciferol 2800 IU/d Placebo PWV 
Pimenta et al., 
2009 (Australia)  
RCT, 
Cross-
over 
55.5±9.4  33% 32.9±6.3 Healthy N= 12 4 wk Low sodium intake Low Sodium (1 
wk)= 50 mmol 
High sodium 
(1 wk)= 250 
mmol 
AIx 
cf-PWV 
Plat et al., 2019 
(Netherlands)  
RCT, 
Cross-
over 
60±9 75% 28.7±2.7 T2D N= 41 3 d Egg protein 
hydrolysate 
10 capsules with 5 
g egg protein 
hydrolysate 
Placebo AIx_HR75 
cf-PWV 
Rathnayake et 
al., 2018 (UK)  
RCT, 
Cross-
over 
58±1 (SEM) 0% 25.9±0.7 
(SEM) 
Healthy N= 31 480 min High-fat meals at 
breakfast and 
lunch  
33-36 g MUFAs 33-36 g SFAs LDI in ACh 
33-36 g n-6 
PUFAs 
LDI in SNP 
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BMI±SD Healthy status Sample size Period Intervention type Dose Control/ 
comparator 
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Richter et al., 
2017a (USA)  
RCT, 
Cross-
over 
51.6±6.6 
(SEM) 
45% 26.4±0.9 
(SEM) 
Healthy N= 20 6 wk Soya protein 25 g/d Placebo AIx_HR75 
cf-PWV 
50 g/d AIx_HR75 
cf-PWV 
Richter et al., 
2017b (USA)  
RCT, 
Cross-
over 
28±2 (SEM) 56.7% 31.5±0.5 
(SEM) 
Healthy and 
Overweight 
N= 30 4hr Freeze-dried 
strawberry powder 
to a high-fat (50 g 
total fat) meal 
40 g macro- and 
micronutrient-
matched 
control meal 
AIx_HR75 
cf-PWV 
Ried et al., 2018 
(Australia)  
RCT, 
Parallel 
Intervention= 
28.6±7.7 
Control= 
29.7±6.2 
45% 24.6±2.6 HTN Intervention= 
23 
Control= 26 
12 wk Kyolic-aged-
garlic-extract 
2 capsules/d (1.2 g 
of the vaso-active 
S-allylcysteine 
(SAC)) 
Placebo 
capsules 
cf-PWV 
Ruel et al., 2013 
(Canada)  
RCT, 
Cross-
over 
45±10 100% 28.3±2.4 Healthy - 
Overweight 
N= 35 4 wk 500 mL Cranberry 
juice cocktail 
Contained 400 mg 
total polyphenols, 
20.8 mg 
anthocyanins, and 
21.84 g 
carbohydrates 
500 mL 
Placebo juice 
AIx 
Ryu et al., 2014 
(Korea)  
RCT, 
Parallel 
Intervention= 
54.5±7.4 
Control= 
56.7±7.9 
N/A Intervention= 
24.4±5 
Control= 
25.3±3.4 
T2D Intervention= 
32 
Control= 30 
6 m Cholecalciferol 2000 IU/d Placebo AIx_HR75 
ba-PWV 
Saban-Ruiz et 
al., 2017 
(Spain)  
RCT, 
Parallel 
Intervention= 
39.9±8.5 
Control= 
40.5±8.9 
23.2% Intervention= 
23.6±3.2 
Control= 
23.8±2.9 
Healthy Intervention= 
48 
Control= 51 
6 wk Ad libitum diet 
with Iberian cured 
ham 
50 g Libitum diet AIx_HR75 
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Sanders et al., 
2013 (UK)  
RCT, 
Parallel 
Intervention= 
51±9.2 
Control= 
51±7.9 
Interventio
n= 37% 
Control= 
40% 
Intervention= 
27.7±3.8 
Control= 
28.5±4.3 
Healthy - At 
risk of 
metabolic 
syndrome 
Intervention= 
38 
Control= 30 
4 wk Low saturated fat 
and high 
carbohydrate 
SFA:MUFA:PUF
A= 21:52:24 
SFA rich diet  
SFA:MUFA:P
UFA= 
50:26:24 
AIx 
cf-PWV 
Intervention= 
51±10.2 
Control= 
51±7.9 
Interventio
n= 32% 
Control= 
40% 
Intervention= 
28.5±4.5 
Control= 
28.5±4.3 
Intervention= 
44 
Control= 30 
Low saturated fat 
and high MUFA 
SFA:MUFA:PUF
A= 18:60:23 
AIx 
cf-PWV 
Smolders et al., 
2018 
(Netherlands)  
RCT, 
Cross-
over 
45-70 63.6% 25-35 Healthy 
overweight 
N= 44 4 wk Theobromine 500 mg Placebo AIx_HR75 
cf-PWV 
Stricker et al., 
2012 
(Switzerland)  
RCT, 
Parallel 
Intervention= 
72.9±8.7 
Control= 
74.8±14.6 
Interventio
n= 61% 
Control= 
61% 
N/A PAD Intervention= 
31 
Control= 31 
4 wk Cholecalciferol 10000 IU single 
dose 
Placebo AIx 
Todd et al., 
2010 (USA)  
RCT, 
Cross-
over 
51.8±7.6 38% 25.7±5.2 HTN N= 34 4 wk Tomato Juice 500 mL of tomato 
(90 mmol Na) 
Tomato juice 
with 0 mmol 
Na 
AIx 
500 mL of tomato 
(140 mmol Na) 
500 mL of tomato 
(90 mmol Na) 
cf-PWV 
500 mL of tomato 
(140 mmol Na) 
Tripkovic et al., 
2015 (UK)  
RCT, 
Cross-
over 
39.8±9 100% 30.2±3 Overweight N= 10 4 wk Inulin 15 g/d Refined grain 
(15g/d) 
cf-PWV 
cr-PWV 
Wheat fibre 15 g/d cf-PWV 
cr-PWV 
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Turner et al., 
2005 
(Denmark)   
RCT, 
Parallel 
Intervention= 
49.6±5.5 
Control= 
50.9±4.6 
39% Intervention= 
24.2±3.9 
Control= 
24.7±2.8 
Healthy Intervention= 
30 
Control= 32 
12 wk Garlic powder 
tablets 
Garlic Powder 
Tablets= 920 mg/d 
Placebo 
capsules 
PWV 
Wang et al., 
2015 (China)   
Not 
RCT 
49±7.9 48% 23.6±2.9 Healthy - 
Smoking 
N= 48 1 wk Low salt meal  Low salt (1 wk)= 
3 g/d 
High salt (1 
wk)= 18g/d 
ba-PWV 
High salt meal 
with potassium 
supplementation  
High salt with 
potassium 
supplementation 
(1 Wk)= 18 g/d + 
4.5 g/d(NaCl) 
Weech et al., 
2018 (UK)  
RCT, 
Parallel 
Intervention= 
43±1 (SEM) 
Control= 45±1 
(SEM) 
43% Intervention= 
27±0.5 
Control= 
26.5±0.5 
Individual with 
moderate CVD 
risk 
Intervention= 
62 
Control= 64 
16 wk MUFA-rich diet 
 
SFAs rish diet AIx_HR75 
Intervention= 
45±1 (SEM) 
Control= 45±1 
(SEM) 
Intervention= 
27±0.5 
Control= 
26.5±0.5 
Intervention= 
66 
Control= 64 
n–6 PUFA-rich 
diet 
cf-PWV 
West et al., 
2014 (USA)  
RCT, 
Cross-
over 
51.7±1.2 
(SEM) 
51% 27.8±0.6 
(SEM) 
Healthy and 
Overweight 
N= 30 4 wk Chocolate bar and 
cocoa beverage 
Chocolate bar= 37 
g/d 
Low-flavanol 
chocolate bar 
and a cocoa-
free beverage 
mix with no 
added sugar 
AIx 
AIx_HR75 
Witham et al., 
2013a (UK)  
RCT, 
Parallel 
Intervention= 
39.4±11.8 
Control= 
41.7±13.4 
0% Intervention= 
28.7±5.5 
Control= 
24.9±3.3 
Healthy Intervention= 
25 
Control= 25 
8 wk Cholecalciferol 100000 IU single 
dose 
Placebo AIx_HR75 
cr-PWV 
LDI in ACh 
LDI in SNP 
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Witham et al., 
2013b (UK)  
RCT, 
Parallel 
Intervention= 
76.7±4.8 
Control= 
76.9±4.5 
Interventio
n= 50% 
Control= 
53% 
Intervention= 
27.9±4.5 
Control= 
28.5±3.5 
HTN Intervention= 
79 
Control= 80 
12 m Cholecalciferol 100000 IU/3m Placebo AIx_HR75 
cr-PWV 
Witham et al., 
2015 (UK)  
RCT, 
Parallel 
Intervention= 
48.1±12 
Control= 
50.7±13.1 
Interventio
n= 28% 
Control= 
20% 
Intervention= 
28.8±7.9 
Control= 
29.8±5.4 
Chronic fatigue 
syndrome 
Intervention= 
25 
Control= 25 
6 m Cholecalciferol 100000 IU/2m Placebo AIx_HR75 
cf-PWV 
Xing et al., 
2018 (China)  
Not 
RCT 
53.4±6.6 60% 25.1±3.4 Healthy  N= 99 7 wk Low sodium 51.3 mmol 
sodium/d 
High-sodium 
(307.8 mmol 
sodium/d) 
AIx_HR75 
High-sodium with 
potassium 
supplementation 
60.0 mmol 
potassium/d 
Yiu et al., 2013 
(HK)  
RCT, 
Parallel 
Intervention= 
65.8±7.3 
Control= 
64.9±8.9 
Interventio
n= 54% 
Control= 
46% 
Intervention= 
25.8±4.3 
Control= 
25.1±3.4 
T2D Intervention= 
50 
Control= 50 
12 wk Cholecalciferol 5000 IU/d Placebo ba-PWV 
Yui et al., 2017 
(Japan)  
RCT, 
Parallel 
Intervention= 
45±7.8 
Control= 
44.8±9.6 
50% N/A Healthy  Intervention= 
14 
Control= 14 
6 wk Lemon balm leaf 
extract 
 
Barley tea ba-PWV 
 
Ref, Reference; M, Male; F, Female; RCT, randomised controlled trial; hr, hour; d, day; wk, week; m, month; BMI, Body mass index; LDI, Laser Doppler 
Imaging; Ach, Acetylcholine; SNP, Sodium nitroprusside; AIx, Augmentation index; AIx@HR75, Augmentation index adjusted to a heart rate of 75 beats/min; 
PAIx, Peripheral augmentation index; CAIx, central augmentation index; PWV, Pulse wave velocity; cf, Carotid-femoral; cr, Carotid-radial; ba, brachial-ankle; 
HTN, Hypertension; CAD, Coronary artery disease; CKD, Chronic kidney disease; T2D, Type 2 diabetes; PCOS, Polycystic ovarian syndrome 
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8.3.1 Study characteristics 
Fifty-eight studies were RCT parallel design while fifty-three studies used a RCT cross-over 
design and two study used non-RCT design. These 113 studies originated from the UK (n= 
36), USA (n= 21), Australia (n= 12), Canada (n= 7), Denmark (n= 7), Netherlands (n= 6), 
Japan (n= 4), China (n= 3), Greece (n= 2), Ireland (n= 2), India (n= 2) and single study from 
Brazil, Finland, Spain, Sweden, Switzerland, European multi-centre, Israel, Hong Kong, 
Singapore, Thailand, and Korea. These studies included a range of acute and chronic studies 
(1 day to 1 year), mean age of the samples studied ranged from 22 to 80 years, and BMI 
from 21 to 37 kg/m2, with mixed health status. Eleven studies evaluated the impact of LDI 
after intervention. Sixty-nine studies evaluated the impact of PWA after intervention. Sixty-
one studies evaluated the impact of PWV after intervention. Thirty-eight studies evaluated 
the impact of both PWA and PWV after intervention.  
8.3.2 Microvascular vasodilation with LDI measurement 
Ten studies assessed the effect of nutritional intervention on microvascular vasodilation 
using LDI techniques (Table 8.2) (Armah et al., 2008; Dreyer et al., 2014; George et al., 
2012a; George et al., 2013; Hobbs et al., 2013b; Jin et al., 2011; Keane et al., 2016; Noad et 
al., 2016; Rathnayake et al., 2018; Witham et al., 2013a). The meta-analysis of 9 studies 
with 467 participants evaluated the effect of nutritional intervention on endothelium 
dependent microcirculation vasodilation (ACh) (Armah et al., 2008; Dreyer et al., 2014; 
George et al., 2012a; George et al., 2013; Hobbs et al., 2013b; Keane et al., 2016; Noad et 
al., 2016; Rathnayake et al., 2018; Witham et al., 2013a). Overall, nutritional intervention 
did not change endothelium dependent microcirculation vasodilation (0.30 (SMD); 95% CI 
-0.03 to 0.63; p=0.07; I2 =66%) (Figure 8.2). Subgroup analysis according to 
supplementation of polyphenols (George et al., 2012a; George et al., 2013; Keane et al., 
2016; Noad et al., 2016), fatty acid (Armah et al., 2008; Rathnayake et al., 2018), 
nitrate/nitrite (Hobbs et al., 2013b) and vitamin D (Dreyer et al., 2014; Witham et al., 2013a) 
was undertaken. Supplementation of polyphenols, fatty acid, nitrate/nitrite and vitamin D 
showed no differences on endothelium dependent microcirculation vasodilation (ACh) 
(Figure 8.2). 
The meta-analysis of 6 studies with 331 participants evaluated the effect of nutritional 
intervention on endothelium independent microcirculation vasodilation (SNP) (Armah et al., 
2008; George et al., 2012a; Hobbs et al., 2013b; Keane et al., 2016; Noad et al., 2016; 
Rathnayake et al., 2018). Overall, nutritional intervention did not change endothelium 
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independent microcirculation vasodilation (0.02 (SMD); 95% CI -0.32 to 0.37; p=0.89; I2 
=60%) (Figure 8.3). Subgroup analysis according to supplementation of polyphenols 
(George et al., 2012a; Keane et al., 2016; Noad et al., 2016), fatty acid (Armah et al., 2008; 
Rathnayake et al., 2018), nitrate/nitrite (Hobbs et al., 2013b) and vitamin D (Dreyer et al., 
2014) was undertaken. Supplementation of polyphenols, fatty acid, and nitrate/nitrite 
showed no differences on endothelium independent microcirculation vasodilation (SNP) 
(Figure 8.3).  
In addition, one study assessing consumption of blackcurrant juice (Jin et al., 2011) was not 
included in the meta-analysis because the study did not provide the raw data. It showed no 
effect on endothelium dependant or independent microcirculation after consumption of 
blackcurrant juice (Jin et al., 2011). 
 
Figure 8.2 Meta-analysis of effect of food interventions on endothelium dependant 
microcirculation (LDI-ACh). 
 
 
 
  Chapter 8 
 191 
Table 8.2 Effects of nutritional intervention on endothelial dependant and independent vasodilation.  
NS: Non-significant change; N/A: Not available; AU: Arbitrary units; PU: Perfusion units.  
Study Duration Type of 
intervention 
Active 
component 
Effect on LDI-ACh (SEM) Effect on LDI-SNP (SEM) 
Armah et 
al., 2008 
Acute  
(4 hours) 
Fish oil n-3 PUFAs NS (Intervention 125 PU±20 vs Placebo 
100±18) 
NS (*Intervention 140 PU±20 vs Placebo 115 ±18) 
*Compare to baseline (p=0.024) 
Dreyer et 
al., 2014 
Chronic  
(6 month) 
Vitamin D Ergocalciferol ^Intervention 1100%±375 (SD) vs Placebo 
540.6%±125 (SD))  
^Compare to placebo (p=0.012)  
NS (Intervention 445.7%±187.5 (SD)vs Placebo 
585.9%±85(SD))  
George et 
al., 2012a 
Chronic 
(6 weeks) 
Fruit and 
vegetable puree 
Polyphenol NS (Intervention 275%±75 vs Placebo 80% 
±50) 
NS (Intervention 250%± 75 vs Placebo 50%± 50) 
George et 
al., 2013 
Acute  
(6 hours) 
Fruit and 
vegetable puree 
Polyphenol NS (Intervention 120% ±80 vs Placebo 0% 
±40) 
N/A 
Hobbs et al., 
2013b 
Acute  
(4 hours) 
Beetroot bread Nitrate NS (Intervention 401 PU±489 vs White 
bread 852±488) 
†Intervention 2270 PU±600 vs White bread 661±639  
†Compare to white bread (p=0.018) 
Jin et al., 
2011 
Acute  
(2 hours) 
Blackcurrant 
juice 
Polyphenol NS NS 
Keane et al., 
2016 
Acute  
(8 hours) 
Montmorency 
tart cherry 
Polyphenol NS (Intervention 1231 PU±157 vs Placebo 
1180±133) 
NS (Intervention 1424 PU±178 vs Placebo 1690±187) 
Noad et al., 
2016 
Chronic 
(4 weeks) 
High 
polyphenol diet 
Polyphenol NS (‡Intervention 107.7% ±84.7 (SD) vs 
Low polyphenol diet 123.9%±99.6 (SD))  
‡Compare to baseline (p=0.02) 
NS (Intervention 107.7%±70.1 (SD) vs Low 
polyphenol diet 126.3%±120.4 (SD)) 
Rathnayake 
et al., 2018 
Acute  
(4 hours) 
PUFA-rich 
meals 
n-6 PUFAs NS (Intervention 778 AU±48 vs SFAs 
736±41) 
NS (Intervention 721 AU±55 vs SFAs 745±45) 
MUFA-rich 
meals 
MUFAs NS (Intervention 776 AU±65 vs SFAs 
736±41) 
NS (Intervention 813 AU±63 vs SFAs 745±45) 
Witham et 
al., 2013a 
Chronic 
(8 weeks) 
Vitamin D Cholecalciferol NS (Intervention 3.3±2.2 vs Placebo 2.7±1.5 
Ratio) 
N/A 
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Figure 8.3 Meta-analysis of effect of food interventions on endothelium independent 
microcirculation (LDI-SNP). 
8.3.3 Meta-analysis of studies evaluated the effect of nutritional intervention on 
arterial stiffness by PWA measurement 
Sixty-six studies, including 4850 participants, evaluated the effect of nutritional intervention 
on arterial stiffness by PWA. Overall, nutritional intervention significantly reduced PWA by 
0.16 (95% CI -0.23 to -0.09; p<0.0001). Heterogeneity levels assessed by the I2 test were 
low at 24% (Figure 8.4).  
Subgroup analysis according to food type intervention was undertaken. Studies were 
separated according to change of diet style and supplementation of polyphenols, fatty acid, 
salt (extra salt, low sodium and high potassium intake), nitrate/nitrite, vitamin, alcohol, 
watermelon/L-citrulline, Ginseng and protein (Table 8.3).  
Two studies, including 342 participants, evaluated the effect of changing of diet style on 
arterial stiffness by PWA (Jennings et al., 2019; Sanders et al., 2013). Changing of diet style 
significantly reduced PWA by 0.54 (95% CI -0.77 to -0.32; p<0.0001). Heterogeneity levels 
assessed by the I2 test were low at 0% (Table 8.3). 
Four studies, including 184 participants, evaluated the effect of supplementing Ginseng on 
arterial stiffness by PWA (Jovanovski et al., 2014; Jovanovski et al., 2010; Keheyan et al., 
2011; Mucalo et al., 2013). Supplementing Ginseng significantly reduced PWA by 0.59 
(95% CI -0.90 to -0.29; p<0.0001). Heterogeneity levels assessed by the I2 test were low at 
0% (Table 8.3). 
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Figure 8.4 Meta-analysis of effect of nutritional intervention on arterial stiffness by PWA 
measurement.  
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Table 8.3 Subgroup analysis of nutritional intervention on arterial stiffness by PWA measurement. 
Subgroup Standard Mean Difference 
(SMD) IV, Random (95%CI) 
P 
(Z-test) 
Heterogeneity 
I2% 
Change of diet style  
(2 studies, n=342)  
-0.54 (-0.77, -0.32) <0.0001 0 
Ginseng  
(4 studies, n=184)  
-0.59 (-0.90, -0.29) <0.0001 0 
Vitamin C  
(2 studies, n=54)  
-1.05 (-1.78, -0.31) 0.005 36 
Vitamin D  
(13 studies, n=1149)  
-0.13 (-0.28, 0.02) 0.09 34 
Alcohol  
(2 studies, n=81)  
-0.42 (-0.88, 0.03) 0.07 0 
Nitrate/ Nitrite  
(4 studies, n=230)  
-0.12 (-0.56, 0.32) 0.60 64 
Protein  
(4 studies, n=371)  
-0.06 (-0.37, 0.25) 0.69 50 
Watermelon/ L-Citrulline  
(4 studies, n=106) 
-0.25 (-0.64, 0.13) 0.20 0 
 
Two studies, including 54 participants, evaluated the effect of supplementing Vitamin C on 
arterial stiffness by PWA (Mullan et al., 2004; Mullan et al., 2002). Supplementing Vitamin 
C significantly reduced PWA by -1.05 (95% CI -(-1.78 to -0.31; p=0.005). Heterogeneity 
levels assessed by the I2 test were low at 36% (Table 8.3). 
Supplementation of Vitamin D, alcohol, Nitrate/Nitrite, protein, and watermelon/L-
Citrulline showed no differences between interventions and controls on PWA (Table 8.3). 
Four studies, including 291 participants, evaluated the effect of fatty acid on arterial stiffness 
by PWA (Chong et al., 2010; Esser et al., 2013; Kristensen et al., 2016; Lithander et al., 
2013). The subgroup analysis of polyunsaturated fatty acid (PUFA) showed no differences 
on PWA (-0.05; 95% CI -0.50 to 0.40; p=0.82; I2 =46%) (Chong et al., 2010; Esser et al., 
2013; Kristensen et al., 2016) (Figure 8.5). Monounsaturated fatty acid (MUFA) showed no 
effect on PWA (-0.19; 95% CI -0.66 to 0.29; p=0.44; I2 =19%) (Esser et al., 2013; Lithander 
et al., 2013) (Figure 8.5).  
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Figure 8.5 Meta-analysis of effect of fatty acid on arterial stiffness by PWA measurement. 
 
Twelve studies, including 976 participants, evaluated the effect of polyphenol on arterial 
stiffness by PWA (Babar et al., 2018; Curtis et al., 2013; Dower et al., 2016; Hazim et al., 
2016; Hollands et al., 2018b; Keane et al., 2016; Macready et al., 2014; Marques et al., 2018; 
McAnulty et al., 2014; Richter et al., 2017a; Ruel et al., 2013; West et al., 2014). Overall, 
the supplementation of polyphenol showed no differences between interventions and 
controls on PWA (-0.54; 95% CI -1.53 to 0.44; p=0.28; I2 =0%) (Figure 8.6).  
 
Figure 8.6 Meta-analysis of effect of polyphenol on arterial stiffness by PWA measurement.  
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Three studies, including 339 participants, showed no effect on PWA after low sodium (Na) 
intake (-0.11; 95% CI -0.32 to 0.11; p=0.32; I2 =0%) (Dickinson et al., 2014b; Hu et al., 
2009; Todd et al., 2010) (Figure 8.7). Three studies, including 272 participants, showed no 
effect on PWA after high potassium (K) intake (-0.16; 95% CI -0.41 to 0.09; p=0.21; I2 =0%) 
(Blanch et al., 2014; Gijsbers et al., 2015; Xing et al., 2018) (Figure 8.7). 
 
Figure 8.7 Meta-analysis of effect of low Na intake and high K intake on arterial stiffness by PWA 
measurement. 
 
In addition, six studies, including 531 participants, evaluated the effect of extra Na intake on 
arterial stiffness by PWA (Dickinson et al., 2014a; Gijsbers et al., 2015; Muth et al., 2017; 
Pimenta et al., 2009; Todd et al., 2010; Xing et al., 2018). Extra Na intake (experimental 
group) significantly increased PWA by 0.22 (95% CI 0.04 to 0.39; p=0.02) (Figure 8.8). 
Heterogeneity levels assessed by the I2 test were low at 0%.  
 
Figure 8.8 Meta-analysis of effect of extra Na intake on arterial stiffness by PWA measurement.  
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8.3.4 Meta-analysis of studies evaluated the effect of nutritional intervention on 
arterial stiffness by PWV measurement 
Fifty-seven studies, including 5126 participants, evaluated the impact of PWV after 
intervention. Overall, nutritional intervention significantly reduced PWV by -0.26 m/s (95% 
CI -0.39 to -0.13; p<0.0001). Heterogeneity levels assessed by the I2 test were high at 53% 
(Figure 8.9).  
Subgroup analysis according to food type intervention was undertaken. Studies were 
separated according to change of diet style and supplementation of polyphenols, fatty acid, 
salt (extra salt, low sodium and high potassium intake), nitrate/nitrite, vitamin, nut, alcohol, 
watermelon/L-citrulline, aging garlic extract and protein (Table 8.4).  
Table 8.4 Subgroup analysis of nutritional intervention on arterial stiffness by PWV measurement. 
Subgroup Mean Difference 
IV, Random (95%CI) 
P 
(Z-test) 
Heterogeneity 
I2% 
Watermelon/ L-Citrulline  
(2 studies, n=33) 
-1.18 m/s (-1.89, -0.48) 0.001 0 
Alcohol  
(1 study, n=51)  
-0.30 m/s (-0.66, 0.06) 0.10 0 
Aging garlic extract  
(2 studies, n=114)  
-0.20 m/s (-0.92, 0.52) 0.58 0 
Nitrate/ Nitrite  
(3 studies, n=176)  
-0.02 m/s (-0.68, 0.64) 0.95 52 
Protein  
(3 studies, n=270)  
-0.21 m/s (-0.58, 0.17) 0.29 0 
Change of diet style  
(3 studies, n=444)  
-0.18 m/s (-0.51, 0.14) 0.26 40 
Nut  
(2 studies, n=122)  
-0.34 m/s (-1.09, 0.40) 0.37 52 
Vitamin D  
(14 studies, n=1645)  
-0.12 m/s (-0.40, 0.16) 0.41 57 
 
Two studies, including 33 participants, evaluated the effect of supplementing watermelon/ 
L-Citrulline on arterial stiffness by PWV (Figueroa et al., 2011; Ochiai et al., 2012). 
supplementing watermelon/ L-Citrulline significantly reduced PWV by 1.18 m/s (95% CI -
1.89 to -0.48; p=0.001) (Table 8.4). Heterogeneity levels assessed by the I2 test were low at 
0%. 
Supplementation of alcohol, aging garlic extract, nitrate/ nitrite, protein, change of diet style, 
nut and vitamin D showed no differences between interventions and controls on PWV 
(Table 8.4). 
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Figure 8.9 Meta-analysis of effect of nutritional intervention on arterial stiffness by PWV 
measurement.  
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Two studies, including 176 participants, evaluated the effect of polyunsaturated fatty acid 
(PUFA) (Karatzi et al., 2013; Kristensen et al., 2016). There was no change in PWV after 
consumption of PUFA (-0.65; 95% CI -2.21 to 0.92; p=0.42; I2 =72%) (Figure 8.10).  
 
Figure 8.10 Meta-analysis of effect of fatty acid on arterial stiffness by PWV measurement. 
 
Eleven studies, including 825 participants, evaluated the effect of polyphenol on arterial 
stiffness by PWV (Curtis et al., 2013; Duthie et al., 2018; Feresin et al., 2017; Hollands et 
al., 2018a; Hollands et al., 2018b; Johnson et al., 2015; Keane et al., 2016; Lynn et al., 2012; 
Macready et al., 2014; McAnulty et al., 2014; Richter et al., 2017a). Overall, the 
supplementation of polyphenol showed no differences between interventions and controls 
on PWV (-0.08 m/s; 95% CI -0.33 to -0.16; p=0.52; I2 =32%) (Figure 8.11).  
 
Figure 8.11 Meta-analysis of effect of polyphenol on arterial stiffness by PWV measurement.  
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Three studies, including 410 participants, evaluated the effect of low sodium (Na) intake on 
arterial stiffness by PWV (Dickinson et al., 2014b; He et al., 2009; Jablonski et al., 2013). 
The low Na intake showed a no effect on PWV reduction (-0.39 m/s; 95% CI -0.96 to 0.18; 
p=0.18) (Figure 8.12). Heterogeneity levels assessed by the I2 test were low at 43%.  
Three studies, including 410 participants, evaluated the effect of high potassium intake on 
arterial stiffness by PWV (Blanch et al., 2014; Gijsbers et al., 2015; He et al., 2010). The 
low Na intake showed a no effect on PWV reduction (-0.20 m/s; 95% CI -0.64 to 0.25; 
p=0.38) (Figure 8.12). Heterogeneity levels assessed by the I2 test were low at 17%. 
 
Figure 8.12 Meta-analysis of effect of low Na intake and high P intake on arterial stiffness by 
PWV measurement. 
 
In addition, four studies, including 350 participants, evaluated the effect of extra Na intake 
on arterial stiffness by PWV (Gijsbers et al., 2015; Muth et al., 2017; Pimenta et al., 2009; 
Todd et al., 2010). Extra Na intake (experimental group) had no effect on PWV (0.20 m/s; 
95% CI -0.12 to 0.53; p=0.22) (Figure 8.13). Heterogeneity levels assessed by the I2 test 
were low at 0%. 
 
Figure 8.13 Meta-analysis of effect of extra Na intake on arterial stiffness by PWV measurement.  
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8.4 Discussion 
8.4.1 Principal findings 
This systematic review and meta-analysis evaluated that nutrition intervention significantly 
improved arterial stiffness, PWA by 0.16 (SMD) and PWV by 0.26 m/s (MD), among adult 
subjects >18 years of age. Intervention type was determined to be a significant influencing 
factor. Extra Na intake was significantly increase PWA. Dietary supplement showed 
significant reduction in arterial stiffness. PWA was significantly reduced after changes of 
diet and supplementation of Ginseng and Vitamin C while PWV was significantly reduced 
after supplementation of watermelon/L-Citrulline. Nineteen of the studies included in the 
present review measured flow-mediated dilation (FMD) concurrently with PWV and/or 
PWA (Berry et al., 2008; Blanch et al., 2014; Blumenthal et al., 2010; Chen et al., 2015a; 
Curtis et al., 2013; Dickinson et al., 2014b; Dower et al., 2016; Fulton et al., 2016; Gepner 
et al., 2012; Karatzi et al., 2013; Kasliwal et al., 2015; Marques et al., 2018; Rathnayake et 
al., 2018; Smolders et al., 2018; West et al., 2014; Witham et al., 2013a; Witham et al., 2015; 
Witham et al., 2013b; Yiu et al., 2013). Eight of them showed significant improvement in 
FMD after the nutritional intervention but not in PWV or PWA (Berry et al., 2008; Blanch 
et al., 2014; Blumenthal et al., 2010; Dickinson et al., 2014b; Karatzi et al., 2013; Kasliwal 
et al., 2015; Marques et al., 2018; Smolders et al., 2018). Four chronic studies showed 
supplementation of vitamin D were no improvement in FMD, as well as PWV and/or PWA 
(Witham et al., 2013a; Witham et al., 2015; Witham et al., 2013b; Yiu et al., 2013). Another 
study on pistachio supplementation (3 months) showed significant improvement in FMD 
and PWV (Kasliwal et al., 2015). Only one study on acute intake of alcohol showed 
significant improvement in FMD, PWV and PWA (Karatzi et al., 2013). Concurrent 
improvements in indices of arterial stiffness, PWV and PWA measuring different aspects of 
vascular function, were not always observed.  
We reviewed microvascular vasodilation with the use of LDI, which measured the response 
to cutaneous perfusion of the forearm with acetylcholine and SNP. The meta-analysis of 
microvascular vasodilation with the use of LDI showed nutrition intervention did not change 
the response to cutaneous perfusion of the forearm with ACh and SNP. Majority 
interventions were investigating polyphenol supplementation and showed no effect on 
microvascular vasodilation. A potential explanation to the lack of effect of polyphenols 
studies could be the fact that the response of polyphenol on microcirculation vasodilation 
has been associated with certain genotypes such as the Glu298Asp (George et al., 2012b). 
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George et al., 2012b showed that acute consumption of a flavonoid-rich drink increased 
dilation of the microcirculation in the forearm in response to acetylcholine after 180 min in 
homozygous for guanine (GG) genotype individuals had no effect on endothelium-
dependent vasodilation or endothelium-independent vasodilation in the heterozygous for 
guanine (GT) genotype individuals (George et al., 2012b).  
The high heterogeneity level (I2>50%) in LDI-ACh, LDI-SNP, PWA (protein and 
nitrate/nitrite) and PWV (all and PUFA) showed that there is inconsistency and high 
variation across the studies. Sensitivity analysis showed that two studies using vitamin D 
(Dreyer et al., 2014) and curcuminoid (Chuengsamarn et al., 2014) supplementation 
contributed to the heterogeneity. The SMD of LDI-ACh and LDI-SNP were 0.11 (95% CI -
0.09 to 0.30; p=0.92; I2=0%) and 0.13 (95% CI -0.16 to 0.42; p=0.37; I2=38%) respectively 
after excluding the vitamin D study (Dreyer et al., 2014). This analysis also showed that food 
interventions still had no effect on both LDI-ACh and LDI-SNP with low heterogeneity 
level. The MD of overall PWV was 0.23 m/s (95% CI -0.34 to -0.11; p=0.0002; I2=40%) 
after excluding the curcuminoid study (Chuengsamarn et al., 2014). It showed that the food 
intervention still significantly reduced PWV with low heterogeneity level.  
8.4.2 Scientific analysis of findings and implications for health 
A focus on the health impact of dietary patterns on cardiovascular risk factors has been a 
growing area of research in recent decades (Mozaffarian et al., 2011). There was significant 
research showing that major dietary patterns, such as the Mediterranean diet, can decrease 
mortality rates and improve cardiovascular health (Knoops et al., 2004). Growing evidence 
now shows that the impact of dietary patterns was the result of the accumulative effects of 
different food groups (Trichopoulou et al., 2009). 
Globally, CVD is one of the leading causes of death. Evidences from this systematic review 
with meta-analysis showed that vascular function was affected by various aspects of the diet. 
Results from this study suggested that vascular function can be improved by dietary changes 
and a cardioprotective diet can reverse or limit previous damage, perhaps caused from 
previous poor diet. It is noteworthy that statistical analysis showed that the nutrition 
interventions significantly improved arterial stiffness, PWA by 0.16 (SMD) and PWV by 
0.26 m/s (MD), however such low improvements may not have significant clinical relevance. 
According to previous studies each 1 m/s increase in PWV was associated with a 15% higher 
CVD risk (Verbeke et al., 2011) and each 10% increase in AIx was 1.48 for CV mortality 
(95% CI 1.16 to 1.90, p<0.0001) (London et al., 2001). 
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Organic compounds such as polyphenols and concentrated extracts showed the greatest 
improvements on arterial stiffness, PWV and PWA, while fish oil supplements and fruit and 
vegetables were both borderline significant in improving vascular function. Together these 
results gain traction and improve significance, following previous research, especially in 
relation to the recent research of the cardiovascular benefits of fish oils and omega-3 fatty 
acids (Kris-Etherton et al., 2002). It is notable that the significant improvements to vascular 
function were observed in studies originating from North America and Europe, whereas 
those from Asia and Oceania reported non-significant improvements to vascular function.  
8.4.3 Strengths and Limitations 
To our knowledge, this is the first systematic review and meta-analysis of nutritional 
interventions on vascular function determined by microvascular vasodilation and arterial 
stiffness. The strengths of this study include the consistency of findings across the studies 
and the results reported seem valid and robust due to the low levels of heterogeneity 
surrounding the findings in this study. The validity of these results is further strengthened 
by a comprehensive search of literature across multiple major scientific databases using pre-
specified criteria.  
There are limitations that merit consideration. There are very few amino acids and alcohol 
studies present, while they showed significant changes, reliability was limited due to a small 
sample of studies. Many of the studies were conducted on older participants, and this widely 
omitted the knowledge on how vascular function is affected in youths. The studies had 
overall small sample sizes, with a narrow range of ethnicities. Larger and longer-term studies 
could give more concrete evidence for the effects of different dietary interventions on EF. 
8.5 Conclusion 
Evidence from the papers analysed showed significant effects of nutritional intervention on 
endothelial dysfunction. PWV and PWA can be accurately and reliably reproduced as 
methods assessing the selected vascular function markers of these studies. Such results are 
however of low clinical value. The systematic review revealed there are a limited number of 
studies for LDI testing methods, and they do show signs of improvement from nutritional 
intervention. More research is needed to identify interventions that are effective in improving 
these outcomes. Future studies are needed to identify the key connections between nutrition 
intervention and endothelial dysfunction to allow intervention study to be designed and 
promulgated.
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Chapter 9 General Discussion 
9.1 Thesis Summary 
Dietary factors are well recognised contributors to common diseases, including heart disease, 
stroke, type 2 diabetes and cancer. Therefore, our food choices are directly affecting our 
health. Conventional dietary guidelines use a “one size fits all” approach to achieve dietary 
change to improve health (Kiefte-de Jong et al., 2014). However, each individual in 
population has different genotype and different lifestyle which play an essential role in 
modulating the likelihood of develop of disease. Therefore, the use of dietary patterns and 
personalised dietary recommendations are becoming more effective in promotion of health 
(Celis-Morales et al., 2017). Among different dietary patterns, Mediterranean diet, which is 
characterised by high intake of vegetables, fruits, grain, fish and olive oil, has received the 
most attention in relation to chronic disease prevalence (Celis-Morales et al., 2017). Specific 
fruits and vegetables found in Mediterranean diet are individually associated with significant 
reductions of CVD. Tomato is one of the main ingredients in the Mediterranean diet that 
plays a key role in reducing the prevalence of CVD. High intake of tomato and lycopene 
have shown improvements in cardiovascular health.  
The main aim of this thesis was to investigate the effect of tomato supplementation on 
cardiovascular health and to evaluate the effects of the two varieties of tomato on vascular 
health. This thesis followed a series of logical steps presented on separated chapters and 
summarised in Figure 9.1. Furthermore, the research questions posed in this thesis are 
summarised in Table 9.1. 
Phase one of the present PhD programme involved an overview of the topic. In phase two, 
the literature on the association between tomato and cardiovascular health was explored 
(Figure 9.1). The first aim of this thesis was to evaluate the evidence from previous 
epidemiological studies on the association of the consumption of lycopene and tomatoes and 
other CVD and mortality. Systematic review and meta-analysis in Chapter 2 showed that 
high tomato/lycopene intake significantly reduced the risk of stroke and CVD by 26% and 
14% respectively (Table 9.1). The second aim of this thesis was to evaluate the evidence 
from previous RCT on the effects of tomato/lycopene supplementation on cardiovascular 
risk factors. Systematic review and meta-analysis in Chapter 3 showed that tomato 
supplementation was associated with significant reductions in LDL-cholesterol and 
improvements in FMD while, lycopene supplementation was associated with significant 
reductions in SBP (Table 9.1). It showed that the consumption of tomato has important 
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public health implications towards the prevalence of CVD. These results showed that dietary 
habits are one of the important modifiable factors that can affect the maintenance of a healthy 
phenotype. Chapter 3 also indicated that other markers of vascular function have not been 
fully investigated and there are no RCT investigating the effects of other varieties of tomato 
apart from red tomato. The results from both systematic reviews can be incorporated into the 
future development of personalised nutrition.  
 
Figure 9.1 Overview of this PhD programme 
 
Phase one Preliminary work  
Systematic reviews of epidemiological evidence on 
tomato and risk of cardiovascular diseases  
Systematic reviews of interventional evidence on 
tomato and cardiovascular risk factor 
Phase two 
Inform intervention 
development 
Defining outcome 
measures Phase three 
  
RCT Testing outcome 
Phase four 
Systematic reviews of interventional evidence on 
arterial stiffness and microvascular vasodilation 
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Vegetables are now available in a variety of colours. Cauliflower heads, commonly white in 
colour, can now be found in shades of purple, yellow, and green, and bags of potatoes are 
popping up in yellow, red, and purple varieties. Some dietary guidelines suggested eating 
different colours of the same vegetable, as they were believed to have different nutritional 
value. However, whether they have different nutritional benefits and have the same 
beneficial effect as the original variety remain unknown. Chapter 3 indicated that previous 
RCT investigated the effects of red tomato on cardiovascular health only. Therefore, it is 
worth to evaluate whether other varieties exert the same effect. Therefore, it could be of 
value to investigate if other colours exert the same effect and this could be an area for 
potential research.  
Phase three of the present PhD programme was the development of dietary intervention on 
comparing the two different tomato varieties (Figure 9.1). In Chapter 3, it showed that 
previous interventions on tomato-based or lycopene supplementation were mainly long-term 
(4-8 weeks) and lycopene doses were mainly 15-30 mg/d. The systematic reviews of the 
scientific literature also identified clinical outcome measures relevant to cardiovascular risk. 
In adherence to previous literature, the selection criteria for the measures included 
biomarkers that responded to dietary interventions (Cheng et al., 2017), particularly to 
tomato-based or lycopene supplementation. We thus selected a tentative panel of biomarkers 
of cardiovascular risk to be tested in our study. Chapter 5 detailed the protocol for dietary 
intervention to examine the effects of Piccolo and Oranjstar on BP, vascular function and 
blood-borne biomarkers. 
In phase four of the present PhD programme, an RCT was conducted to evaluate the effect 
of two varieties of tomato, Piccolo and Oranjstar on vascular health (Figure 9.1). The results 
of the dietary intervention on BP and vascular function were examined in Chapter 6. Both 
Piccolo and Oranjstar reduced BP and improved FMD from baseline values (Table 9.1). 
Moreover, Piccolo is more superior to Oranjstar in reducing BP and improving FMD (Table 
9.1). Chapter 7 examined the effects of Piccolo and Oranjstar on blood lipids profile and 
new established vascular risk markers. Both showed no improvement in blood lipids profile. 
However, both significantly reduced adhesion molecules, sICAM-1 and sVCAM-1, from 
baseline values independent of the blood lipids profile. Oranjstar is more effective at 
reducing adhesion molecules than Piccolo (Table 9.1). The systematic review in Chapter 8 
showed that nutritional intervention significantly improved arterial stiffness. However, the 
results, although statistically significant, might have low clinical value (Table 9.1). The 
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results presented in Chapter 6 showed that both tomato varieties have no significant effects 
on microvascular vasodilation and arterial stiffness.  
9.2 Novelty and Strengths  
The work presented in this thesis contributes to our understanding of the impact of food and 
diet on cardiovascular health. This work it is novel in several ways and has a number of 
strengths. 
Strengths of this work include, adopting a rigorous methodology and a series of logical steps 
on investigating the effect of tomato on cardiovascular health. The design of the clinical trial 
presented here was developed based on evidence from previous relevant literature. Previous 
RCTs focused on investigating the effects of tomato consumption on red tomatoes and 
lycopene supplementations while the effects of different tomato varieties on markers of 
cardiovascular risk had not been previously evaluated. The present work thus fills a gap in 
the literature by reporting results comparing the health impacts of two varieties of cherry 
tomato, Piccolo and Oranjstar. The result of the clinical trial were consistent with previous 
evidence. Furthermore, this is the first clinical trial investigating the effect of tomato on LDI, 
as well as other cardiovascular risk factors which have been less studied such as PWV, PWA, 
sICAM-1, sVCAM-1, E-selectin and P-selectin. 
9.3 Limitations of Present Thesis  
Work presented in this thesis examined only two varieties of cherry tomato. Therefore, the 
effects of other tomato varieties on vascular function require further investigation. In 
addition, only raw tomato was used in this study for the dietary intervention. Thus, the 
findings cannot be extrapolated to tomato products such as tomato paste, juice or cooked 
tomatoes, in which the thermal food processing method is known to enhance the 
bioavailability of lycopene (Dewanto et al., 2002). Future studies could also test whether 
different doses (e.g. lower doses) of tomato or different length of intervention (longer 
periods) are effective.  
Further research is needed to determine the effects of tomatoes on the cardiovascular health 
of other populations. This study was conducted only in healthy male participants. Hence, 
further research is needed to evaluate whether tomato supplementation is equally effective 
on female individuals, population with high CVD risk and patients with CVD and diabetes. 
Finally, compliance, albeit good, was self-reported and there were no objective methods in 
place to measure compliance.  
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9.4 Relevance for Stakeholders 
The results of the present work are of relevance to healthcare professional such as 
nutritionists and dietitians who could use these to encourage the adoption of a diet with an 
increased lycopene intake through tomato consumption to reduce BP and further reduce the 
risk of CVD. These may be useful specially for patients with hypertension or borderline 
hypertension, the intake of fruit and vegetables should be encouraged and the positive effects 
of tomato consumption should be highlighted. 
9.5 Future Work 
To the best of our knowledge, no previous studies have compared the two different varieties 
of tomato (rich in trans-lycopene and cis-lycopene). The positive impacts of lycopene on 
inflammatory biomarkers encourage further studies with a larger population to investigate 
the effects of carotenoid consumption, as well as the influence of other components present 
in tomato, such as vitamin C, polyphenols or other micronutrients, which could act in a 
synergistic/antagonistic way regulating the activity of these molecules. Such studies should 
target the female individual as well as individuals at high CVD risk. It would also be useful 
to evaluate other foods known to reduce CVD risk, such as beetroots, with lycopene-rich 
tomatoes. Beetroots have been shown to lower BP, but they have never been tested alongside 
tomato. This combination might benefit cardiovascular health significantly. 
Lastly, future studies could use different -omics methodologies to identify markers of food 
intake (i.e. tomato), as well as to evaluate the impact of tomato consumption on new markers 
of CVD (Silva et al., 2015).  
  Chapter 9 
(Table 9.1 continues on next page) 209 
Table 9.1 Research questions raised from each chapter.  
Chapter  Question Answer(s) 
1 1. What are the links between diet and 
cardiovascular health? 
The links between diet and cardiovascular health were reviewed. Some epidemiological studies 
showed high intake of fruit and vegetable could reduce the incidence of CVD. 
2. Is there any evidence on specific food 
particularly fruit and vegetables?  
Tomato is one of fruit and vegetable that have beneficial effects on cardiovascular health. 
2 1. What is the epidemiological evidence 
on tomato consumption and its 
association with CVD risk? 
Both high tomato and lycopene consumption play a beneficial role in preventing CVD and early 
death.  
High tomato/lycopene intake or status were associated with significant reductions of 26% in stroke 
(p=0.001), 14% in CVD (p=0.003); while high serum lycopene concentration was associated with 
significant reduction of 37% in mortality (p>0.001). 
2. What is the epidemiological evidence 
on lycopene consumption and its 
association with CVD risk? 
3 1. What is the interventional evidence on 
the effects of tomato supplementation on 
CVD risk factors? 
Tomato supplementation was associated with significant reduction of LDL-cholesterol by 0.22 
mmol/L (p=0.006) and IL-6 by 0.25 pg/mL (p=0.03) and improvement of FMD by 2.53% (p=0.01). 
2. What is the interventional evidence on 
the effects of lycopene supplementation 
on CVD risk factors? 
Lycopene supplementation was associated with significant reductions in SBP by 5.66 mmHg 
(p=0.002). 
4 1. Does the carotenoid content vary in 
different varieties of tomato? 
The mean trans-lycopene and cis-lycopene content of Piccolo were 8.32±0.14 mg/100 g and 
0.42±0.01 mg/100 g respectively, while cis-lycopene content of Oranjstar were 2.64±0.08 mg/100 g. 
The mean β-carotene content of Piccolo over 10 days were 0.89±0.02 mg/100 g while β-carotene 
content of Oranjstar were 0.68±0.03 mg/100 g 
2. Does the carotenoid content change 
during postharvest storage? 
The carotenoid content of Piccolo and Oranjstar did not change significantly over the 10 days of 
storage. 
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Chapter  Question Answer(s) 
5 1. What are the gaps in the literature in 
relation with RCT supplementing tomato 
on cardiovascular risk factors?  
Systematic reviews and meta-analyses revealed that previous controlled experimental studies on the 
effects of tomato consumption have focused on red tomato and red tomato products or lycopene 
supplementation. RCT comparing different varieties is lacking in the literature. 
6 1. Do different varieties of cherry 
tomato have the same extent of 
beneficial effects on BP and vascular 
function? 
The resting SBP was significantly reduced by 3.3 mmHg (p=0.021) after consumption of Piccolo. 
The 24-Hour ambulatory DBP was significantly reduced by 2.33 mmHg (p=0.006) and 1.56 mmHg 
(p=0.049) after the consumption of Piccolo and Oranjstar, respectively.  
In addition, a substantial decrease in nighttime ambulatory SBP by 4.52 mmHg (p=0.039) and 
nighttime ambulatory DBP reduced by 3.82 mmHg (p=0.016) and a significant decrease in daytime 
ambulatory DBP by 1.78 mmHg (p=0.047) following the consumption of Piccolo. 
2. Do these health benefits differ 
according to age? 
In the age group above 30 years of age, consumption of Piccolo was a significant reduction in 
daytime ambulatory SBP (3.3 mmHg, p=0.043) and DBP (3 mmHg, p=0.03) compared with 
Oranjstar. In addition, consumption of Piccolo significantly improved FMD by 3.43% (p=0.026) 
when compared to intake of Oranjstar in age group above 30 years. 
In the age group above 30 years, consumption of Piccolo significantly improved PWA by 2.48% 
(p=0.013) from baseline. 
No significant differences in the younger group, or in any other BP measurements and vascular 
measurements were observed.  
Piccolo improved BP and FMD superior to Oranjstar. 
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Chapter  Question Answer(s) 
7 1. Do different varieties of cherry 
tomato have the same extent of 
beneficial effects on blood-borne 
biomarkers of vascular function? 
Supplementation of Piccolo reduced sICAM-1 by 49.56 ng/mL (p<0.001). 
Consumption of Oranjstar showed a significant reduction of sICAM-1, sVCAM-1 and E-selectin by 
59.14 ng/mL (p<0.001), 67.35 ng/mL (p=0.003) and 6.65 ng/mL (p=0.016) respectively. 
The reduction of sICAM-1, sVCAM-1 and E-selectin were independently to blood lipid profile. 
Oranjstar reduced adhesion molecules superior to Piccolo.  
2. Do these health benefits differ 
according to age? 
In the age group above 30 years of age, supplementation of Piccolo significantly reduced IL-6 by 
1.22 pg/mL (p=0.035), compared with baseline values; Oranjstar consumption was also significantly 
lower (by 0.82 pg/mL, p=0.026) than the changes observed with Piccolo.  
3. Are changes in FMD associated with 
improvements on blood-borne 
biomarkers of vascular function?  
No, only Piccolo was more beneficial to FMD but less beneficial to blood-borne biomarkers of 
vascular function (sICAM-1, sVCAM-1, E-selectin and P-selectin); while Oranjstar was more 
beneficial to blood-borne biomarkers, sICAM-1, sVCAM-1, E-selectin, but less beneficial to FMD 
8 What is the evidence for nutritional 
interventions enhancing microvascular 
vasodilation and arterial stiffness? 
Arterial stiffness showed statistically significant improvement from nutritional interventions, 
however the clinical significance of these is likely to be low. There was a limited number of studies 
for microvascular vasodilation, and they did show signs of improvement from nutritional 
intervention.  
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Appendix A1 PRISMA checklist. 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  37 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
N/A 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  37-38 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
37-38 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
38-39 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
38 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
38 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  39 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in 
the meta-analysis).  
39 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
38-39 
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Section/topic  # Checklist item  
Reported 
on page 
#  
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
38 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
40 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  40 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) 
for each meta-analysis.  
39-40 
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Appendix A2 Funnel Plot of standard error for the association between stroke and serum 
level/intake of lycopene. 
 
  
Appendix A3 Meta-regression on the effect of follow-up duration on the association between 
stroke and serum level/intake of lycopene.  
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Appendix A4 Meta-regression on the effect of age on the association between stroke and serum 
level/intake of lycopene.  
 
 
Appendix A5 Meta-regression on the effect of BMI on the association between stroke and serum 
level/intake of lycopene. 
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Appendix A6 Forest plot of the association between high serum level/intake of lycopene and risk 
of CHD. 
 
  
Appendix A7 Forest plot of the association between high serum level/intake of lycopene and risk 
of CHF and AF. 
 
  
Appendix A8 Forest plot of the association between high serum level/intake of lycopene and risk 
of MI and atherosclerosis. 
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Appendix A9 Forest plot of the association between high intake of tomato and risk of CVD events. 
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Appendix B1 PRISMA checklist. 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  71 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
N/A 
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  71-72 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
71-72 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
72 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
72-73 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
72 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  72 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in 
the meta-analysis).  
73 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
73 
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Section/topic  # Checklist item  Reported 
on page 
#  
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
72-73 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
73-74 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  74 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) 
for each meta-analysis.  
73-74 
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Appendix C1 Red cherry tomatoes (Piccolo) purchased from Marks & Spencer growth by Thanet 
Earth. 
 
 
Appendix C2 Red cherry tomatoes (Piccolo) purchased from Marks & Spencer growth by Andy 
Roe. 
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Appendix C3 Red cherry tomatoes (Piccolo) purchased from Sainsbury's growth by Thanet Earth. 
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Appendix C4 Red cherry tomatoes (Red Comet) purchased from Tesco growth in Spain. 
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Appendix D1 CONSORT 2010 checklist of information to include when reporting a randomised trial. 
  
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 113-114 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 114-118 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 113-114 
2b Specific objectives or hypotheses 113-114 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 114-118 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons N/A 
Participants 4a Eligibility criteria for participants 114 
4b Settings and locations where the data were collected 117 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually 
administered 
114-118 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 118-129 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined 114-115 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
Randomisation:    
Sequence 
generation 
8a Method used to generate the random allocation sequence 116 
8b Type of randomisation; details of any restriction (such as blocking and block size) 116 
Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any 
steps taken to conceal the sequence until interventions were assigned 
116 
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Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions 116 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing 
outcomes) and how 
116 
11b If relevant, description of the similarity of interventions N/A 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 129 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 129 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed 
for the primary outcome 
118 
13b For each group, losses and exclusions after randomisation, together with reasons 118 
Recruitment 14a Dates defining the periods of recruitment and follow-up 114, 130 
14b Why the trial ended or was stopped N/A 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 133, 154 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original 
assigned groups 
118 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 
95% confidence interval) 
135-142, 
153-161 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended N/A 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified 
from exploratory 
135-142, 
153-161 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) N/A 
Discussion 
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Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 150, 161 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings N/A 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 143-151, 
159-162 
Other information  
Registration 23 Registration number and name of trial registry 114 
Protocol 24 Where the full trial protocol can be accessed, if available N/A 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders N/A 
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Appendix D2 Manufacturer’s instructions for Human sVCAM-1 ELISA kit. 
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Appendix D3 Manufacturer’s instructions for Human sICAM-1 ELISA kit.  
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Appendix D4 Manufacturer’s instructions for Human E-selectin and P-selectin ELISA kit. 
 
 
sigma-aldrich.com
Enabling Science to Improve the Quality of Life
3050 Spruce Street, Saint Louis, MO 63103 USA
Tel: (800) 521-8956  (314) 771-5765   Fax: (800) 325-5052  (314) 771-5757
email: techservice@sial.com
Product Information
Sigma's Sandwich ELISA kits are in vitro enzyme-linked immunosorbent assays for the quantitative measurement of soluble proteins in a  
variety of species. Our extensive ELISA selection includes cytokines, growth factors, proteases, soluble receptors, apoptosis effectors, and 
many other soluble proteins.
Sandwich Assay Procedure
1. Bring all reagents and samples to room temperature (18–25 °C) 
before use. It is recommended that all standards and samples be run 
at least in duplicate. 
2. Add 100 µL of each standard and sample into appropriate wells. 
Cover wells and incubate for 2.5 hours at room temperature or  
overnight at 4 °C with gentle shaking. 
3. Discard the solution and wash 4 times with 1× Wash Solution. 
Wash by filling each well with Wash Buffer (300 µl) using a  
multi-channel Pipette or autowasher. Complete removal of liquid 
at each step is essential to good performance. After the last wash, 
remove any remaining Wash Buffer by aspirating or decanting.  
Invert the plate and blot it against clean paper towels.
4. Add 100 µL of 1× prepared Detection Antibody to each well. 
Cover wells and incubate for 1 hour at room temperature with 
gentle shaking. 
5. Discard the solution. Repeat the wash procedure as in step 3. 
6. Add 100 µL of prepared Streptavidin solution to each well.  
Cover wells and incubate for 45 minutes at room temperature with 
gentle shaking. 
7. Discard the solution. Repeat the wash as in step 3. 
8. Add 100 µL of TMB One-Step Substrate Reagent (Item H) to each 
well. Cover wells and incubate for 30 minutes at room temperature 
in the dark with gentle shaking. 
9. Add 50 µL of Stop Solution (Item I) to each well. Read at 450 nm 
immediately.
How It Works
83967
1095
©2015 Sigma-Aldrich Co. LLC. All rights reserved. SIGMA-ALDRICH is a trademark of Sigma-Aldrich Co. LLC, registered in the US and other countries. Warrants that its products conform to the  
information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. This protocol is intended for use as a  
guideline only. Please reference the detailed technical bulletin for each kit for specific instructions.
Capture Antibody pre-coated  
onto the 96-well plate
Biological samples and  
standards added to well
Incubation with 
HRP-Streptavidin
Data Analysis
Biotin labeled detection  
antibody is added to well
Sample and Standard
1 10
10
1
0.1
0.01
100
Human Insulin concentration 
(µLu/mL)
1000
O
D
=4
50
 n
m
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Appendix D5 Manufacturer’s instructions for Human IL-6 ELISA kit. 
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Appendix D6 Manufacturer’s instructions for Human TNF-α ELISA kit. 
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Appendix E1 PRISMA checklist. 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  163 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
163-164 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  163-164 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
163-164 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
164 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
165 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
164 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  164 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included 
in the meta-analysis).  
164 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
165 
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Section/topic  # Checklist item  
Reported 
on page 
#  
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at 
the study or outcome level), and how this information is to be used in any data synthesis.  
165 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  165 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) 
for each meta-analysis.  
165 
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Appendix F2 Copyright license for Figure 1.2, Figure 1.3, and Figure 1.11. 
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